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Abstract 
Ventricular tachycardia (VT) is a debilitating and potentially fatal cardiac arrhythmia. 
Implantable cardioverter defibrillators (ICD) are first-line therapy for treatment of VT. However, 
ICD shocks can have a profound impact on psychological well-being and health-related quality 
of life (HRQoL). Catheter ablation of VT is a novel procedure intended to reduce VT recurrence, 
medication use, and ICD shocks. To-date, there is a paucity of research examining psychological 
well-being and HRQoL in ICD recipients undergoing VT ablation.  
This case-control prospective study aimed to 1) examine predictors of post-traumatic 
stress disorder (PTSD) symptoms, and symptoms of anxiety, and depression in ICD recipients 
following VT ablation and 2) evaluate whether VT ablation is associated with greater 
improvement in HRQoL, and symptoms of anxiety, depression, and PTSD. Hypothesis 1 
assessed whether higher optimism, self-efficacy, and positive health expectations at baseline 
predict improvement in symptoms of PTSD, anxiety, and depression at six-month follow-up. 
Hypothesis 2 tested whether HRQoL, depression, anxiety, and PTSD symptoms improve more 
over six-month follow-up in ICD recipients who underwent VT ablation as compared to ICD 
recipients who did not. Measures of PTSD, anxiety, depression, and HRQoL were administered 
at baseline and follow-up. Measures of optimism, positive health expectations, and self-efficacy 
were administered at baseline. Hierarchical regression analyses were employed to assess the 
hypotheses. 
Results of Hypothesis 1 showed that higher self-efficacy at baseline predicts 
improvement in symptoms of anxiety and PTSD at follow-up, over and above group 
membership. Contrary to hypothesis, optimism and positive health expectations did not predict 
improvement in psychological well-being. Contrary to Hypothesis 2, between-group differences 
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were not detected on HRQoL, symptoms of anxiety, depression, or PTSD symptoms. However, 
ICD participants who underwent VT ablation showed improvement in mental health HRQoL and 
symptoms of PTSD, while control participants showed improvement in domains of anxiety and 
PTSD.   
These findings lend support to the protective function of self-efficacy, particularly with 
respect to anxiety-based outcomes. HRQoL benefits of VT ablation were not detected, although 
the pattern of within group improvements hint at potential benefits related to anxiety and trauma 
symptoms.   
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Ventricular tachycardia (VT) is a debilitating and potentially fatal cardiac arrhythmia. In 
patients with structural heart disease, the majority of sustained VTs originate in the scar tissue of 
the heart which might be congenital or caused by a prior myocardial infarction (MI; Al-Khatib et 
al., 2018; Aliot et al., 2009). Presence of a myocardial scar is more likely to be associated with 
poor tolerance of VT, devolvement of the arrhythmia into ventricular fibrillation, and sudden 
death (Peachey et al., 2014). Thus, individuals with structural heart disease can be a particularly 
vulnerable population of cardiac patients whose health and psychological functioning may be 
profoundly affected by the burden of malignant arrhythmias.  
The implantable cardioverter defibrillator (ICD) is the first line of treatment for patients 
at risk for sudden cardiac death and for most patients with structural heart disease and sustained 
VT (Russo et al., 2013). The ICD restores normal heart function upon detecting an abnormal 
heart rhythm. It does so by delivering precisely timed pulses, antitachycardia pacing (ATP), or 
an electrical shock to the heart muscle. Crucially, while the ICD can effectively terminate the 
malignant arrhythmia it does not prevent VT from recurring (De Ponti, 2011; Liang, Santangeli, 
& Callans, 2015). Studies have shown benefits of the ICD on longevity (Buxton et al., 1999; 
Moss et al., 2002). Despite its life saving benefits, ICD therapy, specifically shocks, is associated 
with increased morbidity. The psychological impact of having an ICD and of receiving shocks 
has also been studied extensively. Many ICD recipients experience fear, anxiety, and diminished 
quality of life in relation to shock therapy (Epstein et al., 2008; Redhead, Turkington, Rao, 
Tynan, & Bourke, 2010), often likened to being kicked by a horse in the chest (Ahmad, 
Bloomstein, Roelke, Bernstein, & Parsonnet, 2000; Burke, Hallas, Clark-Carter, White, & 
Connelly, 2003). It can be anxiety-inducing and frigthening as shocks are typically painful, 
unpredictable, and uncontrollable (Porterfield, Porterfield, Bray, & Sugalski, 1991). ICD 
2 
 
recpients who receive shocks have generally been found to report higher anxiety levels that those 
who have not received shocks (Carroll & Hamilton, 2005; Herrmann et al., 1997; Luderitz, Jung, 
Deister, Marneros, & Manz, 1993; Magyar-Russell et al., 2011; Redhead et al., 2010). The 
prevalence of anxiety and depression disorders is approximately 20% in ICD recipients 
irrespective of whether they received shocks or not (Magyar-Russell et al., 2011). Moreover, 
surviving a cardiac arrest or receiving ICD shocks has been recognized as a possible traumatic 
stressor and even meets Criterion A in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV-TR) for post-traumatic stress disorder (PTSD; Ladwig et al., 2008). A recent 
systematic review argues that acute cardiac events also meet Criterion A in the DSM-5 
(American Psychiatric Association, 2013). ICD recipients live with a constant and internal 
reminder of the precariousness of their health. It is thus not surprising that this group of patients 
may be prone to experiencing trauma symptoms (Hamner, Hunt, Gee, Garrell, & Monroe, 1999) 
with prevalence rates of PTSD ranging from 7.6 to 30% irrespective of shocks (Vilchinsky, 
Ginzburg, Fait, & Foa, 2017). In this population, PTSD can be enduring and impact well-being 
over extended time (Kapa et al., 2010). PTSD has serious implications as it has been associated 
with more anxiety, depression, and cardiac symptoms as well as increased mortality risk 
independent of disease severity, anxiety, and depression (Ladwig et al., 2008).  
Health-related quality of life (HRQoL) has also been assessed in ICD recipients 
compared to VT patients treated with antiarrhythmic therapy alone. Findings vary with some 
studies reporting better HRQoL in ICD recipients (Irvine et al., 2002) with others observing no 
differences or similar trends between groups (Noyes et al., 2007; Passman et al., 2007; Schron et 
al., 2002). ICD shock, especially more than five shocks, has more consistently been shown to be 
associated with emotional distress and poorer HRQoL, physical and mental well-being  (Carroll 
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& Hamilton, 2005; Irvine et al., 2002; Mark et al., 2008; Noyes et al., 2009; Passman et al., 
2007; Schron et al., 2002). ICD shocks have also been associated with increased mortality, 
although this may be a function of deteriorating or advanced cardiac disease rather than shocks 
per se (Peachey et al., 2014; Wilkoff et al., 2016). In summary, although the ICD can be life-
saving, it does not prevent VT recurrence and its therapies can have a profound impact on 
psychological well-being.  
Antiarrhythmic medications are utilized as a form of suppressive therapy in adjunct to the 
ICD or as a stand-alone intervention. Escalated medical treatment (i.e., revision and increase in 
the use of antiarrhythmics) is often used when there is recurrence of VT. However, despite 
successes in reducing VT occurrence and shocks, the use of amiodarone, a potent antiarrhythmic, 
has been associated with adverse side-effects (Al-Khatib et al., 2018; Connolly et al., 2006) and 
decreased HRQoL (Schron et al., 2002). Thus, side-effects of medication and drawbacks of the 
ICD prompted the development of innovative approaches with fewer negative effects. 
Catheter ablation of VT is one such novel and moderately invasive procedure that can 
reduce VT recurrence, medication use, and ICD shocks (Liang et al., 2015). This procedure 
involves delivering radiofrequency energy from the catheter to the heart tissue, creating a burn, 
which can disrupt the malignant VT. The advancement of technology and the understanding of 
VT etiology make it particularly appealing as it is generally safe and efficacious (Liang et al., 
2015; Viana-Tejedor et al., 2010). There is a consensus amongst experts that VT ablation is 
recommended when there is VT recurrence, multiple shocks due to sustained VT, or VT storms 
that are not managed by reprogramming the ICD or by administering antiarrhythmic medications 
(Aliot et al., 2009; Dagres et al., 2012; Peachey et al., 2014; Zeppenfeld, 2012). Prophylactic VT 
ablation in unshocked ICD patients has also demonstrated benefit (Kuck, 2009; Kuck et al., 
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2010; Reddy et al., 2007). Thus, in patients with scar-related VT, VT ablation is frequently 
utilized in conjunction with an ICD and/or antiarrhythmic drug treatment (Aliot et al., 2009). 
Randomized controlled trials (RCT) of VT ablation have reported a lower composite primary 
outcome of death, VT storms, appropriate ICD shocks and ICD therapy overall (Kuck et al., 
2010; Reddy et al., 2007; Sapp et al., 2016). 
There is, however, paucity of research examining HRQoL and psychological factors in 
ICD recipients undergoing VT ablation. Only a few studies examined HRQoL and, to the best of 
our knowledge, none has thoroughly examined constructs of PTSD, depression, and anxiety, nor 
the potential protective factors such as self-efficacy or optimism. Studies comparing HRQoL 
between ICD patients treated by VT ablation versus medication alone have not typically found 
between-group differences (Gula et al., 2018; Kuck et al., 2010). However benefits within the 
ablation group have been detected, which suggest improvement in HRQoL after a successful 
ablation but not an unsuccessful one (Strickberger et al., 1997), as well as improvement in some 
specific domains of HRQoL (Gula et al., 2018; Kuck et al., 2010). Confidence in these findings 
is limited by several factors including low sample size, lack of control group, and advancements 
in ICD technology and VT ablations since study publication (Strickberger et al., 1997). 
Additionally, low response rates to the HRQoL questionnaire and recruitment of participants 
who experienced a first episode of stable VT rather than a more serious event such as cardiac 
arrest or shocks might make it more difficult to detect benefits of the ablation (Kuck et al., 2010). 
Lastly, smaller sample size and attrition rates can compromise confidence in the above findings 
(Gula et al., 2018). Taken together, findings from these studies are inconclusive but provide 
some suggestion for the benefit of ablation therapy on HRQoL in this cardiac population. 
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With regard to psychological outcomes, a secondary aim of a recent RCT (Ventricular 
Tachycardia Ablation versus Escalated Antiarrhythmic Drug Therapy in Ischaemic Heart 
Disease – VANISH; Gula et al., 2018; Sapp et al., 2016) substudy was to assess symptoms of 
anxiety and depression. Results (that were published well after the present study was underway) 
did not observe changes over time (Gula et al., 2018). While this is an important RCT to consider 
it did not assess PTSD or the composite scores of physical and mental health HRQoL. Further, 
trauma symptoms are understudied although a case report suggested that an ICD patient who 
received numerous shocks and met criteria for PTSD showed improvement in trauma symptoms 
following VT ablation (Maryniak et al., 2006).   
Thus, while psychological outcomes and HRQoL have been studied in ICD patients, 
there is a paucity of such data regarding ICD patients undergoing a VT ablation. Moreover, 
while factors such as ICD shocks and the associated impact upon psychological well-being have 
been studied, resilience factors are also important to examine in this group of patients. Factors 
such as optimism, health expectations, and self-efficacy can have a role in buffering or 
mitigating the stress of ICD therapy in a group of patients experiencing high VT burden. 
Optimism and health expectations can help enhance patients’ ability to experience better health 
outcomes (Sears et al., 2004). They can do so by facilitating healthy behavioural practices, such 
as adherence and exercise, and providing a sense of coping and some sense of control over the 
unpredictability of shocks (Sears et al., 2004). Similarly, coping self-efficacy can affect well-
being through beliefs in one’s ability to exercise the behaviours needed to manage a given 
stressful situation such as arrhythmia events or ICD therapy. Having some sense of control in a 
largely uncrontrollable situation can help enhance one’s agency and well-being (Bandura, 1997). 
With the growing rate of VT ablation procedures in ICD recipients, it is imperative to explore the 
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psychological correlates in this population as a way of optimizing patient care. The objectives of 
this dissertation were two-fold: 1) to examine psychological predictors of anxiety, depression, 
and PTSD outcomes in ICD patients undergoing VT ablation therapy, and 2) to explore whether 
VT ablation predicts HRQoL outcome. Background literature and the rationale for these 
objectives are reviewed below. 
Literature review of VT interventions and study variables 
To-date, research in ICD patients has primarily focused on assessing classical domains of 
psychosocial functioning such as PTSD, depression, anxiety, and HRQoL. Much of this research 
has focused on the psychological and HRQoL effects of ICD shocks. It is important, therefore, to 
review and draw upon some of this literature, as well as review the ICD device and the VT 
ablation procedure, when generating hypotheses for the present study especially as catheter 
ablation of VT is meant to ameliorate VT burden. 
The ICD: an overview. Since the first implant in 1980, the ICD has evolved to become 
the first line of treatment for patients at risk for, or who had received, life-threatening 
arrhythmias. Initially large and heavy, the ICD required a thoracotomy for implantation and was 
associated with morbidity and mortality and frequent inappropriate shocks (van Welsenes et al., 
2011). Current devices are significantly smaller and implanted subcutaneously. The ICD 
comprises a pulse generator and leads which serve to monitor heart function, capture data, and 
store and deliver ICD therapy in the form of ATP or shocks. Therapies are deemed appropriate 
when they are delivered in response to a sustained ventricular arrhythmia, either VT or 
ventricular fibrillation. Conversely, they are deemed inappropriate when their delivery is caused 
by something other than a ventricular arrhythmia, for example a supraventricular rhythm or 
dislodgement of an ICD lead (Wilkoff et al., 2016). Third-generation ICDs have an improved 
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ability to discriminate between VTs and supraventricular tachycardias thereby reducing 
incidence of inappropriate shocks (Wilkoff et al., 2016). The ICD can also be programmed in 
such a way as to minimize the occurrence of shocks while appropriately treating the tachycardia. 
Specifically, it can be programmed into zones where detection of the parameters for the 
arrhythmia are defined as well as the sequence of therapies to be delivered. For example, 
algorithms can allow VTs to self-terminate without requiring ICD therapy thus reducing 
inappropriate therapy, or deliver bursts of ATP prior to delivering a shock (Wilkoff et al., 2016). 
Secondary prevention ICDs are implanted in patients who survived one or more cardiac arrests 
or had sustained VTs. Primary prevention ICDs are implanted in individuals at risk for, but who 
have not experienced, a cardiac arrest or sustained ventricular arrhythmia (Russo et al., 2013). 
Large-scale clinical trials supported the use of the ICD in secondary prevention and 
demonstrated significant (The Antiarrhythmics versus Implantable Cardioverter Defibrillators 
[AVID] Investigators, 1997) and non-significant (Connolly et al., 2000) reductions in mortality 
as compared to patients on pharmacological therapy alone (e.g., amiodarone therapy). 
Implantation of the ICD for primary prevention also gained support through large scale trials 
which showed a reduction in mortality in ICD recipients (Buxton et al., 1999; Moss et al., 2002). 
Taken together, the goal of the ICD is to extend life, however morbidity plays a prominent role 
and ICD therapies are associated with adverse outcomes. While ICD shocks can be painful and 
distressing whereas ATP therapies are typically not, both therapies can be associated with 
emotional distress, syncope, and palpitations (Wilkoff et al., 2016).  
Catheter ablation for ventricular tachycardia: an overview. Most patients with VT 
associated with structural heart disease have a standard indication for ICD therapy as a mode of 
treatment (Al-Khatib et al., 2018; Aliot et al., 2009). A consensus statement by the European 
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Heart Rhythm Association and the Heart Rhythm Society recommends VT ablation when 
antiarrhythmic therapy fails to prevent recurrent VT in ICD recipients (Aliot et al., 2009). Even 
when the targeted VTs are successfully ablated the ICD remains an important intervention 
because of the elevated risk for VT recurrence (Aliot et al., 2009; Al-Khatib et al., 2018). 
Ablation of VT can reduce appropriate ICD shocks in patients with ischemic cardiomyopathy 
(Reddy et al., 2007) and early ablation has been suggested to provide significant VT free survival 
after one year and good arrhythmia control (Frankel et al., 2011).  
Catheter ablation of VT is a moderately invasive procedure, performed by a trained 
electrophysiologist, a cardiologist with a specialisation in heart rhythm disorders and the 
electrical system of the heart. During an electrophysiology study, which typically precedes the 
ablation, an assessment of VT morphologies is conducted in order to identify areas in the heart 
where the abnormal heart rhythm originates. During the actual ablation procedure, mapping 
strategies help identify target areas to be ablated. These areas can range in complexity and may 
be small and narrow allowing discrete application of radio-frequency energy or broad, requiring 
larger areas of the tissue to be ablated (Aliot et al., 2009). Various mapping techniques are 
utilized but perhaps the most common are activation and substrate mapping or a combination of 
the two. When VT is inducible and hemodynamically tolerated, activation mapping is typically 
used to identify the re-entry circuits and channels and ablate the VT (Aliot et al., 2009; Kumar et 
al., 2016). When VT is not inducible or there is haemodynamic instability substrate mapping, 
performed during sinus or paced rhythm, helps identify areas of low voltage consistent with the 
scar (i.e., VT substrate) which are then ablated (Aliot et al., 2009; Kumar et al., 2016). Since the 
ICD can sense electrical stimulation and the current, it must be reprogrammed prior to the 
ablation so that it prevents delivery of ATP (Aliot et al., 2009). 
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In order to curtail the pain, anxiety, and awareness related to mapping and ablation, 
varying degrees of sedation or analgesia are administered and may range from minimal to deep 
sedation or general anaesthesia (Aliot et al., 2009). Because VT ablation is often performed in 
individuals with advanced heart disease, it can be associated with complications, which occur 
intraoperatively in about 11% of patients (Yu et al., 2015). Ablation endpoints used to determine 
success include: 1) non-inducibility of clinical (spontaneous) VT, 2) modification of the induced 
VT cycle length, and 3) non-inducibility of any VT (Aliot et al., 2009). 
Several large RCTs provide support for the use of ablation over escalated anti-arrhythmic 
therapy in patients with ischemic heart disease, namely a reduction in incidence of shocks and 
survival which is free from occurrence of VT in the ablation groups (Kuck et al., 2010; Reddy et 
al., 2007; Sapp et al., 2016). A recent large RCT reported that, as compared to individuals on 
escalated antiarrhythmic therapy, ablation patients had a lower composite primary outcome of 
death, VT storms, or appropriate shocks (Sapp et al., 2016). This lent support for the use of VT 
ablation over escalated antiarrhythmic therapy for purposes of reducing VT in ICD patients with 
ischemic heart disease. However, the authors emphasized that these patients are a high risk group 
in which more than half continued to have recurrent VT and over a quarter died despite treatment 
(Sapp et al., 2016). Another seminal study (Reddy et al., 2007) reported that at two-year follow-
up, prophylactic ablation reduced incidence of ICD therapy in secondary prevention ICD 
recipients (12% vs. 33% in the ablation and control group, respectively). ICD storm occurrences 
were significantly fewer in ablation patients (6%) compared with control patients (19%). Patients 
in the ablation group had a 65% reduction in the risk of receiving ICD therapy during the two 
year follow-up and a 73% chance reduction of receiving shocks. The third seminal RCT 
examined prophylactic ablation in secondary prevention ICD recipients (Kuck et al., 2010). 
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Patients were randomized to receive catheter ablation followed by an ICD implant (intervention 
group) or to receive an ICD implant alone (control group). After two years of follow-up, survival 
free from VT favoured catheter ablation (hazard ratio: 0.61) and a reduction in the incidence of 
ICD shocks by 43% (Kuck et al., 2010). Lastly, a small study included 32 ICD recipients with a 
history of electrical storms (three or more distinct episodes of sustained ventricular arrhythmia 
within 24 hours which trigger ICD treatment) who underwent VT ablation (Deneke et al., 2011). 
Ablation successfully suppressed VT with 31% of patients with recurrence of sustained 
ventricular arrhythmias and 6% with recurrence of electrical storms. Given the positive effects of 
these studies on arrhythmia outcomes, it is reasonable to hypothesize positive effects of VT 
ablation on the psychological functioning of ICD patients. 
Outcome measures 
Outcome variables in this study included PTSD, anxiety and depression, and HRQoL. 
Each is reviewed below to better situate study hypotheses. 
Posttraumatic stress disorder. A diagnosis of a life-threatening illness can satisfy the 
criterion for a traumatic stressor according to the Diagnostic and Statistical Manual of Mental 
Disorders 4th Ed. (DSM-IV-TR; American Psychiatric Association, 2000), the accepted version 
at the time this study was designed. Since then, the DSM-5 (American Psychiatric Association, 
2013) has been published with revised PTSD criteria. Criterion A in DSM-5 stipulates that “a 
life-threatening illness or debilitating medical condition is not necessarily considered a traumatic 
event. Medical incidents that qualify as traumatic events involve sudden, catastrophic events 
(e.g., waking during surgery, anaphylactic shock)” (American Psychiatric Association, 2013, p. 
274). While this brings into question whether a life-threatening event meets Criterion A, a recent 
systematic review of cardiac-induced PTSD argues that, based on data, acute cardiac events meet 
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the more stringent Criterion A outlined in the DSM-5 (Vilchinsky et al., 2017). Although many 
cardiac patients might not qualify to meet the PTSD diagnosis as per DSM-5, they can be 
preoccupied with fear of death and experience avoidance, intrusions, negative alterations in 
mood and cognition, and changes in arousal. These symptoms might be subsyndromal when 
assessed by DSM-5 but can, nonetheless, impact well-being and cause significant emotional and 
psychological distress. Since the DSM-IV-TR publication, there has been growing recognition 
that medical stressors share many characteristics with other traumatic stressors such as assault or 
armed combat, including perceived or actual threat to one’s life, a feeling of helplessness and 
extreme fear (Mundy & Baum, 2004). However, unlike trauma arising from an external stressor, 
those originating with medical illness have a number of distinguishing attributes. Namely, the 
stressor can be internal, persistent, and the life threatening event may have already occurred 
and/or there may be threat of future events (Buckely, Green, & Schnurr, 2004). Importantly, in 
medical populations PTSD is not only of clinical significance but has associated medical 
implications and complications. For example, PTSD has been associated with poor adherence to 
treatment regimen (Shemesh et al., 2001; Stoll et al., 2000), increased mortality rates (Vilchinsky 
et al., 2017), poor HRQoL (Ouimette et al., 2004), and higher cardiovascular disease adverse 
event rates (Gradus et al., 2015). Strikingly, in a sample of ICD recipients presenting with PTSD 
the absolute mortality risk was more than double compared to those without PTSD symptoms 
(Ladwig et al., 2008). 
 For cardiac patients, the above-mentioned attributes are particularly poignant as cardiac 
events can be life threatening and patients have no control over when the event will occur. As 
such, the cardiac event can be potentially traumatic (Vilchinsky et al., 2017). Adding further to 
the inherent burden of illness are worries about recurrence, complications, treatment and its side 
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effects, and the impact the illness might have on one’s life (Fait et al., 2018). For ICD recipients 
more specifically, the stressor can be an acute event or chronic in nature. For example, ICD 
shocks which occur acutely have been recognized as meeting criteria for a traumatic stressor 
(Hamner et al., 1999). Conversely, the surgical scar can serve as a constant reminder of one’s 
precarious health and the potential of future shocks (Sears, Hauf, Kirian, Hazelton, & Conti, 
2011). The ICD device itself can also continually remind the patient of his/her underlying 
cardiac disease (von Känel, Baumert, Kolb, Cho, & Ladwig, 2011). Together, these raise the 
point that patients with cardiac arrhythmias might be at particular risk of PTSD. Thereby, they 
seriously challenge one’s ability to take control over their disease. Perceived loss of control and 
helplessness have been identified as important risk factors for PTSD development (Hari et al., 
2010; von Känel et al., 2011). Similarly, more shocks during follow-up have been suggested to 
predict greater PTSD at follow-up (von Känel et al., 2011). In a sample of seriously ill patients 
such as those in the present study, the burden of VT is significant, numerous unpredictable 
shocks are likely to occur, and this can in turn impact trauma levels.  
Studies have examined prevalence rates of PTSD more broadly as well as in cardiac 
populations. A recent systematic review of cardiac-induced PTSD across different cardiac 
disease populations reported that prevalence rates range from 0 to 38% (Vilchinsky et al., 2017). 
More specifically, prevalence rates of PTSD range from 0% to 16% in MI patients (Tedstone & 
Tarrier, 2003) and from 15-38% in patients following a cardiac-arrest (Gamper et al., 2004; 
Ladwig et al., 1999; Vilchinsky et al., 2017). The wide range of PTSD prevalence in both 
populations may be influenced by several characteristics of the studies upon which these rates 
were established. Namely, there exists great variance in: 1) study design (e.g., case-control, 
retrospective, longitudinal, RCT); 2) length of time from index event until the assessment of 
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PTSD where studies capturing symptoms closer to the index event tended to report higher 
prevalence rates; 3) type of PTSD self-report measure used as well as little consensus on optimal 
measures and cut-off scores for classifying PTSD; 4) use of self-report measures versus clinical 
interviews, where self-report measures typically yielded higher prevalence rates irrespective of 
when the PTSD assessment was conducted; 5) sample size of studies which can compromise 
power; 6) gender distribution with largely male samples; and 7) response and attrition rates 
(Tedstone & Tarrier, 2003; Vilchinsky et al., 2017). It is hard to make sense of studies examining 
the change in PTSD over time as many of the studies suffer from high attrition rates thereby 
undermining interpretation of the results observed. More broadly, use of heterogeneous samples 
within and between studies is particularly problematic in establishing prevalence rates in cardiac 
populations (Vilchinsky et al., 2017). Some studies combine patients who experienced a first 
cardiac episode with those who experienced repeated events while other studies combine patients 
with different diagnoses (Vilchinsky et al., 2017). Thus, there is a vastly different lived 
experience among these patients and therefore different degrees of exposure to stressors. Given 
that the studies of PTSD prevalence rates themselves vary in the nature and severity of cardiac 
diseases represented in the samples, it might not be surprising that prevalence rates across studies 
vary widely. For example, prevalence rates of PTSD appear to differ between samples of MI 
survivors and samples of cardiac arrest survivors (Vilchinsky et al., 2017). It is possible that the 
lower rates observed in MI patients might be because the general MI population is heterogeneous 
in terms of severity of the heart attack. Conversely, higher prevalence rates observed in cardiac 
arrest survivors might reflect the severity of the life-threatening event they endured. Indeed, in 
cardiac arrest patients, high prevalence rates were detected even when more rigorous diagnostic 
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methods were employed, such as a diagnostic interview, underscoring the profound impact of 
surviving a life-threatening arrhythmia (Vilchinsky et al., 2017).  
In the ICD population, prevalence rates of PTSD are generally consistent with those 
reported in the cardiac arrest population. A systematic review reported that in ICD recipients, the 
prevalence of PTSD ranges from 8% to as high as 30% (Vilchinsky et al., 2017). Here too, 
factors similar to ones outlined above might contribute to the wide range of prevalence rates, 
including: higher rates when self-report measures are used; the use of varying measures and 
inconsistent cut-off scores for classifying PTSD; length of time between the assessment of PTSD 
and index event; the nature of the index event (e.g., ICD implantation or shock, where the 
experience of shocks might impact differently on trauma symptoms); and variability in study 
design where cross-sectional studies with smaller sample sizes tended to report somewhat higher 
prevalence rates (Vilchinsky et al., 2017). In these cross-sectional studies there is also some 
ambiguity as to when PTSD was assessed in relation to the ICD implant or discharge. Moreover, 
although indication for ICD implant has not been associated with PTSD, studies often contain 
few participants meeting criteria for PTSD, thus compromising statistical power to confidently 
assess the influence of ICD indication on prevalence rates (Habibović, van den Broek, Van der 
Voort, Alings, & Denollet, 2012; Lang et al., 2014). Taken together, the methodological 
differences amongst studies assessing prevalence rates of PTSD in ICD recipients make it 
difficult to confidently judge the robustness of prevalence rates reported across studies.  
Studies of ICD recipients have also examined whether PTSD is a relatively short-lived or 
enduring phenomenon. Rates of PTSD typically decrease over time, with 21% of patients 
reporting symptoms within 2 months of ICD implantation and 12% and 13% reporting symptoms 
at six- and 12-month follow-ups, respectively (Kapa et al., 2010). Nonetheless, there is some 
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suggestion that chronic levels of PTSD can present a clinically significant phenomenon in ICD 
recipients. Rates have been reported to increase and persist from baseline (approximately two 
years after implant) to follow-up (approximately 5.5 years post implant) with approximately 19% 
of patients meeting criteria for PTSD at both time points (von Känel et al., 2011). Together, these 
studies suggest that PTSD can be an enduring problem for some patients in this population. This 
is understandable given the frequently persistent VT burden, the risk of repeated shocks, and 
knowing that one’s medical illness is chronic. Interestingly, one case-report of an ICD recipient 
presenting with signs of acute stress disorder and PTSD re-assessed these symptoms after the 
individual underwent a successful VT ablation procedure (Maryniak et al., 2006). Following the 
ablation symptoms of PTSD were significantly diminished (Maryniak et al., 2006), suggesting 
that mitigating the arrhythmia helps mitigate the stress-related symptoms.  
In summary, PTSD has become a recognized phenomenon in medical populations. 
Prevalence rates, while varying widely, appear to be significant in the ICD population and to 
persist over a long period of time. Because PTSD is associated with adverse outcomes it is 
important to better understand factors or interventions that could help reduce the burden. It is 
reasonable to expect that reducing the risk of malignant arrhythmias and ICD shocks by 
intervening with VT ablation therapy might favourably impact PTSD in this population. The 
present study aimed to determine if undergoing ablation therapy to reduce VT burden is 
associated with a reduction in PTSD symptoms.   
Depression and anxiety. Although some ICD recipients deem the device to be a “safety 
net,” the perceived VT burden may be high, and fear and dread of potential ICD shocks are often 
reported. It is thus not surprising that anxiety and depression are common in ICD patients 
(Ladwig et al., 2014). Together, they can impact adjustment to the device and well-being. 
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Learned helplessness and the associated lack of control over the occurrence of shocks have been 
proposed as a mechanism for the manifestation of depressive symptoms (Sears, Todaro, Lewis, 
Sotile, & Conti, 1999). Faced with the possibility of unpredictable and abrupt shocks, the 
perceived lack of control may amplify feelings of hopelessness and negative beliefs about one’s 
current and future health (Sears et al., 1999). This can, in turn, compromise psychological well-
being of ICD patients who experience repeated shock therapies. Anxiety is often related to ICD-
specific concerns such as fear of shocks, their intensity and unpredictable nature, fear of device 
malfunction, and death (Gallagher et al., 1997; Pauli, Wiedemann, Dengler, Blaumann-
Benninghoff, & Kühlkamp, 1999). Patients may come to anticipate and fear, or even dread, the 
next shock. These negative and catastrophic thoughts can elevate anxiety (Irvine et al., 2010; 
Sears et al., 1999). Thus, the potentially life-saving therapy of the ICD can also play an 
important role in the development and maintenance of depressive and anxiety symptoms. 
Beyond the clinical implications, both anxiety and depression carry medical repercussion as they 
have been associated with increased major cardiac events, increased readmission rates, and 
mortality (Berg, Herning, Svendsen, Christensen, & Thygesen, 2016; Ladwig et al., 2014). 
 Varying prevalence rates of depression and anxiety have been reported across different 
studies of ICD recipients. While the precise reason for such wide ranges is difficult to identify, 
there are several possible contributing factors which will be reviewed below. An early review 
reported prevalence rates of depressive symptoms to range from 24 to 33% following the ICD 
implant (Sears et al., 1999). Clinically diagnosable levels of anxiety were reported in 13-38% of 
ICD patients (Sears et al., 1999). The wide ranges in this study were likely impacted by several 
characteristics of the included studies: studies were often cross-sectional in design and contained 
small sample sizes (range: 8-104 patients); studies utilized different self-report measures to 
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assess symptoms of anxiety and depression; and varied significantly with respect to when 
symptomatology was assessed relative to the ICD implant (Sears et al., 1999).  
A more recent systematic review reported that, when assessed by a validated diagnostic 
interview, between 11% and 28% and between 11% and 26% of ICD patients have a depressive 
and anxiety disorder, respectively (Magyar-Russell et al., 2011). The three studies upon which 
these prevalence rates were based comprised relatively small samples (N = 35-90) raising the 
question of generalizability. Higher prevalence rates were reported in cross-sectional studies of 
predominantly secondary prevention ICD recipients and when symptoms were assessed twelve 
or more months post-implant. Higher rates, thus, likely reflect the impact of shocks or the 
prolonged burden of living with malignant arrhythmia on psychological wellbeing. Lowest rates 
were captured when the mean assessment time was two days post implant likely not capturing 
the impact of experiencing shocks or living with the ICD device. These prevalence rate ranges 
become wider still when elevated levels of depression and anxiety are assessed by way of self-
report measures. Elevated symptoms of depression were reported to be as low as 5% and as high 
as 41%, while elevated symptoms of anxiety were reported to range from 8 to 63% (Magyar-
Russell et al., 2011). Beyond the variability in prevalence rates due to mode of assessment (i.e., 
clinical interview versus self-report), types of self-report measures used varied widely. While the 
same measure in different studies often yielded similar prevalence rates, this was certainly not 
always the case. This raises the question of the measures’ sensitivity to detecting symptoms in 
the ICD population. Moreover, rates of depression and anxiety varied when reported pre-ICD 
implant as compared to shortly after implant, or longer than a year post-implant. However, no 
discernable pattern could be detected as wide prevalence rate ranges for both were reported at all 
time points. One possible explanation however may be that many of the studies assessing 
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symptoms at 12 or more months following implant were cross-sectional in design. They often 
captured symptoms anywhere from 12 to 75 months post implant in largely secondary prevention 
ICD recipients. The farther away from time of implant that the symptoms are assessed, the 
greater the likelihood that patients might require device upgrade, lead changes, pocket revisions, 
and experience more VT burden/shocks. Another potential contributor to the wide ranges 
reported may be that some of the longitudinal studies did not account for attirition rates. More 
broadly, studies encompassed in this review were published between 1996 and 2009, combining 
older and newer generations of ICDs. Earlier implants were more invasive and patients often 
received more inappropriate shocks. As a broader caveat, many symptoms of anxiety and 
depression, such as shortness of breath or lack of energy, may overlap with cardiac symptoms. 
Thus, there may be over or under reporting of mental health symptoms impacting the range of 
prevalence rates (Magyar-Russell et al., 2011).   
The above findings highlight the burden of depression and anxiety in the ICD population. 
Conversely, an older meta-analysis found no differences in mood symptoms between ventricular 
arrhythmia patients treated with an ICD and those treated with medication alone (Burke et al., 
2003). Similarly, no differences were detected on anxiety and depression between pre- and post-
ICD implant (Burke et al., 2003). The discrepancy in findings may have been influenced by the 
fact that the 20 studies included in the meta-analysis were published in the early to late 1990s 
with one study published in 1989 and one in 2000. The data would have been collected much 
earlier suggesting that studies included first generation ICDs which likely would not have 
provided much psychological benefit over antiarrhythmic therapy. Older models of the ICD 
required an invasive thoracotomy and carried with them a greater likelihood of shocks. These 
burdens of illness could have impacted mood symptoms. The meta-analysis also included few 
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studies (e.g., one to six) per variable of interest likely compromising the ability to detect 
differences between groups. Due to the above outlined methodological confounds it is 
challenging to draw firm conclusions with respect to anxiety and depression in these comparison 
groups.  
 Shock is the most salient feature that distinguishes ICD treatment from all other cardiac 
therapies. Increased levels of anxiety have been observed in patients experiencing any shock 
(Carroll & Hamilton, 2005), ≥5 shocks (Herrmann et al., 1997; Irvine et al., 2002; Luderitz et al., 
1993), and shock storms (Redhead et al., 2010). A correlation between the increased number of 
shocks and depression has been reported (Dougherty, 1995). However, discrepant findings from 
earlier studies indicated no difference in depression symptoms between shocked versus no-shock 
groups (Bilge et al., 2006; Burke et al., 2003). Notably, the older meta-analysis which found no 
differences between patients who received ICD shocks and those who did not, compared patients 
who received no shocks versus at least one shock and excluded studies which compared shock 
frequencies (e.g., 0-4 shocks versus >5; Burke et al., 2003). Studies that did not take into account 
the frequency of ICD shocks received, might have undermined the sensitivity to detect an 
increased burden of shocks on symptoms of depression and anxiety. Generally, small to 
moderate differences are reported across studies of higher anxiety scores in patients who 
experience shocks as compared to those who do not (Magyar-Russell et al., 2011). Negligible to 
moderate differences are also reported between shocked and non-shocked patients on meeting 
criteria for clinically elevated or diagnosable levels of depression (Magyar-Russell et al., 2011). 
This suggests that shocks, especially frequent shocks, might add to the VT and psychological 
burden in ICD patients. As with the above discussed prevalence rate ranges, several factors 
might impact the discrepant findings related to shocks. Older studies appear to show greater 
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association between shocks and anxiety. This is perhaps not surprising given that patients would 
more likely have been secondary ICD recipients, had invasive thoracotomy procedures, and 
increased incidence of shocks both appropriate and inappropriate. Measures and cut off levels 
used for diagnosing mood symptoms vary among studies and might provide inconsistent 
findings. While variance exists in how shocks impact anxiety and depression, their effect can be 
profound. Even if diagnosable levels of anxiety and depression are not reached, the experience of 
shocks can impact psychological health at sub-clinical levels. Thus assessing the impact of shock 
burden in this population is important.     
There is a paucity of studies examining depression and anxiety in ICD patients 
undergoing a VT ablation procedure. As noted previously, only one recent RCT of ICD 
recipients randomized to escalated antiarrhythmic treatment or ablation therapy assessed 
HRQoL, depression and anxiety as a secondary outcome (Gula et al., 2018; Sapp et al., 2016). At 
baseline, three, six, 12-months and annual follow-ups, patients completed the Medical Outcomes 
Study Questionnaire (SF-36), ICD Concerns questionnaire (ICDS), Hospital Anxiety and 
Depression Scale (HADS), and EuroQoL (EQ-5D) questionnaires. Of the patients enrolled in the 
main VANISH trial (N = 259), 237 completed the above HRQoL questionnaires at baseline. At 
the six- and 12- month follow-ups, 195 and 175, respectively, completed the HADS. No 
between- or within-group differences were observed on the outcome measures of anxiety and 
depression over time (Gula et al., 2018). The limitation of this VANISH substudy was that both 
subgroups had subclinical scores on depression at baseline. It is possible that the floor effect may 
have been operating which made it difficult to detect between-group differences. No other 
baseline differences were observed. When looking at trends within further subgroups of this 
study, anxiety improved from baseline to six-months in escalated therapy patients who did not 
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receive shocks but worsened in escalated therapy patients who received shocks. This study is 
important as it is the only RCT of cardiac ablation therapy in ICD recipients to measure 
psychological outcomes. However, confidence in the results is undermined by several factors. 
Response and attrition rates related to the anxiety and depression questionnaire might impact 
confidence in the results particularly at the 12-month follow-up. Analyses utilized participants 
who completed the baseline questionnaire and at least one other follow-up questionnaire. As 
such, it is likely that the longitudinal analyses comprised slightly different samples of 
participants across the various time points. Furthermore, the authors indicated that most 
participants received a shock prior to randomisation. However, it is unclear whether the ablation 
participants, who completed the questionnaires, had greater VT burden or greater number of 
shocks at baseline as compared to the control group. This was not controlled for in the linear 
mixed-effects modelling for the outcome measures. It also appears that participants randomized 
to the ablation group experienced fewer shocks during the follow-up period as compared to the 
control group. However, it is unclear whether this was a significant difference. While this study 
has important strengths such as the RCT design, large sample size, and use of validated 
psychological measures, the factors outlined above might compromise the confidence in findings 
related to anxiety and depression outcomes.  
While the range of anxiety and depression symptoms varies, data suggests that the 
prevalence rate for both is high at approximately 20% (Magyar-Russell et al., 2011). Moreover, 
the life-saving shock therapy delivered by the ICD is associated with anxiety and depression 
particularly when repeated shocks are experienced. Since the VT ablation procedure aims to 
reduce arrhythmia and shock burden it is reasonable to hypothesize that it can, through reduction 
of shock burden, ameliorate symptoms of anxiety and depression in this population of ICD 
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recipients. This study aimed to assess whether undergoing a VT ablation is associated with a 
reduction in symptoms of anxiety and depression.  
Health-related quality of life. The World Health Organization defines health as “a state 
of complete physical, mental and social well-being, and not merely the absence of disease and 
infirmity” (World Health Organization, 2014). It is this definition upon which the term HRQoL 
relies as well as the assessment of physical, mental, and social functioning (Moons, Budts, & De 
Geest, 2006). Quality of life (QoL) refers to the satisfaction with life (Moons et al., 2006), 
whereas health status is the “impact of disease on patient function as reported by the patient” 
(Rumsfeld, 2002, p. 5). Although these terms are often used interchangeably, they are distinct. 
Thus, HRQoL is the QoL consequences of health status (Healthy People 2020).  
Across large RCTs which examined HRQoL in ICD recipients versus those treated with 
medication alone results have been inconsistent. One seminal RCT reported significant 
improvement in HRQoL in ICD recipients but not in the medication group (Irvine et al., 2002). 
Conversely, other studies reported benefits to longevity but not HRQoL (Noyes et al., 2007) or 
similar trends in HRQoL between the two groups (Passman et al., 2007; Schron et al., 2002). 
Another RCT concluded that while improved psychological HRQoL is observed at three and 12-
months post implant, as compared to those on medication alone, benefits are no longer detectable 
at 30-months follow-up (Mark et al., 2008). The varied findings might be explained by 
differences in several characteristics of the studies. These RCTs varied in the patient populations 
recruited (e.g., heart failure patients, primary versus secondary ICD recipients), whether they 
statistically assessed health of patients during the follow-up period (e.g., measuring development 
and impact of congestive heart failure), the types of measures administered (e.g., health utility 
index, health status, or heart failure-specific questionnaire), attrition rates, and years of data 
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collection (i.e., inherently differentiating between recipients of older generation ICDs as opposed 
to newer more sophisticated models).  
There is more consistency with respect to findings of the impact of ICD shocks on 
HRQoL. Specifically, differences are often not observed until ICD shocks are experienced and 
accounted for. Studies which show improvement in HRQoL point out that these benefits are not 
observed in patients who received five or more shocks (Irvine et al., 2002). Similarly, 
experiencing one or more shocks (Passman et al., 2007; Schron et al., 2002) as well as three or 
more (Schron et al., 2002) is associated with a decrease in HRQoL. Clinically noticeable effects 
are more apparent when patients receive five or more shocks (Passman et al., 2007) highlighting 
the uniquely taxing nature of this stressor particularly when it is repetitive. Emphasizing the 
above, a recent systematic review concluded that an association exists between reduced HRQoL 
and the number and recency of shocks but that the nature of this association is unclear (Tomzik, 
Koltermann, Zabel, Willich, & Reinhold, 2015). The authors concluded that repeated shocks 
might impact the individual’s perception of his/her health in a negative way or that patients who 
are sicker, and thus have a lower HRQoL, might be more affected by shocks (Tomzik et al., 
2015). Taking together this body of research suggests that ICD therapies and specifically shocks 
can significantly impact an individual’s well-being. As VT ablation aims to reduce shock 
incidence it is important to consider if VT ablation similarly has a positive effect on patients’ 
HRQoL.  
Several studies to date have examined HRQoL in VT ablation patients in comparison to 
those treated with escalated antiarrhythmic therapy as a secondary outcome. While findings 
remain inconclusive and between-group differences are typically not detected, there is evidence 
to suggest improvement in HRQoL within the ablation groups. An older prospective study 
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examined the impact of VT ablation in 21 patients with coronary artery disease (Strickberger et 
al., 1997). All patients received multiple ICD shocks or ATPs, had a previous MI, and were on 
anti-arrhythmic medication. Utilizing an ICD-specific HRQoL measure (i.e., The Index of 
Subjective Concerns for People with ICDs; Vitale & Funk, 1995), significant improvement was 
reported following a successful ablation but not after an unsuccessful one (Strickberger et al., 
1997). Results should be interpreted with caution due to the small sample size and lack of control 
group. Moreover, the study was published over twenty years ago and advancements have been 
made in both the ablation procedure and ICD device. Refinement in ICD programming means 
that fewer people receive shocks and the techniques and invasiveness of the ablation procedure 
has evolved significantly. A more recent study randomized patients with VT and history of MI to 
receive an ablation prior to an ICD implant or to receive an ICD alone (Kuck et al., 2010). No 
between-group differences were found. However, at the 12-month follow-up, ablation patients 
had higher scores in six of eight SF-36 subscales (physical functioning, role-physical 
functioning, bodily pain, vitality, role-emotional functioning, mental health). Similarly, at 24 
months they had higher scores in seven subscales (same as at 12 months with the addition of 
general health subscale). Importantly, the response rate to the SF-36 questionnaire was low. Of 
the total 107 patients recruited (n = 52 ablation, n = 55 control), 94 completed the baseline 
questionnaire. At 12 months, 54 (57%) of participants, and at 24 months 30 (56%) completed the 
questionnaire. Thus, it is possible that the small sample size and low response rates compromised 
the statistical power to detect significant between-group differences. Participants in this study 
had only experienced a first episode of stable VT after the MI rather than the more serious events 
of a cardiac arrest, ventricular fibrillation or ICD shocks prior to the ablation. Thus, the 
psychological impact of VT burden may be very different than in those patients who experienced 
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these more serious arrhythmia events. This perhaps rendered it more difficult to detect a benefit 
from the ablation procedure. Lastly, the substudy of the VANISH trial hypothesized that an 
improvement in HRQoL would be observed in the ablation group by reducing the anxiety 
associated with the anticipation of arrhythmia symptoms or ICD shocks (Gula et al., 2018). Most 
patients enrolled received a shock prior to recruitment. Of the 259 patients enrolled in the main 
VANISH trial, 237 completed the baseline HRQoL questionnaire. At six- and 12-months, 198 
and 178 completed questionnaires, respectively. No between-group differences were detected on 
any of the measures between the ablation and medication only groups. However, within-group 
analyses indicated that at six-months the ablation group improved on social functioning (not 
significant at 12-months) and energy/fatigue domains of the SF-36, had a reduction in ICD 
concerns (significant at 12-months), as well as significant improvement in overall health based 
on the EQ-5D visual analog scale (not significant at 12-months). While the improvement in 
social functioning did not reach conventional levels of significance at 12-months, the subscale 
score is very similar as compared to the score at six-months (68.9 vs. 69.3, respectively), and 
thus the statistical test might have been undermined by the reduced sample size at 12-months. It 
is also possible that there was a slightly different assortment of patients in the six- and 12-month 
analyses contributing to inconsistencies in the statistical results between the two time points. The 
escalated antiarrhythmic therapy group did not see improvements in HRQoL but did have a 
reduction in ICD concerns at six-months (not significant at 12-months). The lack of sustained 
significance suggests that the ICD concerns worsened somewhat from six to 12 months in the 
medication group. This perhaps implies that with time this group of patients might have a re-
emergence of ICD-related concerns. This pattern of effects is somewhat congruent with the 
observations made related to HRQoL, discussed above, and might hint at better HRQoL and 
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cognitive effects in the ablation group. These authors go on to suggest that the improvement in 
energy levels and decreased concerns about ICD shocks may suggest a confidence in the ablation 
procedure and a reduction in anticipation of further arrhythmia events. This RCT is important to 
consider in relation to the present study. However, confidence in findings might be affected by 
study limitations outlined in the discussion of depression and anxiety. In addition, the relatively 
small sample size could have compromised the ability to detect subtle differences. Lastly, the 
health status measure (SF-36) utilized as a proxy for HRQoL is an older version which did not 
provide composite scores; thus, changes in the overall physical and mental well-being did not 
appear to be assessed.   
While HRQoL findings are mixed it appears that ICD recipients who do not receive 
shocks benefit from better HRQoL as compared to patients treated with medication alone. 
However, this benefit is not observed in ICD patients who receive shocks. Interventions such as 
the VT ablation procedure are intended to help reduce the frequency of shocks and VT burden. 
Given their novelty, it is important to assess whether they lead to improvement in well-being, 
particularly in this population that is at risk for deterioration of HRQoL. Lastly, studies 
conducted to-date which assessed HRQoL associated with VT ablation yield ambiguous results. 
This underscores the need for further investigation and highlights the importance of including 
HRQoL as an outcome measure when assessing the health effects of VT ablation in this 
population of ICD patients.  
Predictors of psychological outcomes 
Not all patients demonstrate improved psychological and HRQoL outcomes in 
association with arrhythmia treatments. Cardiac variables, such as ICD shocks, only explain part 
of the variance in these outcomes. Studies of ICD recipients suggest that psychological factors 
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might render some individuals vulnerable to poorer psychological and HRQoL outcomes. It is 
thus important to address the psychological predictors of PTSD, depression, anxiety and 
HRQoL. For example, an abstract reporting on drug-refractory atrial fibrillation patients 
undergoing a catheter ablation noted improvements on measures of anxiety and depression 
(Irvine, Baker, et al., 2010). While there was a reported high prevalence of elevated anxiety, 
regression models revealed that the improvement in anxiety and depression following the 
ablation procedure was associated with an optimistic outlook rather than with the objective 
success of the ablation. Similarly, low optimism and greater symptom preoccupation at baseline 
were associated with depression at follow-up (Khaykin et al., 2010). Moreover, it is important to 
assess predictors of PTSD, as symptoms of PTSD may have implications for treatment adherence 
and health. Taken together, it is important to assess factors which may mitigate the psychological 
outcomes in ICD recipients as this population of individuals can be particularly unwell and at 
risk for deterioration of physical and mental functioning. Independent variables included in this 
study were measures of optimism, positive health expectations, and self-efficacy. Each is 
reviewed below to better situate study hypotheses. 
Optimism and positive health expectations. Positive psychological factors such as 
optimism and positive health expectations have been shown to predict better health outcomes in 
cardiac patients (Barefoot et al., 2011; Leedham, Meyerowitz, Muirhead, & Frist, 1995; Scheier 
& Carver, 1992). Optimism is conceptualized as a personality trait or disposition, reflecting a 
somewhat generalized tendency to expect that good things, rather than bad outcomes, will 
happen across different facets of every-day life, and this characteristic can play a role in self-
regulation of behaviour (Carver, Scheier, & Segerstrom, 2010; Scheier & Carver, 1985). The 
construct of positive health expectations has been conceptualized as one’s beliefs related to the 
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likelihood of positive health outcomes (Leedham et al., 1995). Positive expectations have been 
associated with reduced risk of depression onset and lower levels of depressive symptoms 
(Kleiman et al., 2017). Optimism and positive health expectations together have been suggested 
to provide a sense of coping and control for ICD patients when faced with the uncontrollable 
aspects of their arrhythmia or ICD shocks (Sears et al., 2004).   
Generally, research on optimism suggests that it serves an important function in enabling 
optimists to adapt to a number of different life stressors (Rauch, Defever, Oetting, Graham-
Bermann, & Seng, 2013). Low optimism has been associated with unhealthy mental and physical 
health outcomes (e.g., depression and increased frequency/intensity of somatic complaints; 
Scheier & Carver, 1992). Conversely, optimistic individuals have been found to be less anxious, 
less depressed, and have fewer physical symptoms (Zeidner & Hammer, 1992). Individuals 
reporting greater optimism often employ more adaptive active coping strategies, as opposed to 
avoidance, which draw upon social support and positive aspects of stressful situations. It is 
through this mechanism that optimism has been suggested to exert a positive impact upon quality 
of life and psychological well-being (Carver et al., 2010; Conversano et al., 2010; Rauch et al., 
2013). Optimism has also been conceptualized as a potential predictor for problematic responses 
to trauma (Rauch et al., 2013). In a sample of rescue workers, it was associated with less distress 
at 12 months but not necessarily to the change in distress over time (Dougall, Hyman, Hayward, 
McFeeley, & Baum, 2001). Similarly, higher optimism has been related to lower levels of PTSD 
in a sample of pregnant women (Rauch et al., 2013) and lower levels of depression, anxiety, and 
PTSD post natural disaster (Carbone & Echols, 2017). A composite of resilience factors, 
including optimism, has been associated with trauma where greater resilience predicted 
decreases in PTSD in a sample of cancer survivors (Campo, Wu, Austin, Valdimarsdottir, & 
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Rini, 2017). Not only has optimism been associated with trauma, but it has also been found to 
impact general well-being. For example, in a sample of HIV positive men, optimism positively 
influenced both mental and physical health (Taylor, Kemeny, Reed, Bower, & Gruenewald, 
2000). When faced with a traumatic life-threatening disease, optimism can act as a buffer and 
help the individual cope with the intensely stressful life-threatening events (Taylor et al., 2000). 
By employing fewer avoidant coping strategies, typically seen in individuals presenting with 
PTSD, optimistic individuals might have a buffer against traumatic stress (Rauch et al., 2013). 
This kind of coping can further buffer against hopelessness and thus low mood. For instance, as 
compared to pessimistic individuals, those who scored higher on optimism were found to have a 
higher internal locus of control and lower scores on measures of hopelessness, depression, and 
perceived stress (Scheier & Carver, 1985). When faced with obstacles, optimistic individuals 
were more likely to feel capable of coping with them and reported being less bothered by 
physical symptoms (Scheier & Carver, 1985). More specific to cardiac patients, pre-surgical 
optimism was associated with mental and physical HRQoL but not mortality post heart 
transplant (Jowsey et al., 2012). Lastly, in a sample of acute coronary syndrome patients, 
optimism was found to predict better physical health status and reduced risk of depression at 12 
months (Ronaldson et al., 2015).  
In ICD patients, dispositional optimism has been highlighted as an important construct 
which can promote the utilization of problem-focused coping strategies (e.g., information 
seeking) which have been found to be effective in this population (Dunbar, 2005). Optimism has 
also been proposed as a covariate for better psychological outcomes in ICD patients who receive 
shocks (Dunbar, 2005). Specifically, higher optimism at implant has been associated with better 
mental health functioning and social functioning over the short-term follow-up, a finding which 
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approached significance at long-term follow-up (Sears et al., 2004). An RCT examining a web-
based intervention for distress management in first-time ICD recipients reported that higher 
baseline optimism was associated with lower anxiety and depression at 12-month follow-up after 
controlling for demographic, psychological, and clinical variables (Habibović et al., 2018). This 
relationship, however, was no longer significant after baseline anxiety and depression scores 
were added as covariates to the regression model. Higher baseline optimism was also associated 
with physical and mental health status at 12-months only the latter of which remained significant 
when its baseline value was added as a covariate. These authors concluded that optimism is 
linked to the mental health status and distress scores at the 12-month follow-up but not to the 
change in distress and health status over time.   
Similarly, positive expectations can help predict psychological adjustment in health 
populations (Carver et al., 1993; Scheier & Carver, 1992; Sears et al., 2004) although there are 
some discrepant findings (Habibović, Pedersen, Van Den Broek, & Denollet, 2014). Such 
situation-specific expectations can impact mood even when complications arise. For example, 
self-reported positive health expectations were associated with positive mood, adjustment to 
illness, and HRQoL, in heart transplant patients even when complications post surgery and 
setbacks in health were experienced (Leedham et al., 1995). More specifically, positive health 
expectations were negatively correlated with mood disturbance. In a study of patients undergoing 
coronary angiography, positive recovery expectations at baseline were positively associated with 
long-term survival and functioning after controlling for relevant clinical, psychological, and 
demographic variables (Barefoot et al., 2011). A similar trend has been observed in ICD 
recipients, such that high positive health expectations at baseline were associated with better 
satisfaction with general health at long-term follow up (Sears et al., 2004). This suggests that 
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individuals with high positive health expectations might view their ICD implant and its value 
differently than those with low positive health expectations (Sears et al., 2004). Conversely, an 
RCT aimed at reducing distress in ICD recipients, reported that positive expectations were not 
related to any of the distress outcomes measured after adjusting for demographic and medical 
variables (Habibović et al., 2014). However, negative treatment expectations were associated 
with higher levels of anxiety, depression, and concerns related to the ICD at three-months post 
implant. Similarly, in a small sample of individuals undergoing cardiac surgery negative illness 
beliefs predicted a worsening of physical functioning and depressive symptoms three-months 
post surgery (Juergens, Seekatz, Moosdorf, Petrie, & Rief, 2010). With this in mind, the present 
study examined optimism and positive expectations as predictors of psychological well-being in 
our sample of ICD patients and their impact on adapting to arrhythmia treatments.  
Self-efficacy. Social cognitive theory conceptualizes self-efficacy as a set of specific 
beliefs in one’s own capabilities to perform certain behaviours in order to attain a desired 
outcome within a distinct realm of functioning (Bandura, 1977, 1997). It further highlights self-
efficacy as an important mediator of behaviour change and suggests that the stronger the sense of 
efficacy the greater the likelihood that a given activity will ultimately be performed successfully 
(Bandura, 2006). Accordingly, self-efficacy is a cognitive mechanism which helps mediate 
behaviour, guides participation in activities as well as the effort and persistence in pursuing a 
given activity despite challenges (Du, Everett, Newton, Salamonson, & Davidson, 2011). Self-
efficacy is typically influenced by several sources of information which are related to: 1) past 
and present successful performances and thus mastery (e.g., which serve as indicators of ability, 
offer possibility of refining coping skills), 2) observing behaviour of others (e.g., someone who 
can demonstrate effort and mastery in similar situations), 3) verbal influences (e.g., receiving 
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positive feedback from experts regarding behaviours), and 4) the person’s perception of his/her 
physiological and emotional state, for example interpreting physiological response to anxiety, 
such as increased heart rate, as informative about his/her vulnerability to stress and ability to 
perform given behaviours where those with higher self-efficacy might interpret the physiological 
response as innocuous rather than as a threat (Bandura, 1977, 1997; Dougherty, Johnston, & 
Thompson, 2007; Houston Miller & Barr Taylor, 1995). Thus, self-efficacy is a perceived ability 
to manage personal functioning in a diversity of situations or events. As such, an individual’s 
self-efficacy expectations vary depending on a particular task or situation (Bandura, 1997; 
Dougherty et al., 2007). Most importantly perhaps, it is important to recognize the role of the 
individual as an active agent in the management of his/her own condition with the recognition of 
the central role of self-efficacy to this human agency (Bandura, 1997; Benight & Bandura, 
2004). Moreover, self-efficacy beliefs help regulate the way individuals “function through 
cognitive, motivational, affective and decisional processes” (Benight & Bandura, 2004, p. 1131). 
These beliefs, in turn, factor into whether the individual thinks in ways that are self-enhancing, 
what motivates him/her when faced with adversity or difficulties, the degree to which he/she 
experiences vulnerability to stress and depression, and resilience to adversity. Thus, a person’s 
belief in his/her ability to exercise some control over a situation when faced with stressors helps 
promote a person’s resilience to them. 
Indeed, higher self-efficacy has been shown to be positively associated with behavioural 
and emotional responses in health populations. It is associated with cardiac lifestyle changes 
(Evon & Burns, 2004; Ha, Hare, Cameron, & Toukhsati, 2018), participation in cardiac 
rehabilitation (Grace et al., 2002), responses to traumatic situations (Benight et al., 1997), 
increased adherence to treatment, self-care behaviours and fewer physical and mental health 
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symptoms. In their review of the role of self-efficacy in posttraumatic recovery, Benight and 
Bandura (2004) emphasized the enabling and protective function of one’s belief in his/her ability 
to exercise some control over adversity that arises. Self-efficacy is further highlighted as playing 
a key role in stress reactions and the quality of coping in threatening situations. Studies have 
examined self-efficacy in relation to trauma, depression, and anxiety and generally report an 
inverse relationship between these constructs. In a sample of veterans, self-efficacy was a 
significant predictor of PTSD and depression such that higher self-efficacy was associated with 
lower severity of symptoms (Blackburn & Owens, 2015). A recent trauma-recovery intervention 
study aimed at enhancing self-efficacy and reducing PTSD reported changes in coping self-
efficacy to be negatively correlated with changes in trauma symptoms (Benight, Shoji, Yeager, 
Weisman, & Boult, 2018). Similarly, low perceived self-efficacy was a predictor of PTSD 
following the exposure to violence at the short, medium, and long-term follow-up periods in a 
sample of assault victims (Johansen, Wahl, Eilertsen, & Weisaeth, 2007).  
Emphasizing Bandura’s concept, Dougherty et al., (2007) highlighted that when 
individuals are dealing with chronic illness, self-efficacy can help organize and integrate social, 
behavioural, and cognitive skills needed to address a variety of health-related situations. Coping 
with chronic disease and associated challenges requires the knowledge of specific skills, a belief 
that one can carry them out, and that they will produce desired outcomes (Dougherty et al., 
2007). Thus, one’s perceived self-efficacy can influence the effort that is expended when faced 
with obstacles and impact behaviour change and the maintenance of that behaviour. Indeed, self-
efficacy is suggested to be negatively associated with depression, anxiety, and helplessness in 
chronically ill individuals. Higher self-efficacy predicted greater psychological well-being in 
individuals with Type I and Type II diabetes (Eiser, Riazi, Eiser, Hammersley, & Tooke, 2001) 
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and lower depression in cancer survivors (Philip, Merluzzi, Zhang, & Heitzmann, 2013). 
Perceived self-efficacy to manage recovery following a hurricane predicted severity of PTSD in 
a sample of HIV positive men as well as healthy controls (Benight et al., 1997). Specifically, 
greater perceived self-efficacy was related to lower emotional distress and symptoms of PTSD 
and appeared to function in similar ways in both healthy and chronically ill men. In a sample of 
individuals with substance abuse, higher self-efficacy predicted lower depression and anxiety at 
follow-up (May, Hunter, Ferrari, Noel, & Jason, 2015). Similarly, higher levels of self-efficacy 
were correlated with lower psychological distress and better HRQoL in patients who had a MI or 
congestive heart failure (Joekes & Van Elderen, 2007). Regression analyses of the baseline data 
showed that higher self-efficacy was related to less anxiety and depression and better HRQoL. 
Self-efficacy, however, was no longer a significant predictor in the medium term follow-up when 
the baseline values of the outcome variables were controlled for (Joekes & Van Elderen, 2007). 
Attrition of patients over the follow-up period may have influenced the results at follow-up. This 
relationship has been shown to exist in the opposite direction as well where higher symptoms of 
PTSD and recurrence of illness have been associated with lower self-efficacy (Taylor, Absolom, 
Snowden, & Eiser, 2012). This highlights the complexity of the relationship between self-
efficacy and outcomes as well as the importance of controlling for disease burden factors when 
examining the relationship between self-efficacy and psychological outcomes. In summary, self-
efficacy is an important construct to assess as it can help ameliorate psychological well-being 
which in turn can promote the sense of increased self-efficacy.  
Taking together the aforementioned literature review, one aim of the present study was to 
examine self-efficacy as a predictor of PTSD, depression, and anxiety in this population. If an 
individual doubts his/her self-efficacy, his/her ability to cope lessens. Assessing self-efficacy as a 
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global trait, rather than in relation to a specific situation, has limitations since items on the self-
efficacy scale might not be reflective of the situation at hand and as such might have limited 
explanatory power (Bandura, 2006). Thus, this study adopted a self-efficacy measure specific to 
managing arrhythmia treatments to test the predictive validity of this construct. If we consider an 
unpredictable event such as cardiac arrhythmias, it is reasonable to postulate that lower self-
efficacy could lead to more distress. Benight and Bandura (2004) highlighted the impact of a 
sense of inefficacy to manage demands and exert control over ruminations on successful 
adaptation to adverse events. Much in the same way, if we consider that some patients feel 
incapable of having agency and confidence in their actions related to their arrhythmia and the 
associated treatments, it is reasonable to postulate that lower self-efficacy might be associated 
with greater distress. 
Control variables 
It is important to control for certain variables that can confound the interpretation of the 
results (Shaughnessy, Zechmeister, & Zechmeister, 2012). The present study aimed to control for 
the following cardiac variables: functional status as measured by the New York Heart 
Association (NYHA), left ventricular ejection fraction (LVEF), presence of ablation procedure, 
and occurrence of shocks. It also planned to use general life stress as a control variable. All of 
the control variables are discussed below.  
Functional status was measured by the NYHA. The NYHA has been reported to be 
associated with depressive symptoms. Heart failure patients with NYHA class III and IV had 
significantly more depressive symptoms than patients with class I and II (Rohyans & Pressler, 
2009). In this study, the most endorsed depressive symptom was feeling of tiredness or fatigue. 
NYHA could also be associated with self-efficacy. For example, limited activity and severity of 
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symptoms could undermine an individual’s self-efficacy to perform given behaviours and his/her 
belief in being able to manage his/her behaviour in different situations. Similarly, as done in past 
research, this study planned to control for LVEF, a global measure of cardiac functioning. LVEF 
has been associated with HRQoL outcomes (Sears et al., 2004).  
Shock from the ICD device has been shown to reduce HRQoL (Irvine et al., 2002) and 
has been associated with increased anxiety in ICD recipients (Bilge et al., 2006). In light of their 
unpredictable and uncontrollable nature, the experience of shocks may fulfill the criteria of a 
traumatic stressor for some individuals (Hamner et al., 1999) and thus be associated with an 
increased risk for PTSD. Research also suggests that patients can develop negative appraisals 
about the meaning and consequences of ICD shocks, viewing them as indicative of a 
deteriorating cardiac condition (Sears & Conti, 2002; Sears et al., 1999). Thus, in this study, the 
experience of ICD shocks could be associated with both the predictor variables (e.g. influence an 
individual’s positive expectancies related to his/her arrhythmia treatment, impacting his/her 
positive outcome expectancies and his/her positive health expectations) and outcome variables 
(i.e., HRQoL and psychological well-being). Accordingly, the number of ICD shocks was 
controlled for when testing the predictive effects of the psychological predictors. Similarly, this 
study controlled for the presence of an ablation procedure. Successful ablation has been 
associated with improved HRQoL, while this effect was not seen in unsuccessful ablation 
procedures (Strickberger et al., 1997). Ablation has also been associated with improved 
outcomes on symptoms of PTSD (Maryniak et al., 2006). Akin to ICD shocks, an individual’s 
understanding of the ablation procedure and his/her assessment of its success might be associated 
with positive outcome and health expectancies.  
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Lastly, perceived general life stress was planned to be used as a control variable in order 
to better isolate and illuminate the potentially traumatic and stressful effects of arrhythmia. Life 
stressors such as family discord, job loss, serious injury to a close relative or friend, and financial 
difficulties, among others, are realities of everyday life. Such stressors may interfere with 
psychosocial adjustment in patients with heart disease (Sears et al., 1999). In their allostatic load 
model, McEwen and Stellar (1993) argue that distress accumulates over multiple stressors and 
may contribute to the development and experience of posttraumatic stress. An amalgamation of 
life stressors is associated with a depression and anxiety (Slusarcick, Ursano, Robert, Fullerton, 
& Dinneen, 1999; Vinokur & Selzer, 1975) and HRQoL (Kreitler, Peleg, & Ehrenfeld, 2007). 
Similarly, an amalgamation of life stress might have an impact on one’s optimistic future outlook 
and his/her ability to handle daily occurrences. There is an association between life events and 
lower levels of perceived control (Cairney & Krause, 2008). Thus general life stress is associated 
with both predictor variables (e.g., self-efficacy) as well as with outcome variables (i.e., 
psychological well-being). 
To summarize, the present study planned to control for NYHA class, LVEF, ICD shocks, 
ablation, and life stress in the analyses of the hypotheses about the psychological predictors of 
psychological outcomes. 
Purpose 
Recurrent VT in patients with an ICD has been associated with increased mortality and 
poorer HRQoL (Irvine et al., 2002; Schron et al., 2002). Moreover, patients who experience 
appropriate shocks experience increased mortality compared to patients without shocks (Wilkoff 
et al., 2016). If VT ablation is indeed able to prevent VT recurrence, it is reasonable to 
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hypothesize that it might have an important role to play in alleviating or at least mitigating the 
burdensome psychological side effects of the ICD treatment.   
Given the inconsistency in psychological outcomes following ablation therapy, it is 
reasonable to explore whether differences in personality, outlook, and confidence might 
influence psychological outcomes. Given past research on the influence of these individual 
difference factors on health adaptation generally, it is important to explore their influence in 
predicting psychological wellbeing following VT ablation in ICD patients. Accordingly, the first 
aim of this prospective study was to examine predictors of psychological wellbeing in ICD 
patients presenting with VT. More specifically, this study aimed to examine whether self-
efficacy, optimism, and positive health expectations predict symptoms of PTSD, depression, and 
anxiety following VT ablation. The second aim was to evaluate whether catheter ablation of VT 
is associated with greater improvement in HRQoL compared to matched control ICD participants 
who did not undergo an ablation.  
This study employed a case-control design. The experimental group comprised ICD 
patients, who have previously experienced an ICD ATP and/or shock and who were scheduled to 
undergo VT ablation. A stipulation was made to recruit ablation patients either shortly before 
being scheduled for an ablation procedure, or within two months following the ablation 
procedure. The control group comprised ICD patients with a history of prior ICD shock and/or 
ATP but without VT ablation. The experimental and control groups were matched on: 1) gender, 
2) age (+/- five years), and 3) time since ICD implant (+/- six months, allow for +/-12 month 
time frame if no suitable match was available). All participants completed a battery of 
questionnaires at the time of recruitment (baseline) and at a six-month follow-up. Self-report 
measures assessed HRQoL, psychological functioning (PTSD, depression, anxiety), and cardiac 
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variables. Cardiac variables were extracted through chart-review (see the Methods and Results 
sections for additional details). The aim of this study was to provide, heretofore, unexplored 
insight into the predictors of psychological well-being and HRQoL following catheter ablation.  
 
Hypotheses 
1. The first set of hypotheses will test whether higher optimism, higher perceived self-
efficacy and higher positive health expectations at baseline predict improvement in 
symptoms of PTSD, depression, and anxiety at six-month follow-up. 
2. The second set of hypotheses will test whether HRQoL (global summary measures of 
health status and psychological well-being, i.e., anxiety, depression, and PTSD) improve 
more over six-months follow-up in ICD patients undergoing VT ablation compared to 
ICD patients who do not undergo VT ablation therapy. 
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Method 
 The present study design was an exploratory prospective case-control study. Participants 
were recruited from Toronto General Hospital (TGH) and St. Michael’s Hospital (SMH), both 
located in Toronto, Ontario. The study was approved by the research ethics board at York 
University, University Health Network, and SMH and has complied with the ethics protocols 
established by these three institutions. 
Participants 
Two groups of participants were recruited, both of which had documented history of 
cardiomyopathy/congenital heart disease, an ICD, and a documented history of ICD ATP and/or 
shock. One group of participants were undergoing an ablation procedure for the treatment of 
their VT. It was stipulated that these participants would be eligible for recruitment ranging from 
two weeks prior to their VT ablation up to two months following the ablation. In practice, 
majority of participants were recruited on the day of their ablation procedure. The second group 
of participants were matched-control participants who were not undergoing an ablation 
procedure for the management of VT.  
Because one of the aims of this study was to test HRQoL outcomes, it was important to 
try to recruit age- and sex-matched control patients. Matching criteria were: 1) sex, 2) age (+/-
five years), and 3) time since ICD implant (+/-six months or up to +/- 12 months if no suitable 
match was found within the six-month time frame). For Hypothesis 1 it was decided a priori to 
include all participants in the analyses regardless of whether they had an appropriate match – 
control coupling. Ultimately, matching participants on the above outlined criteria proved to be a 
challenge; thus, the data analyses for Hypothesis 2 also included all participants who were 
recruited rather than a subset of matched participants. For details regarding the data analysis, 
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please refer to the section below entitled Data Entry and Statistical Analyses as well as the 
Results section. Across participants, proficiency in spoken and written English was stipulated as 
an inclusion criterion.  
Exclusion criteria. Participants were excluded if they had a history of severe cognitive 
and/or hearing impairment and/or expressed an unwillingness or inability to participate. 
Undergoing >1 VT ablation during the study period was added as an exclusion criteria as the 
study was underway. 
Procedure 
Consistent with institutional ethics approvals, potential participants were identified by the 
study coordinator or by members of the electrophysiology team (i.e., VT coordinator, nurses, 
physicians, fellows, or ICD clinic nurses). Recruitment followed one of two procedures: face-to-
face recruitment or “remote” recruitment in instances where we were unable to meet the 
individual while he/she was hospitalized or attending his/her clinic visits. For face-to-face 
recruitment, the potential participant was introduced to the study by the EP team and was 
approached by study coordinator either at the time of his/her clinic visit or while he/she was 
admitted to the cardiology ward for the purposes of a VT ablation procedure. The individual was 
provided with the Information Letter (Appendix A) which explained the study. If the individual 
expressed interest in participating in the study after reading the Information Letter, he/she was 
then provided with the Informed Consent Form (Appendix B and C). At that time, the study was 
explained in detail and any questions or concerns were addressed. Upon completing informed 
consent, the Baseline Questionnaire (Appendix D) was provided to the participant along with a 
stamped, self-addressed envelope which he/she used to mail back the completed questionnaire. 
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Alternatively, if the participant was hospitalized for several days, he/she often completed the 
questionnaire while in hospital and a time was arranged for the questionnaire to be picked up.  
Remote recruitment occurred if the potential participant was not approached on the day 
of his/her clinic visit or while he/she was hospitalized due to time constraints or scheduling 
conflicts. Thus, for remote recruitment potential participants were contacted by telephone 
initially by a member of his/her EP team (e.g., nurse, fellow). That individual was then asked if 
he/she would like information about the study and, if so, whether the study coordinator could 
contact him/her. If he/she expressed interest in the study, the study coordinator mailed out a 
complete study package including the Information Letter (Appendix A), the Informed Consent 
form (Appendix B), and the Baseline Questionnaire (Appendix D), as well as a stamped, self-
addressed envelope which the individual could use to mail back the questionnaire package. 
Approximately a week after mailing the package to the individual, the coordinator contacted 
him/her to review the consent form and answer any questions or concerns.  
Data collection. Questionnaires assessing psychosocial functioning were administered at 
recruitment (Baseline Questionnaire – Appendix D) and at six-months follow-up (Follow-Up 
Questionnaire – Appendix E). The package provided at the time of recruitment included the 
Information Letter (Appendix A), Consent Form (Appendix B), and Baseline Questionnaire 
(Appendix D). The package provided at the time of follow-up included a Thank You Letter 
(Appendix F) and a Follow-up Questionnaire (Appendix E). Each questionnaire package took 
approximately 30 – 45 minutes to complete. In instances where questionnaires were mailed out, 
participants were provided with a self-addressed, pre-stamped envelope. A week after mailing 
the questionnaire, the study coordinator telephoned the participant to assist with any questions or 
concerns they may have had about the study. At that time, participants were also encouraged to 
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return the questionnaire at their earliest convenience preferably no later than three weeks after 
receiving the package. If the participant did not return the questionnaire within the time-frame 
specified, he/she was contacted with up to three reminder telephone calls. Participants were free 
to withdraw from the study at any point in time. 
In addition to assessing psychosocial functioning, general demographic data (i.e., living 
situation, level of education) were collected by way of self-report which was built into the 
questionnaires. Similarly, participants reported on several variables related to their arrhythmia 
treatment, namely whether or not they had an ablation, if they did have VT ablations how many 
were deemed successful, the number of ICD shocks they had, whether they experienced phantom 
shocks, as well as any antiarrhythmic, sleep, or psychotropic medications they were taking.  
Demographic and cardiac measures. The patient’s medical chart was reviewed (paper 
chart and/or the electronic patient record chart) by a member of our research team in order to 
extract relevant demographic and cardiac variables. The collection of general medical and 
cardiovascular information was performed in consultation with the electrophysiologists and 
electrophysiology fellows. The following variables were extracted: cardiac diagnosis, left 
ventricular ejection fraction (LVEF) at the time of recruitment, month and year of the ICD 
implant, reason for ICD implant (primary vs. secondary prevention), number of objectively 
recorded ICD shocks and ATPs, presence of phantom shocks (i.e., a patient’s report of having 
experienced a shock without objective evidence of having received one), additional ICD 
procedures (e.g., pulse generator replacement, pocket revision), and prescribed medications. In 
addition to the above, for ablation patients the following data were extracted related to the VT 
ablation: presence and date, ablation procedure approach (i.e., substrate, activation), outcome of 
the ablation (i.e., successful, not successful, partially successful), and complications. These 
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variables are logged routinely in participants’ charts. In order to capture participation rates and 
characteristics of eligible patients, basic demographic data were logged for patients who were 
approached. The patient’s NYHA was obtained from the participant upon his/her consent to 
participate.  
To maintain confidentiality, participants who consented to participate were assigned a 
study identification code. No personal data (e.g., names, full dates of birth) were utilized in the 
questionnaires. Completed questionnaires were stored separately from the consent forms and all 
paper files were kept within a double-locked cabinet in a locked office. Electronic data files were 
password protected and stored on an encrypted hospital computer which used a secure server.  
Outcome measures 
Hospital anxiety and depression scale (HADS). The HADS (Zigmond & Snaith, 1983) 
is widely used for measuring symptoms of anxiety and depression among medical inpatients, 
outpatients, and in the general population (Bjelland, Dahl, Haug, & Neckelmann, 2002). The 
HADS is a 14-item questionnaire that measures symptoms of anxiety (seven items) and 
depression (seven items). For each item, the participant is asked to select a response from four 
possible choices (scored from 0 to 3) that best describes how he/she has been feeling over the 
past week. The HADS yields anxiety (HADS-A) and depression (HADS-D) subscale scores. In 
general, the psychometric properties of the HADS are excellent. Internal consistency for HADS-
A and HADS-D show Chronbach’s alpha coefficients between 0.80-0.93 and between 0.81 and 
0.90, respectively (Bjelland et al., 2002; Herrmann, 1997). Concurrent validity of the HADS is 
very good with strong correlation coefficients (0.62 - 0.73) for HADS-D with other well-
validated depression scales (e.g., Beck Depression Inventory, SCL-90 Depression subscale) and 
strong correlation coefficients (0.49 - 0.81) for HADS-A with well-validated anxiety measures 
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(e.g., Spielberger State-Trait Anxiety Inventory, SCL-90 Anxiety subscale; Bjelland et al., 2002; 
Herrmann, 1997). A score of ≥8 on either subscale is suggestive of “caseness,” a probable 
presence of an anxious or depressive state. HADS is reported to be sensitive to changes resulting 
from disease progression and therapeutic interventions. It takes between 2 and 5 minutes to 
complete (Snaith, 2003). The HADS-A and HADS-D subscale scores range from 0-21 (used as 
continuous scores) and were used as outcome measures for both Hypothesis 1 and Hypothesis 2.  
Impact of Event Scale – Revised (IES-R). The IES-R (Weiss, 2004) was administered 
to assess symptoms of post-traumatic stress disorder (PTSD). The IES-R is a 22-item self-report 
measure comprising three subscales: avoidance, intrusion, and hyperarousal. On a 5-point scale 
(0 = not at all to 4 = extremely), respondents are asked to indicate the degree of distress they 
experience. Subscale scores are computed as the mean of the responses for the items on a given 
subscale. Weiss (2004) stipulates that there is no defined “cut-off” score for this measure nor that 
such a score was envisioned or would be inappropriate as this measure is intended to provide an 
assessment of symptomatic status over the previous week which arises in response to a traumatic 
event. However, a guideline score of 1.5 was found to be the optimal threshold for diagnostic 
significance in a sample of Vietnam veterans seeking treatment for PTSD (Creamer, Bell, & 
Failla, 2003). This cut-off score was suggested to help provide diagnostic accuracy against 
another measure of trauma (the PTSD Checklist; PCLC). IES-R demonstrates high internal 
consistency (alpha = 0.96) and good validity (Creamer et al., 2003). For the purpose of this 
study, the IES-R administration instructions were altered slightly in order to standardize the 
nature of the stressor. Participants were asked to complete the questionnaire “with respect to 
your arrhythmia (i.e., heart rhythm problem) or its treatment (i.e., having an implantable 
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cardioverter defibrillator or ablation).” The IES-R takes approximately 5 minutes to complete. 
The total score as well as the subscale scores were used as outcome measures. 
Short Form Health Survey (SF-36). The SF-36 Health Survey, the short form of the 
Medical Outcomes Study questionnaire, can be self-administered and takes 5-10 min to complete 
(Mcdowell, 2006). The SF-36 is a measure of perceived health-status often used as a proxy for 
HRQoL. It covers eight dimensions of physical and mental health: physical functioning, role 
limitations due to physical health problems, bodily pain, general health, vitality (energy/fatigue), 
social functioning, role limitations due to emotional problems and mental health (psychological 
distress and psychological well-being; Maruish, 2011). The SF-36 also yields two component 
summary scores: the mental component summary (MCS) and the physical component summary 
(PCS). The psychometric properties of the SF-36 are excellent. The mean Chronbach’s alpha 
coefficient for the internal consistency of all scales is 0.84 (Mcdowell, 2006). The SF-36 has also 
been shown to be sensitive to change in health status over a 12-month time period (Mcdowell, 
2006). A license for the SF-36 was purchased and provided the scoring of participant responses. 
The component summary scores were employed as outcome measures in testing Hypothesis 2.  
Predictor measures 
The Life Orientation Test (LOT). The LOT (Scheier & Carver, 1985) is an eight-item 
questionnaire measuring dispositional optimism. It contains an additional four ‘filler’ items to 
disguise the purpose of the measure. Participants are asked to complete the questionnaire by 
answering to what extent they agree with each item (0 = I agree a lot, 1 = I agree a little, 2 = I 
neither agree nor disagree, 3 = I disagree a little, and 4 = I disagree a lot). Four of the items are 
worded positively (Items: 1, 4, 5, 11) and four are worded negatively (Items: 3, 8, 9, 12). The 
LOT yields a total score as well as two factors -- one representing optimism and the other 
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representing pessimism (Scheier & Carver, 1985). The LOT has good internal consistency 
(Cronbach’s alpha = 0.76), and good stability over time (test-retest reliability for a four-week 
interval = 0.79; Scheier & Carver, 1985). Scores for positively worded items were reverse coded. 
All of the items are summed to yield an overall dispositional optimism score (range: 0-32), with 
higher scores reflecting a more optimistic disposition, and this score was used as a predictor 
measure in the test of Hypothesis 1.  
Positive Health Expectations (PHE). The PHE scale (PHE; Leedham et al., 1995) is 
comprised of seven items. It was derived from a Quality of Life Scale and measures the patient’s 
expectations regarding health outcomes. Specifically, the PHE measures beliefs about the 
efficacy of the patient’s treatment, chances for future health and survival, and the individual’s 
more general feelings about the self and the future. The PHE has good internal validity 
(Cronbach’s alpha = 0.81) as well as good internal reliability. The PHE demonstrates good 
convergent validity and is positively associated with HRQoL scores (Leedham et al., 1995). It 
also shows good divergent validity, being negatively associated with mood disturbance scores 
(POMS), and predictive validity (at six-month follow-up) with physical health measures. 
Participants responded to each item on a 7-point Likert scale (range: 7 to 49) where higher scores 
indicated a more positive outlook on health (Leedham et al., 1995). 
Self-Efficacy. Self-efficacy reflects a specific belief and confidence in one’s own ability 
to manage personal functioning in a diversity of situations. Thus, self-efficacy expectations will 
vary depending on a particular task (Dougherty et al., 2007) and measures capturing self-efficacy 
must be specific to the situation being examined (Bandura, 2006). For the present study, the 
Dougherty and colleagues' (2007) measure of self-efficacy, developed in a sample of ICD 
recipients, was adapted in order to capture self-efficacy related to “arrhythmia treatments” rather 
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than to the ICD only. Dougherty et al., (2007) developed two measures – the Self-Efficacy 
Expectations After ICD Implantation Scale (SE-ICD) and the Outcome Expectations After ICD 
Implantation Scale (OE-ICD). Only the adapted version of SE-ICD was used for the present 
analyses (Hypothesis 1). The SE-ICD was originally a 16-item scale where eight items measured 
self-efficacy expectations and eight items measured behaviours required to manage problems 
after the ICD implant following a self-efficacy-based intervention. The SE-ICD showed good 
internal consistency (Cronbach’s α = 0.93) and was responsive to change over time (Dougherty 
et al., 2007). The SE-ICD was adapted and revised into two parts: “Managing Arrhythmia 
Treatments I; MAT I” which captured self-efficacy expectations and “Managing Arrhythmia 
Treatments II; MAT II” which captured the health-management behaviours. MAT II was only 
administered at follow-up since participants needed to have the experience of living with an 
arrhythmia treatment in order to adopt certain behaviours. For Hypothesis 1, MAT I was used as 
a predictor variable. MAT I comprised six items since two questions were removed (one 
regarding driving restrictions and one regarding environmental hazards) both of which pertained 
only to ICD treatment. Thus, MAT I captured self-efficacy expectations which reflected a 
person’s belief in his/her ability to perform a given behaviour. Participants rated their responses 
on a scale from 0 (not at all confident) to 10 (very confident). The wording by Dougherty et al., 
(2007) was revised from “cardiac arrest and defibrillator” to read “arrhythmia treatment” so as to 
reflect the different arrhythmia treatments which participants in this study underwent. A total 
score was obtained by adding the numerical rating of each response and dividing the sum by the 
number of items on MAT I. 
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Control variables 
Functional classification (NYHA). The NYHA developed a system to quantify the 
degree of functional limitation for patients with heart disease. The NYHA classification assesses 
physical activity limitations, symptoms of fatigue, palpitations, dyspnea or angina pain upon 
engagement in ordinary physical activity, and the individual’s status at rest. The NYHA is 
divided into four classes, where Class I denotes no symptoms, Class II denotes mild symptoms 
with ordinary activities, Class III reflects marked symptoms at less than ordinary activity levels, 
and Class IV reflects severe limitations even at rest and the inability to perform any activity. The 
NYHA reflects a subjective assessment by the healthcare provider (Hunt et al., 2005) and can 
change over time. For the purposes of our analyses, reflecting common usage, the NYHA 
Functional Class was dichotomized as NYHA Class I and II versus NYHA Class III and IV 
(Irvine et al., 2002; Rahmawati et al., 2016).  
Left ventricular ejection fraction. LVEF was obtained from the participants’ charts and 
was recorded as a continuous variable in order to not lose granularity of this cardiovascular 
function indicator. Every effort was made to capture an LVEF reading at the time of recruitment. 
However, not every individual had a recent ECHO and thus did not have a recent LVEF 
recording. As per the advice and clinical practice of the electrophysiology fellow who worked on 
this study, we allowed for the LVEF to range +/- six months from the time of recruitment. This 
also coincides with practice in electrophysiology studies (Moss et al., 2005). 
ICD shocks. The ICD therapy variables (i.e., shock and ATP) were extracted from 
participant charts. For the purposes of analyses and in line with previous studies, the shock 
variable was dichotomized into zero to four shocks versus equal to or more than five shocks. 
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Life stress. This Life Stress Scale (LSS) has been adapted from the Holmes and Rahe 
(1967) Social Readjustment Rating Questionnaire. The scale developed by Holmes and Rahe 
(1967) comprises a list of life events that demand an adjustment on the part of the individual 
experiencing a given event. The process of adjustment is considered stressful with some life 
events inherently more stressful than others. The version used in this study is abbreviated and 
includes the 14 items rated most inherently stressful on the Holmes and Rahe Social 
Readjustment Rating Questionnaire. As was planned in the Ontario Health Study (Ontario Health 
Study, 2018), an additional question regarding the death of a pet is included in the present Life 
Stress Scale. The final measurement protocol of the Ontario Health Study, however, did not 
ultimately include the Life Stress Scale. The total score is obtained by summing the number of 
events endorsed.  
Data entry and statistical analyses 
 Questionnaire data were entered manually into a database created in SPSS version 21.0 
(IBM Corp. Released 2012). Data entry was double checked for accuracy by the study 
coordinator and a research assistant. Questionnaire scoring syntax statements were created in 
SPSS for all questionnaires except for the SF-36 for which a scoring license was purchased. All 
statistical analyses were performed using SPSS version 21.0.  
Descriptive statistics (e.g., means and standard deviations, and Pearson correlation 
coefficients within groups) were first performed. To examine Hypothesis 1, namely 
psychological predictors of anxiety, depression, and PTSD, hierarchical regression analyses were 
conducted to examine the predictive validity of the independent variables. The baseline value of 
the given dependent variable was entered in the first model, followed by control variables in the 
second model, and finally psychological predictor variables in the third model. By controlling for 
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the baseline value of a given dependent variable in the first model, these analyses assessed 
residualized change scores. For further details please refer to the Results section below. 
Hypothesis 2 examined the HRQoL comparison between ICD recipients who underwent 
an ablation procedure and those who did not. Initially, it was planned to utilize analysis of 
covariance (ANCOVA) to test the comparison between the two groups over time on outcome 
variables, covarying for the baseline value of SF-36. It was planned to repeat the ANCOVA for 
each of the dependent variables (HADS, IES-R), covarying for their respective baseline value, to 
examine if there was greater improvement on symptoms at follow-up in the ablation therapy 
group. As mentioned previously, it was proposed to run the ANCOVA on participants who were 
matched on sex, age, and time since ICD implant. However, as the study unfolded it became 
apparent that the number of ablation procedures performed at the recruitment sites was lower 
than anticipated and it also became progressively more challenging to find appropriate control 
participants. In consultation with a statistician, it was decided to perform regression analyses 
instead. This was done as a way to retain valuable data from those individuals who completed 
the questionnaires but may not have had a match or whose matching participant was missing 
some questionnaire data. For further details on the regression models for Hypothesis 2, please 
refer to the Results section. 
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Results 
Data screening 
 Data cleaning of the electronic database was performed prior to conducting statistical 
analysis. Any missing data or inconsistencies were verified against hospital paper and electronic 
charts and completed questionnaires. If the data were available, corrections were made in the 
electronic database.    
Similarly, missing data on questionnaires was inspected. At the baseline time-point the 
number of individual missing items on a given questionnaire ranged from 1.6% (e.g., n = 1 on 
IES-R) to 6.6% (e.g., n = 4 on HADS). At the six-month follow-up the number of individual 
missing items on a given questionnaire ranged from 14.8% (e.g., n = 9 on SF-36) to 19.7% (e.g., 
n = 12 on IES-R). Missing data were handled in two ways. The SF-36 questionnaire was scored 
electronically by way of QualityMetric scoring software. This scoring system handled missing 
data by way of QualityMetric’s Missing Score Estimator (Maruish, 2011). With this algorithm, 
the Physical Component Summary (PCS) and the Mental Component Summary (MCS) scores 
can be calculated when seven scale scores are available and the Physical Functioning Scale or 
the Mental Health Scale are not missing for the PCS and MCS, respectively. With respect to the 
remainder of the questionnaires, data were screened and determined to be missing at random as 
evaluated by Little’s Missing Completely At Random Test (Tabachnick & Fidell, 2007). Thus, 
missing data were imputed by calculating means from the available data points and the missing 
values were replaced prior to analysis (Tabachnick & Fidell, 2007; von Känel et al., 2011). A 
conservative approach of imputing data was adopted, namely data were imputed only if at least 
80% of items were completed. Missing values were not imputed for data related to ICD function 
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(i.e., ICD therapy) or for other control variables (e.g., functional status) in order to preserve 
internal validity. 
Hierarchical regression analyses were performed in order to test both hypotheses. 
Regression diagnostics examining assumptions of normality, linearity, and homoscedasticity 
between the predicted dependent variable scores and the errors of the prediction were performed 
for all models (Tabachnick & Fidell, 2007). Inspection of the histograms of standardized 
residuals of the regressions and the normal probability plot of residuals suggested that the 
residuals were approximately normally distributed. Standardized residuals were plotted by 
predicted values. Across the optimal linear combination of the predictors, the residuals were 
approximately linear and homoscedastic. Outliers were assessed by way of standardized 
residuals, Cook’s Distance, and Centered Leverage Value and no observation was excessively 
influential thus none was removed from the analyses. Independence of errors was assessed by the 
Durbin-Watson statistic and all were well within the 1-3 range and suggested that the data was 
not autocorrelated. The Variance Inflation Factor for each predictor was well below 5 and did not 
suggest a problem with multicollinearity.  
Participants 
Patient accrual. Of 885 individuals who were screened for the study, 92 were eligible 
and approached for study participation. Nineteen individuals declined participation due to not 
feeling well (n = 6), lack of interest (n = 12), and participating in another study (n = 1). Another 
three eligible patients could not be reached. Nine additional patients were excluded for the 
following reasons: cognitive difficulties/deafness (n = 2), ultimately did not undergo an ablation 
procedure (n = 1), underwent heart transplant shortly after being approached for this study (n = 
1), during the data cleaning process it was discovered that an individual consented and 
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completed questionnaires but was incorrectly recruited (n = 1), incorrect packages were sent for 
completion (i.e., a baseline questionnaire was mailed rather than a follow-up questionnaire; n = 
2), and underwent subsequent ablation procedures between their baseline and follow-up 
questionnaires (n = 2). Relating to the last-stated reason, since the completed follow-up 
questionnaires may have reflected the participants’ experience related to subsequent VT 
ablations rather than the index ablation for which they were recruited, a rule was developed to 
exclude the follow-up data from analyses. Thus, as the study evolved, this was instituted as an 
exclusion rule. Of the 31 individuals not recruited or excluded from the analysis, 26 (83.9%) 
were male and 17 (54.8%) were in the ablation group.  
Of the 61 individuals enrolled to participate, 50 completed all of the questionnaires at 
follow-up, whereas 11 completed only some or none of the questionnaires at follow-up. Partial or 
non-completion of follow-up questionnaires was due to heart transplant (n = 1), loss to follow-up 
(n = 6), choosing not to answer specific scales on the questionnaire (n = 2), and death (n = 2; see 
Figure 1).  
Sample characteristics at baseline 
 Demographic and medical characteristics of study participants are presented in Table 1. 
Participants ranged in age from 23 to 86 years, with a mean age of 63.66 years (SD = 14.34). The 
majority of participants were male (n = 56, 91.8%), living with a family member or roommate (n 
= 52, 85.2%), and had completed greater than a high school education (n = 45; 73.8%).  
With respect to cardiac diagnosis, 54.1% (n = 33) of participants were diagnosed with 
ischaemic cardiomyopathy, 39.3% (n = 24) were diagnosed with non-ischaemic cardiomyopathy, 
and 6.6% (n = 4) had congenital heart disease. Assessment of functional capacity by way of the 
NYHA indicated that 82% (n = 50) of participants could perform all activities of daily living 
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with minimal or no cardiovascular symptoms (NYHA I or II), and 16.4% (n = 10) were markedly 
affected by their cardiac disease (NYHA III or IV). NYHA class was missing for one participant. 
With respect to medications, Class II antiarrhythmic beta-adrenergic blockers (n = 53, 88.3%) 
were most commonly used. Use of psychotropic medication, anxiolytic or mood, was present in 
13.3% (n = 8) of participants.  
 About half of the participants (n = 32, 52.5%) had an ICD implanted for secondary 
prevention. Forty-one percent of patients had previously had one or two ICD shocks, 33% had 
more than four shocks, and about 10% had only ATP. Approximately half of the participants 
underwent an ablation procedure for their ventricular arrhythmia (n = 34, 55.7%). Of these 
individuals, 32.4% (n = 11) had an ablation by way of the activation approach, 58.8% (n = 20) 
had the substrate approach, while 8.8% (n = 3) had a combined approach. Seventy-nine percent 
of the ablations were deemed to be successful (n = 27). 
Differences on demographic and clinical variables between participants who completed 
all of the questionnaires (i.e., “Completers”) and those who were missing at least some 
questionnaires (i.e., “Non-completers”) were tested by way of independent samples t-tests and 
chi-square tests. Completers and non-completers did not differ on age, t(59) = .20, p = .84, level 
of education, χ2(5) = 4.26, p = .51, living situation, χ2(3) = 1.20, p = .75, NYHA, χ2(1) = .56, p = 
.46), cardiac diagnosis, χ2(2) = .16, p = .92, indication for ICD implant, χ2(1) = .57, p = .45, 
number of ICD shocks, χ2(3) = .24, p = .95, group membership, χ2(1) = .58, p = .45, ablation 
approach, χ2(2) = 1.24, p = .54, or the outcome of the ablation procedure, χ2(2) = 2.85, p = .24. 
There were no differences between groups on any of the medications consumed whether 
antiarrhythmic or psychotropic.  
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Table 2 presents the descriptive statistics displaying baseline means, standard deviations, 
ranges and reliability estimates for outcome and predictor variables utilized in this study. 
Reliability estimates suggest that most scales had high internal consistency (Cronbach’s  = .83 - 
.95) with HADS-Depression showing moderate internal consistency (Cronbach’s  = .76). 
Testing for equality of means on the predictor and outcome variables by way of an independent 
samples t-test yielded no significant differences between completers and non-completers on any 
of the outcome or predictor measures, HADS-A, t(56) = 1.02, p = .31; HADS-D, t(56) = .44, p = 
.66; IES-R Total, t(58) = .63, p = .53; IES-R Intrusion, t(58) = .86, p = .39; IES-R Avoidance, 
t(58) = .16, p = .87; IES-R Hyperarousal, t(58) = .73, p = .47; LOT, t(58) = .15, p = .88; PHE, 
t(58) = .07, p = .95; MAT I, t(58) = -.68, p = .50; MCS, t(58) = -.94, p = .35; PCS, t(58) = .02, p 
= .98.  
Pairwise sample effect approach to analyses 
 Due to the small sample size, a consideration was made whether to employ pairwise or 
listwise sample effects when performing regression analyses to test Hypothesis 1 and 2. Several 
steps were taken to make an informed decision. Firstly, both pairwise and listwise sample effects 
were performed and the given regression results were similar. Moreover, since more participants 
completed baseline than follow-up questionnaires, any important potential baseline differences 
were examined to determine if differences existed between those participants who completed all 
questionnaires at follow-up and those who completed only some questionnaires. No differences 
were detected on demographic or clinical variables or on baseline measures (please refer to the 
discussion above). Given that no appreciable differences were detected, it was decided to 
proceed with pairwise sample tests. Importantly, in light of the small sample size, this approach 
to handling data allowed for the optimal use of data which were available and was thus likely to 
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minimize Type II error. As a result, all the regression tables that are displayed also indicate the 
sample size for each comparison or regression.  
Univariate testing of predictive value of psychotropic medication prescription 
Prior to running regression analyses, an exploratory univariate analysis was conducted to 
assess whether prescription of psychotropic medications had predictive value and as such 
whether medication use should be included in the regression models as a control variable. 
Medication data was obtained through chart review. Regressions were performed by entering the 
baseline value of the respective dependent variable (e.g., HADS-A baseline) in the first step and 
psychotropic medication in the second step. Not surprisingly, the baseline scores of the 
dependent variables predicted a significant amount of variance for each respective dependent 
variable, however psychotropic medication did not help explain a further significant proportion 
of the variance in predicting HADS-Anxiety, ΔR2 = .01, F[1, 45] = 1.38, p = .25, HADS-
Depression, ΔR2 = .002, F[1, 45] = .33, p = .57, IES-R Total, ΔR2 = .003, F[1, 46] = 2.05, p = 
.57, IES-R Intrusion, ΔR2 = .03, F[1, 46] = 2.82, p = .10, IES-R Avoidance, ΔR2 = .00, F[1, 46] = 
.00, p = .99, or on IES-R Hyperarousal, ΔR2 = .01, F[1, 46] = .49, p = .49. Consequently, 
psychotropic medications were not included in the regression models. 
Hypothesis 1: Psychological predictors of anxiety, depression, and PTSD  
Descriptive statistics. Table 3 displays means, standard deviations, and ranges for 
baseline and follow-up outcome and predictor measures for participants who completed a given 
questionnaire at both time points. As pairwise sample effects were employed, the table also 
captures the sample size included when calculating these descriptors for each measure.  
Scores were compared with published norms or relevant literature to examine whether 
they were clinically elevated. Also, in order to examine differences between baseline and follow-
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up, paired sample t-tests were conducted for each measure and are displayed in Table 3. With 
respect to anxiety and depression, Snaith (2003) outlined guidelines for interpreting HADS-A 
and HADS-D scores and defined caseness as score of ≥8 on either scale. The proportion of those 
who scored above the cut-off on HADS-A were 36.7% and 24.4% on HADS-D. Neither the 
mean HADS-A nor HADS-D scores in the current sample reached the level of caseness. The 
baseline scores were comparable with a similar sample of ICD patients in an earlier RCT (Irvine, 
Stanley, et al., 2010) and a group of ICD recipients with congenital heart disease (Ingles, Sarina, 
Kasparian, & Semsarian, 2013). Overall, improvements in anxiety were noted over the follow-up 
period (see Table 3). With respect to PTSD, the current sample of participants had comparable 
scores to ICD participants enrolled in an RCT (Irvine et al., 2010). Improvement over time was 
observed for IES-R Total and the Intrusion and Hyperarousal subscales (see Table 3).  
Correlations between independent measures, control variables, and outcome measures are 
presented in Table 4. Initially, NYHA, LVEF, group, shocks, and life stress were planned to be 
used as control variables. Due to the small sample size, control variables were reviewed in order 
to assess which might be removed. Upon reviewing the data, it became apparent that the two 
measures of functional status were candidates for removal; NYHA was retained as it is symptom 
based and was, in this study, more strongly related to the outcome measures than LVEF. 
Moreover, most recent LVEF measurements were not available for each patient, whereas NYHA 
was obtained upon recruitment. Thus, NYHA was deemed a more appropriate measure to retain. 
Life stress was similarly removed as it correlated very poorly with predictor measures (e.g., LOT 
r = .01, p = .95) as well as the control measures (e.g., shocks r = -.09, p = .46). Beyond the 
aforementioned measures, age was included in the regression analyses as it was correlated to 
both the predictor measures as well as anxiety and intrusion symptoms of trauma.  
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 Regression summaries 
 Hypothesis 1 assessed whether higher optimism, positive health expectations, and self-
efficacy at baseline would predict improvement in symptoms of depression, anxiety, and PTSD 
at follow-up. Hierarchical regression analysis was adopted in order to test the predictive validity 
of psychological predictors. Baseline values of the given dependent variable were entered in the 
first step, control variables (i.e., group, shocks, age, NYHA) were entered in the second step, and 
the predictor variables were entered in the third step (i.e., LOT, PHE, and MAT I).   
 Prediction of anxiety and depression symptoms at follow-up. Tables 5 and 6 
summarize the results of the regression models examining anxiety and depression outcomes. For 
anxiety, Models 1 and 2 explained a significant proportion of variance although Model 3, which 
included the psychological predictors, did not. Model 1, as would be expected, indicated that 
baseline HADS-A significantly predicted anxiety at follow-up (unstandardized Β = .74), 
accounting for 72.6% of the variance, F(1,47) = 126.48, p < .001, where individuals with higher 
baseline anxiety scores showed higher anxiety at follow-up. Including control variables in Model 
2 indicated that functional status (unstandardized Β = 2.63) explained a significant proportion of 
variance, 5.3%, F(4, 43) = 2.61, p = 0.048, over and above baseline HADS-A. Individuals with 
poorer NYHA functional status experienced less improvement in anxiety at follow-up. In the 
third model psychological predictors were examined. While this model did not reach 
conventional levels of significance, ΔR2 = 0.026, F(3, 40) = 1.78, p = 0.167, it is possible that it 
would have with a larger sample size, thus, a brief overview is warranted. This model suggests a 
trend where those participants with higher perceived self-efficacy at baseline experienced an 
improvement in symptoms of anxiety at follow-up (unstandardized Β = -.52) over and above 
other predictors. 
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 With respect to depression, not surprisingly, Model 1 explained a significant proportion 
of variance, 62.9%, F(1,47) = 105.78, p < .001. Here, individuals with higher baseline depression 
scores showed less improvement in depression at follow-up (unstandardized Β = .90) relative to 
baseline although overall depressive symptoms appear to have remained relatively stable over 
time. Models which included control variables, ΔR2 = 0.028, F(4, 43) = 1.07, p = 0.384, and 
psychological predictors, ΔR2 = 0.023, F(3, 40) = 1.20, p = 0.322, did not add explanatory value.  
 Prediction of PTSD symptoms at follow-up. Tables 7 – 10 summarize the results of the 
regression analyses examining symptoms of PTSD at follow-up. When investigating the overall 
PTSD score (Table 7), Models 1 and 3 explained a significant proportion of variance while 
Model 2 explained a borderline significant amount of variance. In Model 1, as expected, greater 
PTSD at baseline was a significant predictor of deteriorating PTSD levels at follow-up 
(unstandardized Β = .62), accounting for 56.4% of the variance, F(1,47) = 60.87, p < .001. Model 
3 which included psychological variables explained an additional 7.2% of variance, F(3, 40) = 
3.32, p = 0.029, where greater perceived self-efficacy at baseline (unstandardized Β = -.12) was 
an independent predictor of improved PTSD levels at follow-up, over and above other predictors. 
Baseline levels of PTSD and functional status remained significant predictors of PTSD levels at 
follow-up. 
Examining symptoms of PTSD by way of individual domains showed that when looking 
at symptoms of intrusion all three models accounted for a significant amount of variance (Table 
8). Model 2 accounted for an additional 9.6% of the variance, F(4, 43) = 2.69, p = .044, where 
functional status emerged as an independent predictor (unstandardized Β = .51) over and above 
baseline level of intrusion. Model 3, which included psychological predictors, explained another 
13.2% of the variance, F(3, 40) = 7.04, p < .001. Perceived self-efficacy at baseline emerged as 
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an independent predictor over and above other predictor variables where greater self-efficacy at 
baseline predicted an improvement in symptoms of intrusion at follow-up (unstandardized Β = -
.16). Interestingly, the model suggested that higher positive health expectations at baseline 
predicted less improvement in levels of intrusion at follow-up. Notably, the unit of change is 
small and suggests that for every one unit difference in positive health expectations there is less 
improvement in symptoms of intrusion by .02 (unstandardized Β = .02). This finding is counter 
to the hypothesis being tested. This raises the question of whether individuals who have greater 
positive expectations might be more disappointed when these expectations are not met. 
Importantly, however, as the unstandardized beta is so small the presence of a Type I error 
cannot be ruled out. Baseline levels of intrusion and functional status remained significant 
predictors in Model 3.    
Unlike for symptoms of intrusion, the two models with control and psychological 
variables did not explain a significant proportion of the variance in avoidance symptoms at 
follow-up (Table 9). Not surprisingly, only Model 1 which included baseline levels of avoidance 
accounted for a significant proportion of variance, 23.6%, F(1, 47) = 14.54, p < .001, in 
symptoms of avoidance at follow-up. 
Lastly, Models 1 and 3 explained a significant proportion of the variance in symptoms of 
hyperarousal while Model 2 explained a borderline significant amount of variance (Table 10). 
Model 2 saw functional status (unstandardized Β = .53) as an independent predictor over and 
above baseline levels of hyperarousal. Model 3 accounted for an additional 8.00% of the 
variance, F(3, 40) = 3.58, p = .022, where greater perceived self-efficacy at baseline 
(unstandardized Β = -.14) predicted improved symptoms of hyperarousal at follow-up over and 
above other predictor variables.  
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 To summarize, perceived self-efficacy emerged as a significant predictor of improved 
symptoms of anxiety, overall PTSD as well as symptoms of intrusion and hyperarousal. 
However, contrary to hypothesis, higher optimism at baseline did not help predict improvement 
in symptoms of anxiety, depression, or PTSD. Similarly, higher positive health expectations at 
baseline did not help predict improvements in these domains. Indeed, higher positive health 
expectations were found to predict a small worsening of symptoms of intrusion at follow-up. 
Simply examining changes of the dependent measures between baseline and follow-up, the 
current sample of participants showed improvement on symptoms of anxiety, overall PTSD as 
well as symptoms of intrusion and hyperarousal. 
Hypothesis 2: HRQoL and psychological well-being in ablation and control groups 
Descriptive statistics per group of all recruited participants. Table 11 presents 
demographic, cardiovascular, and pharmacologic characteristics of all recruited participants 
based upon whether they underwent an ablation or not. Independent samples t-tests and chi-
square tests were utilized to test differences on these variables between the two groups. Ablation 
and control participants did not differ on age, t(59) = .38, p = .71, level of education, χ2(5) = 
2.12, p = .83, living situation, χ2(3) = 3.53, p = .32, cardiac diagnosis, χ2(2) = 3.52, p = .17, or 
number of ICD shocks, χ2(1) = 2.45, p = .12. For purposes of statistical analyses, ICD data were 
collapsed into two groups: zero to four shocks and five or more shocks. Zero to four shocks was 
received by 58.8% of ablation and 77.8% of control participants. Five or more shocks were 
received by 41.2% of ablation and 22.2% of control participants. Differences were detected on 
NYHA, χ2(1) = 5.94, p = .02, and indication for ICD implant, χ2(1) = 5.73, p = .02. With respect 
to medication use, differences were noted on use of Class III antiarrhythmics, χ2(2) = 18.70, p < 
.001, but not on other types of medication.  
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Table 12 presents baseline means, standard deviations, and ranges for outcome variables 
per group. Testing for equality of means on the outcome variables by way of an independent 
samples t-test yielded significant differences between the ablation and control groups on the 
PTSD measure, IES-R Total, t(58) = -2.71, p = .009; IES-R Intrusion, t(58) = -2.77, p = .008; 
IES-R Avoidance, t(58) = -2.34, p = .02; IES-R Hyperarousal, t(58) = -2.25, p = .03. Significant 
between-group differences were not detected on measures of HRQoL or anxiety and depression, 
MCS, t(58) = 1.56, p = .12; PCS, t(58) = -.38, p = .70; HADS-A, t(56) = -1.15, p = .26; HADS-
D, t(56) = .08, p = .94. 
 An exploratory regression analysis was performed to examine whether there were any 
differences on outcome measures between participants whose ablation was deemed to be 
successful as compared to those whose ablation was deemed unsuccessful. The baseline value of 
the dependent variable was controlled for in the first step while the grouping variable was 
entered in the second step. Due to the low number of unsuccessful ablations (n = 5), the two 
additional participants whose ablations were deemed to be partially successful were recoded as 
unsuccessful for this analysis. Significant differences were not detected between the successful 
and unsuccessful ablations on any of the outcome measures: MCS (unstandardized Β = -2.35, p = 
.52), PCS (unstandardized Β = 1.84, p = .59), HADS-Anxiety (unstandardized Β = 1.08, p = .34), 
HADS-Depression (unstandardized Β = -1.04, p = .30), IES-R Total (unstandardized Β = .04, p = 
.84), IES-R Intrusion (unstandardized Β = -.04, p = .85), IES-R Avoidance (unstandardized Β = 
.16, p = .60), or on IES-R Hyperarousal (unstandardized Β = .21, p = .38).  
 Likewise, an exploratory regression analysis was performed to assess whether there were 
any differences on outcome measures between participants who received ICD shocks during the 
follow-up period as compared to those who did not. Overall, only 7 participants from the study 
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sample received shocks during the follow-up period. No significant differences were detected. 
However, as the number of participants who received shocks is very small as compared to those 
who did not, it is difficult to assess whether any true differences exist.  
Tables 13 and 14 present correlations among the predictor and outcome variables within 
study group. Overall correlations were examined for variables and their relationship to the 
grouping variable. Shocks (r = .20, p = .12) were not strongly correlated to the grouping variable 
and were thus not included in the regression model. NYHA was correlated to the grouping 
variable (e.g., r = .32, p = .01) as well as outcome measures (e.g., PCS; r = .31, p = 03) and was 
included in the regression.   
Table 15 displays means and standard deviations for each group, as well as the within-
group comparisons on the psychological measures. An examination of within group differences 
highlighted areas of improvement for ablation participants over the follow-up period. Ablation 
participants saw improvements on MCS, t(28) = -3.35, p = .002, 95% CI [-7.84, -1.89], IES-R 
Total, t(27) = 3.05, p = .005, 95% CI [.09, .44], IES-R Intrusion, t(27) = 3.04, p = .005, 95% CI 
[.10, .53], and IES-R Hyperarousal, t(27) = 2.95, p = .007, 95% CI [.10, .53]. 
Control participants saw improvements between baseline and follow-up on HADS-
Anxiety, t(20) = 2.49, p = .02, 95% CI [.23, 2.54], IES-R Total, t(20) = 2.20, p = .04, 95% CI 
[.01, .48], IES-R Intrusion, t(20) = 2.18, p = .04, 95% CI [.01, .48], and IES-R Hyperarousal, 
t(20) = 2.63, p = .02, 95% CI [.07, .58]. They did not, however, see any improvements with 
respect to HRQoL on either the MCS, t(21) = -1.51, p = .15, 95% CI [-8.33, 1.32] or PCS, t(21) 
= -1.24, p = .23, 95% CI [-5.73, 1.44]. 
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Regression summaries 
Hypothesis 2 assessed whether global measures of HRQoL, anxiety, depression, and 
PTSD would improve more over the follow-up period in ICD recipients who underwent an 
ablation procedure as compared to those who did not. Two types of regression analyses were 
performed for each dependent variable. To test the original hypothesis, a simple regression with 
the baseline value of the dependent variable was entered in the first model and the grouping 
variable (i.e., ablation versus control) was entered in the second model. To account for the 
variables that were used to recruit participants and potential confounds, a three-step hierarchical 
regression was performed where baseline values of the given dependent variable were entered in 
the first model, variables which were used to recruit and match participants (i.e., age, gender, 
time since ICD implant) and control variables (i.e., NYHA) were entered in the second model, 
and the grouping variable (i.e., ablation or control) was entered in the third model. Regression 
analyses of both the simple model and the three-step model are presented below. 
Prediction of HRQoL at follow-up. Overall, between-group differences were not 
observed on either the Mental Component Summary (MCS; Table 16 and 17) or on the Physical 
Component Summary (PCS; Table 18 and 19) when looking at the three-step regression or the 
simple model. Not surprisingly, the baseline values of MCS and PCS accounted for a significant 
proportion of the variance across the models. With respect to MCS, no other variable contributed 
significant explanatory power. Similarly, when examining PCS the addition of control variables, 
ΔR2 = .064, F(4, 44) = 1.74, p = .16, and the grouping variable, ΔR2 = .001, F(1, 43) = .06, p = 
.81, did not help explain additional variance.   
Prediction of anxiety and depression symptoms at follow-up. As with HRQoL, 
between-group differences were not observed on symptoms of anxiety (Table 20 and 21) or 
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depression (Table 22 and 23) over the follow-up period in the three-step model or the simple 
model. Not surprisingly, baseline levels of anxiety accounted for a significant proportion of 
variance across models. Gender (unstandardized Β = -2.65) and functional status (unstandardized 
Β = 2.31) were significant predictors over and above other predictor variables in Model 2 which 
explained a significant proportion of variance, ΔR2 = .074, F(4, 43) = 4.01, p = .007. Examining 
depression, it was only the first model which accounted for a significant proportion of variance, 
R2 = .629, F(1, 47) = 105.78, p<.001. Addition of control variables, ΔR2 = .038, F(4, 43) = 1.51, 
p = .22, or the grouping variable, ΔR2 = .006, F(1, 42) = .88, p = .35, did not help add 
explanatory power.  
Prediction of PTSD symptoms at follow-up. Symptoms of trauma are next reviewed 
with respect to overall symptoms of PTSD as well as specific PTSD domains. The three-step 
regression as well as the simple model yielded similar results and thus the more complex model 
findings will be reviewed below. Generally, group differences were not detected across 
symptoms of PTSD.  
With respect to the total IES-R scores (Table 24 and 25), as expected baseline levels of 
PTSD accounted for a significant proportion of the variance across models. Model 2 accounted 
for an additional 17% of the variance, F(4, 43) = 2.38, p = .13, where age (unstandardized Β = 
.01), gender (unstandardized Β = -.79), and functional status (unstandardized Β = .31) emerged as 
independent predictors over and above other predictor variables. Model 3 did not add further 
explanatory power, ΔR2 = .007, F(1, 42) = 1.19, p = .28. A similar pattern was observed with 
respect to symptoms of intrusion (Table 26 and 27). Baseline levels of intrusion, as expected, 
accounted for a significant proportion of the variance across the three models. Model 2 helped 
account for an additional 18.6% of the variance, F(4, 43) = 6.87, p < .001, with age 
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(unstandardized Β = .01), gender (unstandardized Β = -.85), and functional status 
(unstandardized Β = .42) emerging as independent predictors over and above other predictor 
variables. However, the grouping variable did not account for a significant amount of variance. 
Similarly, and not surprisingly, baseline levels of avoidance (Table 28 and 29) accounted for a 
significant proportion of variance across the three models. Model 2 was borderline significant, 
ΔR2 = .141, F(4, 43) = 2.43, p = .06, whereby participants who had their ICDs implanted for a 
longer period of time showed a borderline significant decrease in symptoms of avoidance 
(unstandardized Β = -.003). Model 3 did not add further explanatory power, ΔR2 = .033, F(1, 42) 
= 2.38, p = .13, and this was also true for the grouping variable in that model (unstandardized Β 
= .28; p = .13). Lastly, symptoms of hyperarousal (Table 30 and 31) followed a similar pattern as 
the two aforementioned subscales. As expected, baseline levels of hyperarousal accounted for a 
significant proportion of the variance across the three models. Model 2 explained an additional 
15.2% of the variance, F(4, 43) = 5.22, p = .002, with gender (unstandardized Β = -.80) and 
functional status (unstandardized Β = .41) emerging as independent predictors over and above 
other predictor variables, revealing that men changed more than women and that poorer 
functional status was related to more of an improvement in hyperarousal symptoms. Yet again, 
group differences were not observed when the grouping variable was entered into the third 
model.  
In summary, contrary to hypothesis, between-group differences were not detected with 
respect to HRQoL, anxiety, depression, or PTSD symptoms. However, upon examining within-
group changes both the ablation and control participants showed improvements in specific 
domains. Participants with an ICD who underwent an ablation procedure showed improvement 
in HRQoL specifically on the MCS, overall PTSD symptoms as well as levels of intrusion and 
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hyperarousal. Improvements in HRQoL were not observed for those ICD recipients who did not 
undergo an ablation procedure. However, this group did see an improvement in symptoms of 
anxiety, overall PTSD, and symptoms of intrusion and hyperarousal over the follow-up period. 
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Discussion 
The first aim of this case-control, prospective, study was to examine whether self-
efficacy, optimism, and positive health expectations predict improvement in symptoms of PTSD, 
anxiety, and depression following VT ablation in ICD recipients. The second aim was to assess 
whether the VT ablation procedure was associated with greater improvement in HRQoL in 
patients who underwent the procedure as compared to matched control ICD recipients who did 
not. To date, only a few studies have examined the psychological and HRQoL effects of VT 
ablation in ICD recipients (Gula et al., 2018; Kuck et al., 2010; Maryniak et al., 2006; 
Strickberger et al., 1997). The present study is the first to explore symptoms of PTSD in a larger 
sample of VT ablation patients, assess individual differences as they predict psychological well-
being after VT ablation in ICD recipients, and utilize state-of-the-art psychological measures to 
assess the aforementioned hypotheses. Moreover, the uniqueness and importance of this study lie 
in the population of ICD recipients; namely, those who have a long history of cardiac illness and 
profound and incessant VT burden. Participants who underwent a VT ablation procedure 
generally had more advanced disease and significant cardiac symptoms. This is the case even 
when compared to their own matched controls, as ablation patients experienced recurrent 
sustained VT, VT storms, or recurrent shocks despite antiarrhythmic treatment which is what 
necessitated the ablation. Thus, this population has had longstanding cognitive, behavioural, and 
emotional reactions to the stressful cardiac events associated with their VT and arrhythmia 
treatments. For this reason, the merit of this study, beyond examining whether the VT ablation 
exerts an impact on HRQoL, is the exploration of individual differences which might impact 
psychological well-being for this profoundly unwell group of patients. 
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The chief findings for Hypothesis 1 are that higher perceived self-efficacy at baseline 
significantly predicted improvement in anxiety-based symptoms (i.e., symptoms of anxiety, 
overall PTSD, intrusion and hyperarousal) at follow-up over and above group membership and 
presence of ICD shocks. Contrary to the hypothesis, positive health expectations and optimism at 
baseline did not predict improvement in symptoms of PTSD, anxiety, or depression. Hypothesis 
2 was not supported in that significant between-group differences were not found on measures of 
HRQoL, anxiety, depression, and PTSD over the study follow-up. Ablation participants, 
however, showed improvement in mental health HRQoL, overall PTSD, and symptoms of 
intrusion and hyperarousal. Participants in the control group showed improvement in symptoms 
of anxiety, overall PTSD, intrusion and hyperarousal. Study findings as they relate to each 
hypothesis are discussed below. 
Design, recruitment, and sample  
Prior to discussing study findings, it is important to note that the design of this study 
deviated in several ways from the original proposal. With respect to Hypothesis 1, LVEF and life 
stress were not included as control variables in the regression analyses. Hypothesis 2 was 
originally planned to be analysed by way of analysis of covariance. In order to retain valuable 
data from participants who completed questionnaires but did not have an appropriate match, 
regression analyses were performed instead.   
The recruitment procedure for this study seems to have generated a sample of patients 
fairly similar to samples recruited in other related studies of ICD and VT ablation patients (Gula 
et al., 2018; Irvine et al., 2011; Kuck et al., 2010; Sapp et al., 2016; Sears et al., 2004). For 
example, while the current study had somewhat more male participants as compared to studies of 
first-time ICD recipients (Irvine et al., 2011; Sears et al., 2004), the gender distribution was 
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nearly on par with RCTs of VT ablation patients (Gula et al., 2018; Kuck et al., 2010; Sapp et al., 
2016). The current sample was similar in age to the above-named studies but somewhat more 
educated (Irvine et al., 2011; Sears et al., 2004). The current sample displayed poorer functional 
status compared to first-time ICD recipients (Irvine et al., 2011) but was similar to other studies 
examining ICD patients undergoing a VT ablation (Gula et al., 2018; Kuck et al., 2010; Sapp et 
al., 2016). Lastly, the current study is similar to a recent RCT of VT ablation (Gula et al., 2018; 
Sapp et al., 2016) in that participants who were recruited already had an ICD and had thus been 
exposed to arrhythmia treatments prior to undergoing a VT ablation. However, it differs in this 
respect from studies of first-time ICD recipients and an RCT of prophylactic ablation patients 
(Irvine et al., 2011; Kuck et al., 2010; Sears et al., 2004) as participants in the current study 
generally lived with an ICD for an extended period of time. They were thus likely to have been 
exposed to greater arrhythmia burden and repeated arrhythmia treatments. This fortifies the 
suggestion that this is a profoundly unwell sample of participants who have lived with 
arrhythmia burden for a prolonged period. Overall, however, the current sample appears to be 
representative of this population of ICD recipients and those undergoing a VT ablation. As such, 
the present findings are unlikely to be due to sampling error or bias.   
With respect to psychological outcome variables, the only RCT similar in study 
population was the VANISH trial (Gula et al., 2018). Mean baseline scores of anxiety and 
depression in the VANISH study were generally similar to those in the present study although 
ICD participants who did not undergo an ablation in the current study appeared to have lower 
baseline anxiety as compared to their counterparts in the VANISH trial. This, however, did not 
appear to impact detection of between-group differences. While the VANISH RCT (Gula et al., 
2018) provides some comparison the comparative measures are very limited as that trial utilized 
72 
 
an older version of the HRQoL measure and did not assess symptoms of PTSD. As such the 
comparison of baseline mean scores of psychological outcomes has been extended to other 
studies that have used similar measures in ICD recipients or ablation patients. Such a comparison 
suggests that the present baseline mean scores of depression, anxiety, PTSD, and HRQoL are 
generally similar to those of other studies of ICD recipients (Irvine et al., 2011; Kapa et al., 
2010). As such, the participants in the current study appear to be a representative sample.  
Hypothesis 1 
 In line with the study hypothesis, higher perceived self-efficacy at baseline significantly 
predicted improvement in symptoms of anxiety, overall PTSD, as well as PTSD symptoms of 
intrusion and hyperarousal at follow-up. Specifically, self-efficacy at baseline was a significant 
predictor of the above-named outcomes after controlling for baseline values of the respective 
outcome variable, demographic, and cardiac variables. Importantly, self-efficacy emerged as a 
significant predictor over-and-above group membership (i.e., VT ablation or control) as well as 
occurrence of shocks. This suggests that self-efficacy is a protective factor even in individuals 
who experienced a recent cardiac event, such as recurrent VT or shocks, which necessitated a VT 
ablation. In this study, the VT ablation procedure itself was not associated with psychological 
outcomes. While self-efficacy was predictive of anxiety-based measures, contrary to the 
hypothesis, it was not predictive of depression. Furthermore, and contrary to expectations, 
optimism and positive health expectations at baseline did not predict improvement in symptoms 
of PTSD, anxiety, or depression at follow-up.  
Self-efficacy. Study findings pertaining to self-efficacy are congruent with findings from 
other studies involving health and non-health populations (Benight et al., 1997; Blackburn & 
Owens, 2015; Joekes & Van Elderen, 2007; Johansen et al., 2007). The finding that greater self-
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efficacy was associated with improved PTSD levels at follow-up fits with the longitudinal 
findings of Johansen et al. (2007). Their study of predominantly male victims of violence used 
the IES-R to assess trauma symptoms. Self-efficacy was negatively correlated with total trauma 
across the follow-up periods and predicted symptoms of PTSD in the short, medium, and long 
term. Although both studies utilized the IES-R it is difficult to compare mean scores as there is 
not an agreed upon way of scoring the measure. While the present study scored the IES-R based 
upon the Weiss (2004) recommendation, and consistent with previous research (Irvine et al., 
2011), the Johansen et al. (2007) study did not. Nevertheless, findings remain consistent 
highlighting the protective nature of self-efficacy as it relates to trauma outcome.  
Similarly, results from the present study are in line with the cross-sectional findings of 
Blackburn and Owens (2015) where hierarchical regression analyses revealed higher self-
efficacy to be a predictor of lower PTSD. Blackburn and Owens (2015) also assessed the 
interaction between self-efficacy and exposure to combat and reported that when exposure to 
combat was high, as self-efficacy increased, PTSD severity decreased. Although such an 
interaction was not tested for in the present study, certain parallels might exist. It is not 
unreasonable to extrapolate to our study the idea that in a sample of patients experiencing high 
and repetitive VT burden, as self-efficacy increases, symptoms of PTSD lessen. Namely, when 
faced with repetitive stressors, such as recurrence of shocks, VT storms, or arrhythmia 
treatments, those individuals who feel that they can control at least some aspect of their cardiac 
situation might report lower levels of trauma.  
Findings are also in line with those of Benight et al. (1997) who studied self-efficacy in a 
sample of men with HIV (n = 37) and healthy controls (n = 42) following a hurricane. In both 
studies, strong negative correlations were reported between self-efficacy and trauma as well as 
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emotional distress. Their results indicate that higher levels of self-efficacy were related to lower 
emotional distress and lower symptoms of trauma in both groups over and above control 
variables (e.g., perceived life threat, education, time since hurricane). It appears that perceptions 
of self-efficacy acted in similar ways in both healthy controls and men with HIV. Notably, using 
the Symptom Checklist-90-Revised, Benight et al. (1997) assessed general emotional distress 
including depression and anxiety, among other emotional difficulties such as hostility and 
interpersonal difficulties. While their results show that greater self-efficacy is related to less 
general distress, results cannot be entirely extrapolated to the present study as Benight et al. 
(1997) did not examine depression and anxiety subscales per se. Due to the differences in study 
design, however, comparisons between the present study and that of (Benight et al., 1997) is 
tentative at best.  
Present findings lend partial support to those of Joekes and Van Elderen (2007) where 
self-efficacy, anxiety, depression and HRQoL were examined in a sample of MI (n = 41) and 
congestive heart failure patients (CHF; n = 41). Similar to the present study, an inverse 
correlation between self-efficacy and anxiety and depression as measured by HADS was 
observed. Higher self-efficacy was predictive of less anxiety and depression, and better HRQoL 
on baseline scores. Self-efficacy was no longer predictive of these outcomes when baseline 
values of outcome variables were controlled for in the longitudinal analysis, suggesting that self-
efficacy at baseline did not influence change in outcomes. The reduced sample size at follow-up 
(n = 67) may have compromised the ability to detect the predictive validity of self-efficacy. An 
alternative explanation may be that the low baseline mean scores for anxiety and depression 
produced a floor effect which might have contributed to the lack of significant findings in their 
longitudinal analysis. In other words, there might have been limitations in how much change 
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relative to baseline scores was possible. Credence for a floor-effect undermining the analyses in 
the Joekes and Van Elderen's (2007) study is lent when comparing their mean scores to the 
means observed in the present study. The present study had comparatively higher mean baseline 
anxiety and depression scores (5.78 vs. 5.02 and 4.89 vs. 3.91, respectively). This is particularly 
evident with respect to the depression outcome where both studies captured very low depression 
scores and failed to find predictive validity of self-efficacy in the longitudinal analyses. Another 
potential contributor to the lack of longitudinal effects for self-efficacy may be that the follow-up 
period in the Joekes and Van Elderen (2007) study was too short (i.e., three months) whereas the 
present study followed patients over a six-month period. If one considers that self-efficacy is in 
part honed through mastery, observing others, and receiving reinforcement it may be that longer 
than three months is necessary to foster one’s ability to organize and integrate behavioural and 
cognitive skills needed to address one’s health condition in such a way as to impact 
psychological outcomes.  
Contrary to the study hypothesis, self-efficacy was only predictive of anxiety-based 
measures and not depression. This finding is incongruent with the cross-sectional study by 
Blackburn and Owens (2015) which reported higher general self-efficacy to be predictive of 
lower depression symptom severity. However, given the design differences between the 
Blackburn and Owens (2015) study and this study, it is impossible to draw confident 
comparisons. Unlike this study, the former study did not examine change in depression over 
time. The lack of an effect on depression outcome in this study might be explained by a floor 
effect as the depression scores in the present study rendered it difficult to detect improvements in 
this domain as discussed above.  
76 
 
In summary, results suggest that the appraisal of one’s ability to cope with the stressors of 
the arrhythmia and its associated treatment play an important role in psychological adjustment 
following arrhythmia treatments. Those individuals who perceive themselves to be efficacious at 
baseline show improved psychological function, as compared to their baseline functioning, on 
anxiety-based measures. Importantly, the presence of a VT ablation did not augment these 
results. ICD recipients undergoing a VT ablation procedure are a profoundly unwell group of 
participants. These individuals have typically sustained numerous, and stressful, cardiac events 
or procedures. Thus, due to the chronic nature of their disease and lack of reprieve from VT 
symptoms, it is perhaps not surprising that benefits of a VT ablation procedure itself are not 
easily detected. This group of ICD recipients might be so unwell to begin with that any physical 
intervention is unable to restore their psychological well-being, particularly within a short 
follow-up time-frame of six-months, on the psychological variables which were measured in this 
study. However, it cannot be assumed that no improvements would be observed in other 
psychological domains which were not assessed in the current study. Encouragingly, however, 
individual differences and resilience factors such as self-efficacy appear to contribute above and 
beyond the arrhythmia treatment even in the most unwell ICD recipients. If higher self-efficacy 
helps individuals organise cognitive, motivational, and affective processes (Benight & Bandura, 
2004) these results suggest that even when faced with serious health adversity, agentic 
individuals are able to regulate how they navigate their arrhythmia and treatments. The 
specificity of the self-efficacy measure as it relates to arrhythmia management, as opposed to the 
more general measures of optimism and health expectations, may have contributed to its 
predictive validity in relation to anxiety-based outcomes. Behaviour and actions are context-
specific. As such, assessing self-efficacy in relation to navigating arrhythmia burden may have 
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allowed for the patterns of strengths and limitations to emerge in relation to psychological 
outcomes (Bandura, 2006). Importantly, Benight and Bandura (2004) conclude that individuals 
who believe they can overcome the source of the stressor take an active role in navigating their 
life circumstances rather than letting the circumstances navigate their life. In line with this, 
participants may have gained a sense of “mastery” through repeated arrhythmia events, which 
exposed them to the anxious stimulus and necessitated them to face the stressor head-on. Thus, 
one possible explanation for the effect of self-efficacy may be that through repeated exposures to 
the arrhythmia stressor, certain participants may have gained a greater sense of control and how 
they might deal with the situation should it arise again. In turn, individuals might employ coping 
strategies which allow them to think in self-enhancing ways that offer some sense of control in a 
largely unpredictable situation thus reducing distress.  
Optimism and positive health expectations. Contrary to the study hypothesis, neither 
optimism nor positive health expectations at baseline were predictive of improvement in 
symptoms of anxiety, depression, or PTSD over the study follow-up. This finding was somewhat 
surprising as it relates to optimism given it has previously been proposed as a covariate for better 
psychological outcomes in ICD recipients (Dunbar, 2005). Current findings are incongruent with 
those of Sears et al. (2004) who reported high optimism to be associated with better HRQoL 
(mental health and social functioning) at eight-months follow-up in ICD recipients. While both 
studies reported similar baseline optimism scores (22.05 vs. 21.5, respectively) several factors 
may have impacted the discrepant findings. First-time ICD recipients which comprised the Sears 
et al. (2004) sample would have very different arrhythmia burden as compared to patients who 
have had numerous arrhythmia interventions, complications, and stressors. This difference in 
samples possibly impacted the ability to detect a predictive relationship between optimism and 
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psychological outcomes in the present study. Attrition of patients over follow-up (baseline n = 
88; eight-months n = 42; 14-months n = 49) may also have had an impact. Lastly, the Sears et al. 
(2004) study is unique in its use of median splits (i.e., high vs. low optimism and high vs. low 
positive health expectations) to assess their hypotheses whereas other studies to be reviewed 
below did not. Employing this statistical choice may have impacted their findings and as such 
might have been an anomaly. Moreover, and contrary to findings from the current study, higher 
optimism has been reported to predict reduced risk of depressive symptoms at 12-months post-
acute coronary syndrome after adjusting for baseline depression (Ronaldson et al., 2015). As 
discussed previously, the relatively small range in depression scores and the minimal change in 
scores over time might have resulted in a floor effect in the present study, which could have 
impacted the ability to detect a predictive effect of optimism as it relates to depression.  
Conversely, and consistent with the current study, longitudinal studies of first-time ICD 
recipients (Habibović et al., 2018) and of a different trauma population (Dougall et al., 2001) 
showed that optimism did not predict the change in overall symptoms of distress when baseline 
distress was controlled. However, in their analyses of absolute scores, rather than residual change 
scores, these two studies reported a more optimistic disposition at baseline to be associated with 
lower distress at follow-up. Together, these findings suggest that while optimism may be related 
to distress at a given time-point, it is not necessarily related to the way distress changes over 
time.   
 Lastly, while not assessing the association between optimism and change in 
psychological outcome per se, Rauch et al. (2013) reported higher optimism to be related to 
lower levels of trauma. Methodological differences likely account for discrepant findings. For 
example, inherent differences in samples may have impacted study outcomes. Childbearing 
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women from largely urban U.S. centers and from a wide range of socioeconomic strata may have 
very different experiences with trauma, distress, and optimism as compared to largely older 
males in a Canadian urban centre. While the range of optimism was fairly wide in the present 
study, it is possible that the wide range and high sample size allowed Rauch et al. (2013) to 
detect the predictive validity of optimism. However, the cross-sectional nature of that study 
precludes confident comparison with the present study.   
In summary, while some studies report optimism to be predictive of less distress at 
follow-up, it is often not associated with the change in distress over time. Carver et al. (2010) 
argue that while optimism is a fairly stable trait, there are moment-to-moment variations as well 
as variations over time. Many patients in the current study survived a cardiac arrest, endured an 
ICD implant and associated therapies, repetitive VT, and VT ablation. It is possible that the 
inherent variability in optimism taken together with intermittent and yet repetitive nature of the 
arrhythmia events experienced by this population of ICD patients, rendered it difficult to detect 
an association between optimism and psychological outcome in this study.  
Findings as they relate to PHE are incongruent with those of Sears et al. (2004) where 
high PHE was associated with better HRQoL outcome. PHE scores were lower in the present 
study as compared to Sears et al. (2004) (34.47 vs. 43.5, respectively). Thus, perhaps PHE scores 
were not high enough in the present study to detect an influence on outcome. This explanation 
seems plausible given the participants in the present study might have had their health 
expectations negatively impacted by the fact that they had a long history of poor health 
outcomes. Participants in the Sears et al. (2004) study were getting an ICD for the first time and 
thus might have had more reason to have more positive health expectations. Of course, 
methodological inconsistencies between the two studies might also account for the discrepancies 
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seen on baseline PHE scores. Sears et al. (2004) collected questionnaire data via telephone which 
may have elicited responses which were deemed to be more socially desirable by the patient. 
Moreover, in the present study PHE showed small correlations with outcome variables in the 
predicted direction, however not all correlations were significant. It is unclear what the 
correlations were between PHE and outcome variables in the Sears et al. (2004) study but if 
stronger correlation coefficients were present it may have impacted study findings. Issues related 
to the use of median splits and attrition of patients, discussed above, also remain relevant to the 
construct of PHE (Sears et al., 2004). It is of course possible that both studies reflect chance 
findings due to the small sample sizes. 
Present findings lend support to the study of ICD recipients which examined treatment 
expectations as they relate to anxiety and depression at three-months post implant (Habibović et 
al., 2014). Treatment expectations, both positive and negative, were assessed by an ICD-specific 
questionnaire which the authors developed. Positive expectations were not associated with 
anxiety nor depression, while negative expectations were associated with more anxiety and 
depression after adjusting for demographic and clinical variables. Notably, baseline levels of 
distress were not controlled. Unlike in the study of Sears et al. (2004) which assessed treatment 
expectations and its relationship to HRQoL, the present study and that of Habibović et al. (2014) 
assessed anxiety and depression. This might suggest that health expectations are more intimately 
related with general mental and physical health rather than specific psychological domains. 
Difference in measure and construct used may have played a factor in discrepant findings. 
Moreover, Sears et al. (2004) captured data over a longer period of time (eight and 14 months) 
raising the possibility that positive expectations may be relevant at a later time point following 
an arrhythmia treatment.  
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Lastly, Leedham et al. (1995) suggest that positive health expectations might act as a 
buffer against low mood in a sample of heart transplant patients. The current study and that of 
Leedham et al. (1995) utilized the same instrument to assess this construct. Baseline PHE scores 
were slightly lower in the present study as compared to Leedham et al. (1995) (32.24 vs. 38.5, 
respectively) with the current study showing a wider range of scores (13-49 vs. 27-49, 
respectively). Beyond the small sample size (N = 31) of the Leedham et al. (1995) study, the 
correlational nature of their analysis precludes direct comparisons with the present study.  
Briefly, a review of the regression analyses suggests that functional status, as measured 
by the NYHA, emerged as a significant predictor of outcome variables. Moreover, it typically 
remained significant even when psychological predictors, such as self-efficacy and optimism, 
were entered into the regression model. This is perhaps not unusual as NYHA is a symptom-
based measure which assesses fatigue, light-headedness, and racing heart. As these symptoms 
are frequently captured by psychological measures, especially anxiety-based measures, there 
may be overlap between NYHA and these measures. A similar association between greater 
functional impairment, measured by NYHA, and depression and anxiety has been reported in 
heart failure patients (Haworth et al., 2005; Lossnitzer et al., 2013; Thomas et al., 2009). 
Hypothesis 2  
Contrary to study hypothesis, HRQoL, anxiety, depression, and PTSD did not improve 
more during the study follow-up in ICD recipients undergoing a VT ablation procedure as 
compared to ICD recipients who did not undergo an ablation. Within-group differences, 
however, showed that participants who underwent a VT ablation exhibited improvement in 
mental health HRQoL, overall PTSD, and symptoms of intrusion and hyperarousal. Participants 
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in the control group showed improvement in symptoms of anxiety, overall PTSD, intrusion and 
hyperarousal. 
The lack of between-group differences is consistent with other studies which also failed 
to detect differences between ICD patients who underwent an ablation as compared to those who 
did not on measures of HRQoL (Gula et al., 2018; Kuck et al., 2010), depression and anxiety 
(Gula et al., 2018). The robust RCT study design of those trials fortifies the current finding that 
the ablation procedure itself does not necessarily improve psychological well-being and HRQoL 
over follow-up as compared to outcomes in non-ablation patients. The current hypothesis is 
informed by prior research which has highlighted the detrimental effects of ICD shocks on 
HRQoL and psychological well-being (Carroll & Hamilton, 2005; Herrmann et al., 1997; Irvine 
et al., 2002; Luderitz et al., 1993; Magyar-Russell et al., 2011; Maryniak et al., 2006; Passman et 
al., 2007; Redhead et al., 2010; Schron et al., 2002; von Känel et al., 2011). Thus, hypothesizing 
that psychological and HRQoL outcomes would improve more over study follow-up in 
participants who underwent an ablation as compared to those who did not was predicated on the 
idea that the ablation procedure would reduce the shock burden thereby helping improve these 
outcomes. The two groups did not differ with respect to shocks at baseline and the shock variable 
had a weak correlation with the grouping variable. Moreover, few participants received shocks 
during the follow-up period and the two groups did not differ with respect to shock burden 
during that period. Thus, it appears that shock burden was not impacted by the ablation 
procedure possibly helping explain the lack of between-group differences. Perhaps had the 
follow-up period been longer, there would have been more time to see a difference in shock 
burden emerge between the two groups, and thereby see a positive effect of ablation therapy on 
HRQoL and psychological wellbeing.  
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An alternative explanation for lack of between-group differences may be that, as 
compared to the control group, participants who underwent a VT ablation were inherently a more 
unwell group. They exhibited poorer functional status as captured by NYHA Class III/IV and 
had significantly more ICDs implanted for secondary prevention. The latter indicates that 
ablation participants had more often experienced life-threatening arrhythmias or survived a 
cardiac arrest which prompted the ICD implant. Moreover, in order to necessitate a VT ablation, 
participants have to experience persistent sustained VT, VT storms, or ICD shocks. This too 
strengthens the argument that ablation participants are a more unwell group. Considering the 
above, it is possible that any physical intervention, such as a VT ablation, might not be able to 
ameliorate HRQoL and psychological well-being in this group of ICD recipients experiencing 
high VT burden, at least within the first six-month post ablation. Importantly, between-group 
effects were small as indicated by the R2 of the grouping variable in the regression analyses. This 
suggests that even with a larger sample size significant differences are unlikely to have been 
detected.  
While studies to date have failed to detect between-group differences, within-group 
improvements detected in the present study align with results of others who have shown 
psychological and HRQoL improvements after the VT ablation procedure (Gula et al., 2018; 
Kuck et al., 2010; Maryniak et al., 2006; Strickberger et al., 1997). Some findings illustrate 
improvements in most domains of HRQoL over a two-year follow-up (Kuck et al., 2010). Others 
detect improvements only in certain domains of HRQoL (social functioning and energy/fatigue) 
and ICD-related concerns (Gula et al., 2018) or only after a successful ablation (Strickberger et 
al., 1997). Results from the current study show that, as compared to baseline, the mean mental 
health component scores (MCS) of the SF-36 increased by almost 5-points in the ablation group. 
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Such an improvement was not detected on the physical component summary as these scores 
remained stable. Previous research has proposed 3-points as a minimally important difference 
which can be considered socially and clinically significant (Maruish, 2011). Baseline mean 
scores of both MCS and PCS were in the moderately to severely impaired range as compared to 
Canadian normative data for the appropriate age range (Hopman et al., 2000). Improvements on 
MCS suggest a clinically important shift. To achieve such an improvement in the MCS domain, 
overall health should be rated as “good” at the very least (Maruish, 2011). This suggests that, 
from the subjective perspective of the ablation participants there may be confidence related to the 
ablation procedure which in turn impacts MCS. Moreover, as in this study, a single case-report 
detected improvements in symptoms of PTSD in an ICD recipient following a VT ablation 
(Maryniak et al., 2006).  
These findings suggest that ICD recipients who undergo a VT ablation gain some 
benefits. One possible explanation for these observed improvements is that ICD recipients who 
necessitate an ablation are profoundly unwell and might experience elevated psychological 
distress. This may be the case irrespective of whether they receive ICD shocks. Namely, the 
stressors may exist as a result of high and repetitive VT burden, repeated exposure to arrhythmia 
treatments, and survival of a life-threatening event. Burke et al. (2003) point out that poor 
psychological outcomes in ICD recipients might be due to factors associated with the ventricular 
arrhythmia, such as having experienced a cardiac arrest, rather than shocks or device itself. 
Indeed, ablation participants in this study were more likely to have secondary prevention ICDs, 
suggesting that they would have experienced the burdens highlighted by Burke et al. (2003). 
Moreover, a recent RCT reported significantly less sustained VT below the ICD detection limit 
and a trend toward fewer VT storm events following a VT ablation (Sapp et al., 2016). 
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Unfortunately, the HRQoL substudy which emerged from that RCT did not provide sufficient 
information to ascertain whether the ablation subgroup who completed HRQoL questionnaires 
differed in terms of VT storms or shocks from the subgroup who did not undergo an ablation 
(Gula et al., 2018). Concerns related to the ICD have been also been reported to decrease 
following a VT ablation over a year-long follow-up (Gula et al., 2018). Taking these 
observations together, if the VT ablation reduces arrhythmia burden or is able to provide some 
confidence that the likelihood of further interventions or arrhythmia events are lower, then there 
might be a favourable impact on HRQoL and psychological outcomes in patients undergoing the 
procedure. Simply put, this might suggest that there are subtle cognitive benefits, namely a 
decrease in stress and worry, associated with ablation therapy. It might be that a longer follow-up 
period is needed to detect the benefits of the ablation on psychological domains and HRQoL and 
for this change to truly become apparent as compared to their control counterparts. 
Lastly, in line with findings from Gula et al. (2018) differences were not detected on 
measures of anxiety and depression in the ablation group. In that study, anxiety and depression 
scores remained stable over time precluding detection of within-group changes (Gula et al., 
2018). In the current study, low anxiety and depression scores at baseline suggest a floor effect 
might have undermined the ability to see much improvement in scores and, thus, precluded the 
detection of within-group changes. Interestingly, ablation participants in the current study 
showed significantly higher levels of trauma at baseline as compared to the control group. No 
differences were detected on measures of anxiety, depression, or HRQoL. This might suggest 
that the trauma measure is more relevant for ablation participants whereas the anxiety measure is 
more pertinent for control participants when assessing psychological outcomes. This is clinically 
sound as ablation participants are more likely to have sustained a life-threatening arrhythmia as 
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well as have experienced more repetitive stressors in the form of VT burden, arrhythmia 
interventions, and compromised functional status. Notwithstanding the clinical sense of this 
suggestion, regression to the mean might have impacted the findings. In other words, in most 
instances, the psychological scores that changed within the ablation versus the control group 
were also those that had more room to change as compared to baseline scores.  
Overall, effect size estimates of within group findings range from small to medium 
providing some confidence in the improvements observed within the ablation group. However, 
due to the small sample size in the current study, the relatively brief follow-up period, and the 
lack of between-group differences, further study is warranted to better understand the HRQoL 
and psychological benefits of VT ablation therapy in the ablation group. 
 
Due to the paucity of studies examining HRQoL in patients undergoing VT ablation, the 
above discussion has been slightly extended to consider research examining radiofrequency 
catheter ablation (RFA) of atrial fibrillation (AF). Studies have demonstrated improvement in AF 
burden in patients undergoing a RFA as compared to treatment with antiarrhythmic drug therapy 
(Cosedis Nielsen et al., 2017; Jaïs et al., 2008; Siontis et al., 2016). This is particularly the case 
when RFA is used as a second-line rhythm control therapy (i.e., following the failure of one or 
more antiarrhythmic drugs). RFA as a first-line rhythm control therapy (i.e., patients who are 
anti-arrhythmic drug naïve) has gained support but requires further study (Calkins et al., 2018; 
Raatikainen et al., 2015). Similar to VT ablation, findings with respect to HRQoL in RFA 
treatment of AF are less consistent. Results from RCTs examining RFA as a second-line 
treatment generally demonstrate improvement in HRQoL relative to baseline and better HRQoL 
as compared to patients treated with medication alone (Jaïs et al., 2008; Wilber et al., 2010). One 
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of these studies showed more improvement in PCS over one-year follow-up and a trend in MCS 
improvement in the RFA group (Jaïs et al., 2008) while the other suggested greater 
improvements in both domains (Wilber et al., 2010). RCTs examining RFA as first-line 
treatment suggest improvement in both RFA and medication groups, with the ablation group 
showing a significantly greater improvement (Calkins et al., 2018). Collapsing across RFA as 
first- or second-line treatment, a recent meta-analysis examined twelve RCTs which compared 
treatment with RFA to medication alone (Siontis et al., 2016). While RFA led to greater 
improvements in some areas of HRQoL (i.e., mental component summary, physical functioning, 
vitality and role emotional) from baseline to three-months follow-up, between-group differences 
diminished with increasing follow-up and none were detected beyond the nine-month follow-up 
(Siontis et al., 2016). Lending support to the meta-analysis is a recent RCT which did not detect 
between-group differences for patients treated with RFA or medication alone (Cosedis Nielsen et 
al., 2017). Although improvements were observed from baseline to the two-year follow-up and 
persisted to the five-year follow-up, between-group differences were not detected. Authors 
explain this as possibly being related to less AF burden in both groups as compared to baseline. 
Similarly, an on-treatment analysis of an RCT of RFA as first-line treatment of patients with 
paroxysmal AF detected no between-group (i.e., RFA, medication alone, cross-over groups) 
differences with all groups showing improvement on PCS and MCS from baseline to one- and 
two-year follow-up periods (Raatikainen et al., 2015). Overall, while findings remain mixed, 
there is suggestion of RFA benefit over medication-alone although it appears to be most 
prominent during a short-term follow-up. Interestingly, it has been proposed that lower AF 
burden or even a placebo effect associated with the more invasive RFA procedure might account 
for improved HRQoL of RFA patients in the short term and that AF recurrence or the 
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diminishing placebo effect might help explain the lack of differences at longer-term follow-up 
(Siontis et al., 2016). This argument, however, has been disputed by others who detected 
sustained improvements over a one-year follow-up (Jaïs et al., 2008). 
Importantly, it can be challenging to directly compare some of the above findings to the 
current study as many studies of RFA patients include lower risk, younger, and relatively healthy 
patients with AF (Calkins et al., 2018; Cosedis Nielsen et al., 2017; Jaïs et al., 2008; Siontis et 
al., 2016; Wilber et al., 2010). The AF population typically appears to be less unwell based on 
having LVEF in the mild to normal range (Cosedis Nielsen et al., 2017; Jaïs et al., 2008; Wilber 
et al., 2010) and often no heart failure symptoms (Siontis et al., 2016). Moreover, AF patients do 
not sustain the burdensome effects of ICD shocks as VT patients do. In line with the 
aforementioned, the benefits sometimes observed in AF patients as compared to those treated 
with medication alone and the lack of such differences in the current study might reflect the 
nature of the profoundly ill population of VT patients where even a state-of-the-art intervention 
such as a VT ablation is not able to improve HRQoL. Alternatively, despite the population 
differences discussed above, the lack of reliable between-group differences in the AF and VT 
populations might suggest that the ablation procedure does not yield the expected benefits with 
respect to HRQoL despite the improved rhythm control.  
Limitations of the study 
The present study employed a case-control design which is a limitation when testing 
between-group differences of novel interventions such as a VT ablation procedure, particularly 
in the case of Hypothesis 2. Although participants were not randomly assigned to treatment 
groups, control participants were recruited based on best available data and carefully selected 
matching criteria. Nonetheless, due to lack of random assignment, the two groups had inherent 
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differences; one group had arrhythmia-related indications which necessitated an undertaking of a 
VT ablation while the other group did not. This may have impacted responses on the measures 
administered as participants had differing experiences with arrhythmia interventions. This may 
have, in turn, influenced the detection of between-group differences. Importantly, a case-control 
design was adopted for the current study given the value of advancing knowledge on 
psychological outcomes in this novel but growing population of cardiac patients. A more robust 
RCT design was beyond the scope of this dissertation. Notably, however, RCTs examining a 
similar group of ICD recipients also failed to detect benefits of VT ablation on measures of 
HRQoL and psychological well-being (Gula et al., 2018; Kuck et al., 2010) lending support to 
current findings. 
The small sample size is another study limitation. A priori power analysis was conducted 
for the hierarchical regression analyses utilized to test the hypotheses. A sample size of 109 
participants with complete data would have been required in order to detect a medium effect size, 
powering the study at 80%, while accounting for control and predictor variables in the regression 
analyses (Faul, Erdfelder, Buchner, & Lang, 2009; Tabachnick & Fidell, 2007). As recruitment 
unfolded it became evident that fewer VT ablation procedures were performed at both TGH and 
SMH than originally anticipated. Moreover, it was profoundly challenging to find and recruit 
appropriate match control participants. Even when matching criteria were expanded (e.g., 
matching on time since implant based on +/-12 months rather than +/-six months) the same 
challenge remained. As a result, the sample size for this study was smaller than planned thus 
compromising power to detect significant differences. In order to mitigate, at least in part, the 
limitations of the small sample size control variables were reviewed and two were removed from 
the regression analyses in Hypothesis 1. The first variable removed was functional status as 
90 
 
measured by LVEF. Every attempt was made to obtain an LVEF within +/-six months of 
recruitment, as measured by an ECHO, however not every patient had a recent LVEF recording. 
Since not all participants had a recent LVEF measure and since functional status assessed by 
NYHA is symptom based and was more strongly related to outcome measures in this study than 
the LVEF, the latter was deemed to be the more appropriate measure to retain in the regression 
analyses. Although lack of an objective measure of functional status is a limitation, the LVEF 
was not highly correlated with psychological outcomes. Thus, it is unlikely that being unable to 
include it in the analyses undermined confidence in results. The second variable removed was 
life stress as it correlated poorly with predictor measures and other control measures. The 
challenge of recruiting large sample sizes is also reflected by the sample sizes of recent RCTs. 
Since VT ablations are relatively novel they are not performed as frequently as ICD implants, for 
example, even in major cardiac centres. One recent RCT recruited 259 participants (n = 132 
ablation) across 22 different centers over a five-year time span (Sapp et al., 2016). Another RCT 
recruited 110 participants (n  = 54 ablation) across 16 cardiac centers over a four-year period 
(Kuck et al., 2010). While the sample size was small in the present study relative to these RCT 
studies, it is important to note that effect size analyses suggest that even with a larger sample in 
the current study significant differences were not likely to have been detected. Thus, while study 
design and sample size are limitations, results of recent RCTs and effect size analyses lend 
credence to the current findings. 
 Another limitation is the short follow-up period of six-months. A longer follow-up time-
frame of two years might have offered insights into further gains or losses. An RCT examining 
effects of a prophylactic VT ablation detected benefits in HRQoL for ablation patients over a 
two-year follow-up (Kuck et al., 2010). This raises the possibility that for individuals who 
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experience high VT burden and subsequently undergo a VT ablation a longer follow-up period 
might provide insight into longer-term psychological benefits of this procedure, particularly 
since the effects of the ablation on VT burden could be captured over a longer period. A longer 
follow-up might also offer the opportunity to assess protective factors such as self-efficacy in the 
management of arrhythmia and associated treatments. As self-efficacy develops over time 
through past successful performances, verbal influences, and observing others a longer follow-up 
would offer a more robust way of testing its effects (Bandura, 1977, 1997; Dougherty et al., 
2007; Houston Miller & Barr Taylor, 1995). 
Future directions for research  
Results of the current research highlight the importance of self-efficacy as a resilience 
factor in relation to symptoms of PTSD and anxiety, over and above the occurrence of shocks or 
presence of a VT ablation procedure. The suggestion in this study that higher self-efficacy is 
protective in this patient population is based on an observational design. An RCT aimed at 
increasing self-efficacy might provide more insight into the value of offering specific 
psychological interventions for a population living with ongoing unpredictable and life-
threatening arrhythmias. Clinically, self-efficacy would be important to bolster in patients 
experiencing repeated and unpredictable ventricular arrhythmias. Self-efficacy can help enhance 
a sense of agency and provide cognitive, behavioural, and emotional tools toward coping with an 
essentially unpredictable illness. A group intervention might build upon those facets which have 
been shown to promote self-efficacy; namely, providing education about arrhythmia treatments, 
discussing past successful coping experiences of dealing with the arrhythmia and associated 
treatments, and correcting misconceptions about physiological and emotional responses (e.g., 
follow-up discussion with health-care professionals to help re-interpret symptoms and provide 
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reassurance; Ashford, Edmunds, & French, 2010; Du et al., 2011). A group format would 
advance this goal since vicarious learning has been identified as an important part of honing self-
efficacy (Ashford et al., 2010). Information provided in-hospital as part of usual care is 
important in terms of providing knowledge about arrhythmia interventions. However, education 
and intervention post hospitalization is important in terms of building upon and maintaining 
knowledge and self-efficacy (Dougherty, Thompson, & Lewis, 2005).   
While no between-group differences were detected, ablation participants saw 
improvements in several domains, a finding corroborated by other studies (Gula et al., 2018; 
Kuck et al., 2010; Strickberger et al., 1997). Future research might focus on replicating these 
findings in a larger sample so as to investigate whether domains of PTSD, anxiety, and HRQoL 
improve consistently following an ablation procedure and how such improvements arise. A 
larger sample would allow for an investigation of how VT ablation impacts VT burden both in 
the form of shocks (i.e., multiple shocks as well as shock storms) as well as sustained VT (e.g., 
VT below the ICD detection threshold or VT storms with the delivery of ATP) and, relatedly, 
how anxiety-based measures change following a VT ablation. While shocks have been identified 
as major contributors to poor psychological functioning, participants in this study did not differ 
on shock burden at baseline or follow-up. Psychological factors varied, however, with the 
ablation participants generally showing poorer function, which might suggest that arrhythmia 
burden, even in the absence of shocks, might contribute to poor psychological function. 
Employing a measure such as the Cardiac Anxiety Questionnaire (Eifert et al., 2000), which 
assesses heart-focused anxiety and fear, avoidance of strenuous activity, and heart-focused 
attention and checking, might provide insights into how VT ablation impacts arrhythmia burden 
and associated distress. Moreover, the ablation group showed more PTSD symptoms at baseline 
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as compared to the control group and exhibited within-group improvements following the 
ablation. This begs the question of how the ablation procedure relates to and augments symptoms 
of PTSD in this subgroup. The Enduring Somatic Threat model of PTSD in chronically ill 
individuals has been put forth by Edmondson (2014). It argues that the acute nature of a life-
threatening medical event differs from external/discrete trauma since the threat is internal and 
enduring and fears are future-oriented. A recent study has lent support to Edmondson’s theory 
and reported an association between cardiac-induced PTSD and fear of disease progression (Fait 
et al., 2018). Fear of illness progression is a construct particularly important for individuals who 
are chronically ill and one which has been strongly associated with cardiac-induced PTSD (Fait 
et al., 2018; Herschbach et al., 2005). As such, it would be informative to assess how the ablation 
procedure impacts PTSD specifically and whether the within-group improvements which were 
observed might be related to the ablation procedure helping mitigate the fear of disease 
progression in this subgroup of ICD patients.  
Conclusions  
Results of Hypothesis 1 show that higher self-efficacy at baseline predicts improvement 
in symptoms of anxiety and PTSD at follow-up. Self-efficacy emerged as a significant predictor 
over and above demographic and cardiac factors, as well as shocks and group membership. This 
offers support to the protective function of self-efficacy in this profoundly unwell group of ICD 
recipients. Self-efficacy, contrary to the hypothesis, was not predictive of depression. Generally, 
low mean baseline depression scores were detected in the current study. As such a floor effect 
may have precluded the detection of improvements in this domain. Similarly, contrary to 
hypothesis, optimism and positive health-expectations at baseline did not predict improvement in 
anxiety, depression, or PTSD. As discussed above, this might reflect momentary variations in 
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optimism (Carver et al., 2010) whereby participant responses to key optimism items, might be 
impacted by the long and stressful experience of dealing with repetitive VT events. Nonetheless, 
results as they pertain to self-efficacy and its relationship to anxiety-based psychological 
symptoms are encouraging. These findings reinforce the importance of individual resilience 
factors and the role of self-efficacy in ICD recipients who are consistently faced with 
unpredictable and uncontrollable arrhythmia. Together they suggest that the appraisal of one’s 
ability to cope with and navigate the stressors of illness, of arrhythmia and its treatments play a 
significant role in the psychological adjustment following arrhythmia treatments. 
Results of Hypothesis 2 failed to detect differences between the ablation and control 
groups on HRQoL, anxiety, depression, or PTSD outcomes. This finding is consistent with past 
studies, some of which were more robust in study design (Gula et al., 2018; Kuck et al., 2010). 
Shock burden was similar between groups at baseline as well as during follow-up. This 
hypothesis was driven by past research which highlights the detrimental effect of shocks on 
psychological functioning and the notion that ablation therapy would reduce shock occurrence. 
Thus, it is possible that lack of differences in shocks precluded detection of between-group 
differences. Alternatively, as individuals undergoing an ablation are profoundly unwell it is 
possible that any intervention might not be able to yield positive psychological effects at least 
within a six-month time frame. Encouragingly, however, ICD recipients who underwent a VT 
ablation showed improvement in mental health HRQoL and symptoms of PTSD. Control 
participants showed improvement on anxiety and PTSD although ablation participants had 
significantly worse trauma scores at baseline. This might suggest that trauma measures might be 
more sensitive to capturing psychological functioning in the ablation group as they have 
undergone significant and repetitive stressors. While effect size estimates for within-group 
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changes were small to medium, due to the study’s small sample size and lack of between-group 
differences, results should be interpreted with caution and warrant further investigation.  
Even though participants in the present study, particularly those undergoing a VT 
ablation, are an unwell group, self-efficacy exerted a protective function with respect to anxiety-
based outcomes from baseline to follow-up. The belief and confidence in personal ability to deal 
with a specific situation related to the arrhythmia might represent small wins that allow the 
individual to “check off” specific manageable tasks which in turn provide a greater sense of 
control. In this way, the individual might feel more agentic and engaged, less anxious and 
traumatized, rather than withdrawn. Ablation participants also showed improvement in mental 
health HRQoL and symptoms of PTSD. Future directions for research include replicating 
findings in larger samples as well as testing the role of self-efficacy by way of a longitudinal 
intervention study. 
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Table 1  
 
Baseline characteristics table of demographic and clinical variables for all participants 
 
Variable All recruited 
participants 
(n=61) 
Completersx 
 
(n=50) 
Non-completersz
 
(n=11) 
Age (years), mean (SD) 63.66 (14.34) 63.48 (14.38) 64.45 (14.77) 
Male 91.8 92.0 90.9 
Greater than high school 
education 
73.8 74.0 72.7 
Living alone 6.6 8.0 0 
Clinical Variables    
Cardiac Diagnosis 
    Ischaemic CMP 
    Non-Ischaemic CMP 
    Other 
 
54.1 
39.3 
6.6 
 
54.0 
40.0 
6.0 
 
54.5 
36.4 
9.1 
NYHA class I & II 82.0 81.6 90.9 
NYHA class III & IV 16.4 18.4 9.1 
NYHA unknown 1.6   
ICD implantation 
   Primary 
   Secondary 
   Unknown 
 
52.5 
45.9 
1.6 
 
50.0 
48.0 
2.0 
 
63.6 
36.4 
Medications    
Psychotropic Medications 28.3 32.0 10.0 
Antiarrhythmic Medication    
   Class I  14.7 14.0 18.2 
   Class II  86.9 86.0 91 
   Class III  60.7 64.0 45.5 
   Class IV  6.6 8.0 0 
   Class V 18.0 16.0 27.3 
ICD therapy pre-baseline 
ATP 
      1-2 
      3-4 
      More than 4 shocks  
 
9.8 
41.0 
16.4 
32.8 
 
10.0 
40.0 
16.0 
34.0 
 
9.1 
45.5 
18.2 
27.3 
Underwent VT ablation 55.7 58.0 45.5 
Ablation Approach 
   Activation 
 
32.4 
 
34.5 
 
20.0  
120 
 
   Substrate 
   Activation and Substrate 
58.8 
8.8 
55.2 
10.3 
80.0 
0 
Ablation outcome 
  Successful 
  Partially successful 
  Unsuccessful 
 
79.4 
5.9 
14.7 
 
79.3 
3.4 
17.2 
 
80.0 
20.0 
0 
Note. Data are shown as percentages unless stated otherwise. CMP = Cardiomyopathy; NYHA = New York Heart 
Association Functional Classification; ICD = Implantable Cardioverter Defibrillator; VT = Ventricular Tachycardia. 
x = completers defined as individuals who completed all questionnaires at follow-up; z = non –completers defined as 
individuals who were missing at least some questionnaires at the follow-up. 
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Table 2  
 
Baseline characteristics – psychological variables for all participants 
 
Variable All who 
completed 
given 
measure 
(n) 
M (SD) Range  Completersx 
 
 
 
(n) 
M (SD) Non-completersz
 
 
 
(n) 
M (SD) 
HADS-A 58 6.14 (4.97) 0 – 18 0.90 48 5.83 (4.98) 10 7.60 (4.95) 
HADS-D 58 4.96 (3.50) 0 – 14 0.76 48 4.86 (3.50) 10 5.40 (3.63) 
IES-R-T 60 0.81 (0.73) 0 – 2.73 0.95 49 .78 (.72) 11 .93 (.84) 
IES-R-I  60 0.80 (0.80) 0 – 2.75 0.90 49 .78 (.76) 11 .99 (.99) 
IES-R-A 60 0.79 (0.79) 0 – 2.75 0.83 49 .79 (.78) 11 .83 (.86) 
IES-R-H 60 0.84 (0.82) 0 – 3.00 0.85 49 .80 (.81) 11 1.0 (.91) 
MCS 60 46.27 (12.13) 16.68 – 62.80  50 46.93 (11.22) 10 42.98 (16.27) 
PCS 60 42.26 (9.31) 18.37 – 58.05  50 42.25 (9.75) 10 42.31 (7.10) 
LSS 60 2.63 (2.25) 0 – 10  49 2.80 (2.36) 11 1.91 (1.51) 
LOT 60 22.05 (7.42) 5 – 32 0.86 49 21.98 (6.94) 11 22.36 (9.68) 
PHE 60 34.47 (8.91) 13 – 49 0.89 49 34.43 (8.76) 11 34.64 (9.98) 
MAT I 60 7.52 (1.90) 3.50 – 10 0.87 49 7.60 (1.84) 11 7.17 (2.23) 
Note. M = Mean; SD = Standard Deviation; HADS = Hospital Anxiety and Depression Scale; IES-R = Impact of Event Scale – Revised; IES-R-T = IES-R Total 
score; IES-R-I = IES-R Intrusion subscale; IES-R-A = IES-R Avoidance subscale; IES-R-H = IES-R Hyperarousal subscale; MCS = Mental Health Component 
Summary Score on the SF-36; PCS = Physical Component Summary Score on the SF-36; LSS = Life Stress Scale; LOT = Life Orientation Test; PHE = Positive 
Health Expectations Scale; MAT I = Managing Arrhythmia Treatments I (Self Efficacy Scale). 
 x = completers defined as individuals who completed all questionnaires at follow-up; z = non –completers defined as individuals who were missing at least some 
questionnaires at the follow-up. 
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Table 3 
 
Descriptive statistics for Hypothesis 1 (Inclusive of all participants who completed baseline AND 
follow-up questionnaires).  
 
Variable n M SD Range t p 
HADS-A 
Baseline 
Follow-up 
 
49a 
49a 
 
5.78 
4.65 
 
4.94 
4.43 
 
0 – 17 
0 – 18  
 
3.05 
 
 
 
.004 
HADS-D 
Baseline 
Follow-up 
 
49a 
49a 
 
4.89 
4.63 
 
3.47 
3.85 
 
0 – 14 
0 – 17 
 
.830 
 
 
 
.411 
IES-R-T 
Baseline 
Follow-up 
 
49a 
49a 
 
0.79 
0.52 
 
0.72 
0.61 
 
0 – 2.73 
0 – 2.23 
 
 
3.56 
 
<.001 
IES-R-I 
Baseline 
Follow-up 
 
49a 
49a 
 
0.76 
0.47 
 
0.76 
0.64 
 
0 – 2.63 
0 – 2.63 
 
 
3.76 
 
<.001 
IES-R-A  
Baseline 
Follow-up 
 
49a 
49a 
 
0.79 
0.60 
 
0.78 
0.70 
 
0 – 2.75 
0 – 2.38 
 
 
1.72 
 
.092 
IES-R-H 
Baseline 
Follow-up 
 
49a 
49a 
 
0.80 
0.48 
 
0.81 
0.69 
 
0 – 3.00 
0 – 2.67 
  
 
3.99 
 
<.001 
LSS 50b 2.80 2.24 0 – 10 
 
  
LOT 50b 22.06 6.89 5 – 32 
 
  
PHE 50b 34.24 8.77 13 – 49 
 
  
MAT I 50b 7.57  1.83 3.50 – 10 
 
  
Note. M = Mean; SD = Standard Deviation; t = paired t-test comparing Baseline and Follow-up values; HADS = 
Hospital Anxiety and Depression Scale; IES-R = Impact of Event Scale – Revised; IES-R-T = IES-R Total score; 
IES-R-I = IES-R Intrusion subscale; IES-R-A = IES-R Avoidance subscale; IES-R-H = IES-R 
Hyperarousal subscale; LSS = Life Stress Scale; LOT = Life Orientation Test; PHE = Positive Health 
Expectations Scale; MAT I = Managing Arrhythmia Treatments (Self Efficacy Scale). 
 a = the n reflects 49 participants completed HADS and a different set of 49 participants completed IES-R ; b = the n 
of 50 participants reflects those individuals who completed both baseline and follow-up of HADS or baseline and 
follow-up of IES-R.  
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Table 4  
 
Correlations among predictor, control, and dependent measures 
 
Variable 
(n) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. LOT  -- .59** 
60 
.61** 
60 
.30* 
60 
.09 
60 
-.01 
60 
-.03 
60 
-.16 
60 
-.21 
60 
-.19 
59 
-.58** 
51 
-.45** 
51 
-.44** 
49 
-.48** 
49 
-.25 
49 
-.48** 
49 
2. PHE   -- .54** 
60 
.34** 
60 
.07 
60 
.16 
60 
.01 
60 
-.00 
60 
-.12 
60 
-.11 
59 
-.30* 
51 
-.43** 
51 
-.27 
49 
-.21 
49 
-.22 
49 
-.31* 
49 
3. MAT I   -- .29* 
60 
.19 
60 
.18 
60 
-.10 
60 
-.12 
60 
-.08 
60 
-.26 
59 
-.67** 
51 
-.41** 
51 
-.65** 
49 
-.68** 
49 
-.44** 
49 
-.66** 
49 
4. Age    -- .49** 
61 
.01 
61 
-.05 
61 
-.04 
61 
-.24 
61 
-.10 
60 
-.30* 
52 
-.18 
52 
-.27 
50 
-.31* 
50 
-.15 
50 
-.28 
50 
5. Gender     -- -.13 
61 
.10 
61 
-.17 
61 
-.03 
61 
-.19 
60 
-.30* 
52 
-.19 
52 
-.39** 
50 
-.43** 
50 
-.22 
50 
-.41** 
50 
6. Time since 
implant 
     -- .08 
61 
.40** 
61 
-.06 
61 
-.16 
60 
-.07 
52 
-.09 
52 
-.09 
50 
.09 
50 
-.21 
50 
-.13 
50 
7. Group       -- .20 
61 
.00 
61 
.32* 
60 
.19 
52 
-.08 
52 
.32* 
50 
.29* 
50 
.31* 
50 
.26 
50 
8. Shocks        -- -.06 
61 
.16 
60 
.24 
52 
-.09 
52 
.20 
50 
.30* 
50 
.15 
50 
.07 
50 
9. LVEF         -- -.12 
60 
-.03 
52 
-.05 
52 
-.10 
50 
-.06 
50 
-.08 
50 
-.13 
50 
10. NYHA           -- .45** 
51 
.37** 
51 
.49** 
49 
.46** 
49 
.38** 
49 
.50** 
49 
11. HADS-A           -- .55** 
52 
.79** 
50 
.75** 
50 
.62** 
50 
.78** 
50 
12. HADS-D            -- .57** 
50 
.46** 
50 
.47** 
50 
.62** 
50 
13. IES-R-T             -- .91** 
50 
.86** 
50 
.92** 
50 
14. IES-R-I              -- .61** 
50 
.86** 
50 
15. IES-R-A               -- .66** 
50 
16. IES-R-H                -- 
** p≤.01; * p≤.05
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Table 5  
 
Model summaries for HADS Anxiety at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2 .729 .782 .808 
∆R2 .729 .053 .026 
P value  <0.001 .048 .167 
F value  F[1,47]=126.48 F[4,43]=2.61 F[3,40]=1.78 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline HADS-A 58 .74 <.001 [.61, .87] .71 <.001 [.56, .86] .60 <.001 [.41, .79] 
Group  
(Ablation vs. 
Control) 
61    -.01 .99 [-1.33, 1.31] -.01 .98 [-1.31, 1.28] 
Shocks (0-4 vs. ≥5) 61   .07 .92 [-1.31, 1.44] .12 .86 [-1.23, 1.46] 
Age 61   .02 .40 [-.03, .07] .02 .45 [-.03, .07] 
NYHA  
(I&II vs. III&IV) 60    2.63 .005 [.84, 4.41] 2.29 .009 [.63, 4.15] 
Baseline LOT 60    -.002 .98 [-.13, .12] 
Baseline PHE 60     .03 .55 [-.07, .12] 
Baseline MAT I 60    -.52 .03 [-.98, -.05] 
Note. n = 52 for follow-up HADS Anxiety.  
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Table 6  
 
Model summaries for HADS Depression at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2 .629 .720 .743  
∆R2 .629 .028  .023  
P value  <.001 .384  .322  
F value  F[1,47]=105.78  F[4,43]=1.07 F[3,40]=1.20 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline HADS-D 58 .90 <.001 [.72, 1.07] .87 <.001 [.67, 1.07] .87 <.001 [.64, 1.11] 
Group  
(Ablation vs. 
Control) 
61  
 
 -.66 .32 [-1.99, .66] -.68 .30 [-2.00, .64] 
Shocks (0-4 vs. ≥5) 61   -.82 .22 [-2.15, .51] -.70 .30 [-2.06, .65] 
Age 61   .02 .48 [-.03, .06] .02 .31 [-.02, .07] 
NYHA  
(I&II vs. III&IV) 
60  
 
 1.17 .22 [-.72, 3.05] 1.10 .25 [-.80, 3.00] 
Baseline LOT 60    .08 .21 [-.05, .20] 
Baseline PHE 60  
 
 
  
 -.06 .18 [-.15, .03] 
Baseline MAT I 60    -.19 .39 [-.62, .25] 
Note. n = 52 for follow-up HADS Depression. 
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Table 7  
 
Model summaries for IES-R-Total at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2  .564 .638  .710  
∆R2  .564 .073  .072 
P value  <0.001  .088 .029 
F value  F[1,47]=60.87 F[4,43]=2.18 F[3,40]=3.32 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IESR-T 60 .62 <.001 [46, .78] .56 <.001 [.37, .74] .46 <.001 [.24, .69] 
Group  
(Ablation vs. 
Control) 
61  
 
 .02 .88 [-.23, .27] .03 .80 [-.21, .27] 
Shocks (0-4 vs. ≥5) 61   -.03 .79 [-.28, .22] -.02 .83 [-.26, .21] 
Age 61   .001 .76 [-.01, .01] .001 .81 [-.01, .01] 
NYHA  
(I&II vs. III&IV) 
60  
 
 .45 .007 [.13, .77] .40 .011 [.10, .70] 
Baseline LOT 60    .01 .33 [-.01, .03] 
Baseline PHE 60  
 
  .007 .40 [-.01, .02] 
Baseline MAT I 60    -.12 .003 [-.20, -.04] 
Note. n = 50 for follow-up IES-R Total. 
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Table 8  
 
Model summaries for IES-R-Intrusion at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2  .522 .617  .750  
∆R2  .522 .096  .132 
P value  <0.001  .044 .001 
F value  F[1,47]=51.28 F[4,43]=2.69 F[3,40]=7.04 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IES-R-I 60 .58 <.001 [.42, .74] .52 <.001 [.33, .71] .39 <.001 [.18, .59] 
Group  
(Ablation vs. Control) 
61  
 
 -.05 .69 [-.33, .22] -.02 .86 [-.26, .22] 
Shocks (0-4 vs. ≥5) 61   .14 .32 [-.14, .41] .12 .30 [-.11, .35] 
Age 61   .001 .82 [-.01, .01] -.001 .87 [-.01, .01] 
NYHA  
(I&II vs. III&IV) 
60  
 
 .51 .005 [.17, .86] .41 .009 [.11, .71] 
Baseline LOT 60    .000 .98 [-.02, .02] 
Baseline PHE 60  
 
  .02 .01 [.01, .04] 
Baseline MAT I 60    -.16 <.001 [-.24, -.09] 
Note. n = 50 for follow-up IES-R Intrusion. 
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Table 9  
 
Model summaries for IES-R-Avoidance at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2  .236 .310  .363  
∆R2  .236 .074  .053 
P value  <0.001  .348 .354  
F value  F[1,47]=14.54 F[4,43]=1.15 F[3,40]=1.12 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IESR-A 60 .43 <.001 [.20, .66] .35 .01 [.08, .61] .29 .06 [-.02, .59] 
Group  
(Ablation vs. Control) 
61  
 
 .18 .91 [-.21, .56] .18 .36 [-.21, .57] 
Shocks  (0-4 vs. ≥5) 61   -.04 .86 [-.44, .36] -.02 .94 [-.42, .39] 
Age 61   .000 .99 [-.01, .01] .002 .79 [-.01, .02] 
NYHA  
(I&II vs. III&IV) 
60  
 
 .42 .11 [-.09, .94] .37 .16 [-.15, .89] 
Baseline LOT 60    .01 .41 [-.02, .05] 
Baseline PHE 60  
 
  -.01 .68 [-.03, .02] 
Baseline MAT I 60    -.10 .13 [-.23, .03] 
Note. n = 50 for Follow-up IES-R Avoidance. 
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Table 10  
 
Model summaries for IES-R-Hyperarousal at six-month follow-up 
 
  Model 1 Model 2 Model 3 
R2  .536 .620  .700  
∆R2  .536 .084  .080 
P value  <0.001  .066 .022 
F value  F[1,47]=54.24 F[4,43]=2.38 F[3,40]=3.58 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IESR-H 60 .61 <.001 [.44, .77] .52 <.001 [.34, .70] .40 <.001 [.19, .61] 
Group  
(Ablation vs. Control) 
61  
 
 .01 .95 [-.27, .29] .03 .82 [-.23, .29] 
Shocks (0-4 vs. ≥5) 61   -.14 .32 [-.42, .14] -.16 .23 [-.42, .11] 
Age 61   -.003 .60 [-.01, .01] -.002 .71 [-.01, .01] 
NYHA  
(I&II vs. III&IV) 
60  
 
 .53 .01 [.16, .91] .48 .01 [.13, .83] 
Baseline LOT 60    .004 .73 [-.02, .03] 
Baseline PHE 60  
 
  .008 .38 [-.01, .03] 
Baseline MAT I 60    -.14 .002 [-.23, -.05] 
Note. n=50 for Follow-up IES-R Hyperarousal. 
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Table 11  
 
Baseline characteristics of demographic and clinical variables for all participants recruited to 
the ablation and control groups 
 
Variable Ablation Group
(n=34) 
Control Group 
(n=27) 
 
Age (years), mean (SD) 63.03(14.78)  64.44(13.99) 
Male 94.1 88.9 
Greater than high school 
education 
70.6 77.7 
 Living alone 2.9 11.1 
Clinical Variables   
Cardiac Diagnosis 
    Ischaemic CMP 
    Non-Ischaemic CMP 
    Other 
 
52.9 
35.3 
11.8 
 
55.6 
44.4 
0 
NYHA class I & II 70.6 96.3 
NYHA class III & IV 26.5 3.7 
NYHA unknown 2.9 0 
ICD implantation 
    Primary 
    Secondary 
    Unknown 
 
39.4 
60.6 
2.9 
 
70.4 
29.6 
0 
Medications   
    Psychotropic  35.3 19.2 
    Class I  23.5 3.8 
    Class II  88.2 88.5 
    Class III  85.3 30.8 
    Class IV  2.9 11.5 
    Class V  14.7 23.1 
ICD therapy pre-baseline 
ATP 
      1-2 
      3-4 
      More than 4 shocks  
 
5.9 
38.2 
14.7 
41.2 
 
14.8 
44.4 
18.5 
22.2 
 
Note. Data are shown as percentages unless stated otherwise. CMP = Cardiomyopathy; NYHA = New York Heart Association 
Functional Classification; ICD = Implantable Cardioverter Defibrillator; VT = Ventricular Tachycardia. 
 x = completers defined as individuals who completed all questionnaires at follow-up; z = non –completers defined as individuals 
who were missing at least some questionnaires at the follow-up. 
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Table 12  
 
Baseline characteristics – psychological variables for ablation and control groups 
 
Variable Ablation 
(n) 
 
M (SD) Range Control
(n) 
M (SD) Range 
MCS 33 44.09 (12.98) 16.68 – 62.77 27 48.95 (10.64) 26.97 – 62.80 
PCS 33 42.68 (9.52) 18.37 – 54.87 27 41.75 (9.20) 22.29 – 58.05 
HADS-A 33 6.79 (5.53) 0 – 18  25 5.28 (4.08) 0 – 16 
HADS-D 33 4.92 (3.28) 0 – 12  25 5.00 (3.84) 0 – 14 
IES-R-T 33 1.03 (.76) 0 – 2.73 27 .54 (.61) 0 – 2.05 
IES-R-I 33 1.05 (.88) 0 – 2.75 27 .50 (.58) 0 – 1.75 
IES-R-A 33 1.00 (.80) 0 – 2.75 27 .54 (.71) 0 – 2.25 
IES-R-H 33 1.04 (.91) 0 – 3 27 .58 (.63) 0 – 2.33 
Note. M = Mean; SD = Standard Deviation; HADS = Hospital Anxiety and Depression Scale; IES-R = Impact of 
Event Scale – Revised; IES-R-T = IES-R Total score; IES-R-I = IES-R Intrusion subscale; IES-R-A = IES-R 
Avoidance subscale; IES-R-H = IES-R Hyperarousal subscale; MCS = Mental Health Component Summary Score 
on the SF-36; PCS = Physical Component Summary Score on the SF-36. 
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Table 13  
 
Ablation participants – correlations among predictor, control, and dependent measures 
 
Variable 
(n) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age -- .40* 
34 
.12 
34 
.02 
34 
-.26 
34 
-.02 
33 
.23 
29 
-.31 
29 
-.39* 
29 
-.07 
29 
-.32 
29 
-.35 
29 
-.20 
29 
-.32 
29 
2. Gender  -- -.13 
34 
-.30 
34 
-.13 
34 
-.13 
33 
.25 
29 
-.07 
29 
-.24 
29 
-.11 
29 
-.37 
29 
-.43 
29 
-.20 
29 
-.42 
29 
3. Time since implant   -- .43* 
34 
-.14 
34 
-.22 
33 
.02 
29 
.21 
29 
-.07 
29 
-.14 
29 
-.002 
29 
.17 
29 
-.13 
29 
-.08 
29 
4. Shocks    -- -.06 
34 
.16 
33 
-.27 
29 
.00 
29 
.34 
29 
.15 
29 
.26 
29 
.36 
29 
.20 
29 
.10 
29 
5. LVEF     -- -.12 
33 
-.08 
29 
-.03 
29 
.09 
29 
.09 
29 
.03 
29 
.02 
29 
.06 
29 
-.02 
29 
6. NYHA      -- -.35 
28 
-.31 
28 
.32 
28 
.40* 
28 
.35 
28 
.33 
28 
.24 
28 
.38* 
28 
7. MCS       -- .52** 
29 
-.73** 
29 
-.79** 
29 
-.79** 
29 
-.70** 
29 
-.70** 
29 
-.76** 
29 
8. PCS        -- -.28 
29 
-.70** 
29 
-.30 
29 
-.14 
29 
-.35 
29 
-.33 
29 
9. HADS-A         -- .48** 
29 
.79** 
29 
.73** 
29 
.67** 
29 
.75** 
29 
10. HADS-D          -- .65** 
29 
.46* 
29 
.70** 
29 
.61** 
29 
11. IES-R Total           -- .92** 
29 
.87** 
29 
.92** 
29 
12. IES-R Intrusion            -- .63** 
29 
.84** 
29 
13. IES-R Avoidance             -- .70** 
29 
14. IES-R 
Hyperarousal 
             -- 
** p≤.01; * p≤.05 
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Table 14  
 
Control participants – correlations among predictor, control, and dependent measures 
 
Variable 
(n) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age -- .62** 
27 
-.16 
27 
-.09 
27 
-.21 
27 
-.32 
27 
.18 
22 
-.01 
22 
-.18 
23 
-.28 
23 
-.27 
21 
-.35 
21 
-.12 
21 
-.27 
21 
2. Gender  -- -.16 
27 
-.09 
27 
.06 
27 
-.56** 
27 
.26 
22 
.12 
22 
-.45* 
23 
-.26 
23 
-.55** 
21 
-.65** 
21 
-.32 
21 
-.50* 
21 
3. Time since implant   -- .32 
27 
.06 
27 
-.16 
27 
-.02 
22 
.21 
22 
-.09 
23 
-.03 
23 
-.38 
21 
-.16 
21 
-.44* 
21 
-.30 
21 
4. Shocks    -- -.07 
27 
-.11 
27 
.22 
22 
.02 
22 
-.12 
23 
-.33 
23 
-.24 
21 
-.15 
21 
-.20 
21 
-.25 
21 
5. LVEF     -- -.20 
27 
.19 
22 
.26 
22 
-.21 
23 
-.19 
23 
-.31 
21 
-.23 
21 
-.27 
21 
-.28 
21 
6. NYHA      -- -.50* 
22 
-.33 
22 
.78** 
23 
.60** 
23 
.85** 
21 
.83** 
21 
.59** 
21 
.81** 
21 
7. MCS       -- .30 
22 
-.74** 
22 
-.79** 
22 
-.60** 
20 
-.74** 
20 
-.19 
20 
-.75** 
20 
8. PCS        -- -.44* 
22 
-.52* 
22 
-.60** 
20 
-.53* 
20 
-.43 
20 
-.61** 
20 
9. HADS-A         -- .77** 
23 
.79** 
21 
.86** 
21 
.44* 
21 
.83** 
21 
10. HADS-D          -- .70** 
21 
.79** 
21 
.32 
21 
.83** 
21 
11. IES-R Total           -- .87** 
21 
.81** 
21 
.89** 
21 
12. IES-R Intrusion            -- .43 
21 
.94** 
21 
13. IES-R Avoidance             -- .47* 
21 
14. IES-R 
Hyperarousal 
             -- 
** p≤.01; * p≤.05 
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Table 15  
 
Within group comparisons between baseline and follow-up measures for ablation and control 
participants 
  
Variable n Ablation 
M (SD) 
ta p d n Control 
M (SD) 
tb p d 
MCS 
Baseline 
Follow-up 
 
29 
29 
 
45.89 (11.55) 
50.76 (8.88) 
 
-3.35 
 
 
.002 
 
.45 
 
22 
22 
 
49.13 (10.54) 
52.63 (10.70) 
 
 
-1.51 
 
.146 
 
.33 
PCS 
Baseline 
Follow-up 
 
29 
29 
 
42.15 (9.91) 
43.11 (10.68) 
 
-.75 
 
.457 
 
.09 
 
22 
22 
 
42.30 (9.65) 
44.45 (9.90) 
 
 
-1.24 
 
.227 
 
.22 
HADS-A 
Baseline 
Follow-up 
 
28 
28 
 
6.32 (5.40) 
5.39 (4.89) 
 
1.86 
 
.073 
 
.18 
 
21 
21 
 
5.05 (4.26) 
3.67 (3.60) 
 
 
2.49 
 
.022 
 
.34 
HADS-D 
Baseline 
Follow-up 
 
28 
28 
 
4.66 (3.19) 
4.25 (3.33) 
 
.917 
 
 
.367 
 
.13 
 
21 
21 
 
5.19 (3.87) 
5.14 (4.49) 
 
 
.118 
 
.908 
 
.01 
IES-R-T 
Baseline 
Follow-up 
 
28 
28 
 
.95 (.75) 
.69 (.68) 
 
3.05 
 
.005 
 
.37 
 
21 
21 
 
0.55 (.61) 
0.30 (.42) 
 
 
2.20 
 
.04 
 
.45 
IES-R-I 
Baseline 
Follow-up 
 
28 
28 
 
.94 (.83) 
.63 (.75) 
 
3.04 
 
.005 
 
.40 
 
21 
21 
 
0.51 (.57) 
0.27 (.38) 
 
 
2.18 
 
.041 
 
.49 
IES-R-A 
Baseline 
Follow-up 
 
28 
28 
 
.97 (.81) 
.78 (.74) 
 
1.17 
 
.254 
 
.24 
 
21 
21 
 
0.55 (.68) 
0.36 (.59) 
 
 
1.32 
 
.201 
 
.29 
 
IES-R-H 
Baseline 
Follow-up 
 
28 
28 
 
.95 (.88) 
.64 (.75) 
 
2.95 
 
 
.007 
 
.38 
 
21 
21 
 
0.60 (.67) 
0.27 (.54) 
 
2.63 
 
.016 
 
.53 
Note. M = Mean; SD = Standard Deviation; d = Cohen’s d; MCS = Mental Health Component Summary Score on the 
SF-36; PCS = Physical Component Summary Score on the SF-36; HADS = Hospital Anxiety and Depression Scale; IES-
R = Impact of Event Scale – Revised; IES-R-T = IES-R Total score; IES-R-I = IES-R Intrusion subscale; IES-R-A = 
IES-R Avoidance subscale; IES-R-H = IES-R Hyperarousal subscale.   
a = Paired sample t-test examining within group difference for the ablation group between baseline and follow-up; b = 
Paired sample t-test examining within group difference for the control group between baseline and follow-up. 
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Table 16  
 
Regression of baseline MCS and demographic, control, and grouping variables on MCS 
 
  Model 1 Model 2 Model 3 
R2  .381 .475 .477 
∆R2 .381 .094 .002  
P value   <.001 .12 .68 
F value  F[1, 48]=29.58 F[4,44]=1.97 F[1,43]=.17 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline MCS 60 .49 <.001 [.31, .67] .47 <.001 [.28, .66] .48 <.001 [.28, .67] 
Age 61      -.03 .73 [-.21, .15] -.03 .77 [-.21, .15] 
Gender 61      9.28 .051 [-0.3,18.58] 8.86 .07 [-.76, 18.48] 
Time since ICD 
implant 61      -.01 .74 [-.05, .03] -.01 .69 [-.05, .03] 
NYHA  
(I&II vs. III&IV) 
60      -3.53 .26 [-9.76, -2.70] -3.98 .24 [-10.65, 2.69] 
Group  60           .96 .68 [-3.74, 5.65] 
Note. n = 51 for MCS follow-up. 
 
 
 
 
Table 17  
 
Simple model – regression of baseline MCS and grouping variable on MCS 
  
  Model 1 Model 2 
R2 .381 .382 
∆R2 .381 .001 
P value   <.001 .81 
F value  F[1,49]=30.20 F[1,48]=.06 
  n Β p 95% CI Β p 95% CI 
Baseline MCS 60 .49 <.001 [.31,.67] .50 <.001 [.31,.68] 
Group  61       .54 .81  [-3.95, 5.03] 
Note. n = 51 for MCS follow-up. 
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Table 18  
 
Regression of baseline PCS and demographic, control, and grouping variables on PCS 
 
  Model 1 Model 2 Model 3 
R2  .533 .597 .597 
∆R2 .533 .064 .001  
P value   <.001 .16 .81 
F value  F[1, 48]=54.73 F[4,44]=1.74 F[1,43]=.06 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline PCS 60 .81 <.001 [.59, 1.02] .78 <.001 [.55, 1.02] .78 <.001 [.55, 1.02] 
Age 61      -.07 .37 [-.24, .09] -.08 .36 [-.24, .09)] 
Gender 61      -1.91 .66 [-10.59,6.77] -1.67 .71 [-10.69, 7.34] 
Time since ICD 
implant 61      -.01 .57 [-.05, .03] -.01 .61 [-.05, .03] 
NYHA  
(I&II vs. III&IV) 
60      -6.52 .02 [-12.00, -1.04] -6.26 .04 [-12.22, -.30] 
Group  60           -.52 .81 [-4.89, 3.86] 
Note. n = 51 for PCS follow-up 
 
 
 
 
Table 19  
 
Simple model – regression of baseline PCS and grouping variable on PCS 
 
  Model 1 Model 2 
R2 .533  .543 
∆R2 .533 .010 
P value   <.001 .30 
F value  F[1,49]=55.87 F[1,48]=1.09 
  n Β p 95% CI Β p 95% CI 
Baseline PCS 60 .81 <.001 [.59,1.02] .81 <.001 [.59,1.02] 
Group  61       -2.09 .30  [-6.12, 1.94] 
Note. n = 51 for PCS follow-up. 
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Table 20  
 
Regression of baseline HADS-A and demographic, control, and grouping variables on HADS-A 
 
  Model 1 Model 2 Model 3 
R2  .729 .803 .804 
∆R2 .729 .074 .001  
P value   <.001 .007 .65 
F value  F[1, 47]=126.48 F[4,43]=4.01 F[1,42]=.22 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline HADS-A 58 .74 <.001 [.61, .87] .72 <.001 [.58, .85] .72 <.001 [.58, .85] 
Age 61      .05 .08 [-.01, .10] .05 .08 [-.01, .10] 
Gender 61      -2.65 .04 [-5.17,-.13] -2.79 .04 [-5.40, -.17] 
Time since ICD 
implant 61      -.001 .84 [-.01, .01] -.002 .78 [-.01, .01] 
NYHA  
(I&II vs. III&IV) 
60      2.31 .01 [.63, 3.99] 2.17 .02 [.36, 3.97] 
Group  61           .30 .65 [-1.00, 1.60] 
Note. n = 52 for HADS-Anxiety follow-up. 
 
 
 
 
Table 21  
 
Simple model – regression of baseline HADS-A and grouping variable on HADS-A 
 
  Step 1 Step 2 
R2 .729 .733 
∆R2 .729 .004 
P value   <.001 .40 
F value  F[1,47]=126.48 F[1,46]=.72 
  n Β p 95% CI Β p 95% CI 
Baseline HADS-A 58 .74 <.001 [.61,.87] .73 <.001 [.60,.87] 
Group  61       .56 .40  [-.77, 1.90] 
Note. n = 52 for HADS-Anxiety follow-up. 
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Table 22  
 
Regression of baseline HADS-D and demographic, control, and grouping variables on HADS-D 
 
  Model 1 Model 2 Model 3 
R2  .629 .730 .736 
∆R2 .629 .038 .006  
P value   <.001 .22 .35 
F value  F[1, 47]=105.78 F[4,43]=1.51 F[1,42]=.88 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline HADS-D 58 .90 <.001 [.72, 1.07] .93 <.001 [.73, 1.13] .91 <.001 [.71, 1.11] 
Age 61      .04 .10 [-.01, .09] .04 .14 [-.01, .09] 
Gender 61      -2.40 .07 [-5.00, .19] -2.09 .12 [-4.78, .59] 
Time since ICD 
implant 61      .004 .43 [-.01, .02] .005 .36 [-.01, .02] 
NYHA  
(I&II vs. III&IV) 
60      .40 .65 [-1.38, 2.18] .76 .43 [-1.18, 2.70] 
Group  61           -.62 .35 [-1.96, .72] 
Note. n = 52 for HADS-Depression follow-up. 
 
 
 
 
Table 23  
 
Simple model – regression of baseline HADS-D and grouping variable on HADS-D 
 
  Model 1 Model 2 
R2 .692 .698 
∆R2 .692 .006 
P value   <.00 .36 
F value  F[1,47]=105.78 F[1,46]=.84 
  n Β p 95% CI Β p 95% CI 
Baseline HADS-D 58 .90 <.001 [.72,1.07] .90 <.001 [.72,1.07] 
Group  61       -.56 .36  [-1.79, .67] 
Note. N=52 for HADS-Depression follow-up. 
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Table 24  
 
Regression of baseline IES-R Total and demographic, control, and grouping variables on IES-R 
Total 
 
  Model 1 Model 2 Model 3 
R2  .564 .734 .742 
∆R2 .564 .170 .007  
P value   <.001 <.001 .28 
F value  F[1, 47]=60.87 F[4,43]=6.88 F[1,42]=1.19 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IES-R Total 60 .62 <.001 [.46, .78] .60 <.001 [.45, .75] .58 <.001 [.42, .73] 
Age 61      .01 .03 [.001, .02] .01 .03 [.001, .02] 
Gender 61      -.79 <.001 [-1.20,-.37] -.83 <.001 [-1.26, -.41] 
Time since ICD 
implant 61      -.002 .09 [-.003, .00] -.002 .07 [-.003, .00] 
NYHA  
(I&II vs. III&IV) 
60      .31 .03 [.03, .59] .27 .07 [-.02, .56] 
Group  61           .12 .28 [-.10, .33] 
Note. n = 50 for IES-R Total follow-up. 
 
 
 
 
Table 25  
 
Simple model – regression of baseline IES-R Total and grouping variable on IES-R Total 
 
  Model 1 Model 2 
R2 .564 .570 
∆R2 .564 .006 
P value   <.001 .43 
F value  F[1,47]=60.87 F[1,46]=.63 
  n Β p 95% CI Β p 95% CI 
Baseline IES-R Total 58 .62 <.001 [.46,.78] .60 <.001 [.43,.76] 
Group  61      .10 .43  [-.15, .35] 
Note. n = 50 for IES-R Total follow-up. 
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Table 26  
 
Regression of baseline IES-R Intrusion and demographic, control, and grouping variables on IES-R 
Intrusion 
 
  Model 1 Model 2 Model 3 
R2  .522 .708 .709 
∆R2 .522 .186 .001  
P value   <.001 <.001 .77 
F value  F[1, 47]=51.28 F[4,43]=6.87 F[1,42]=.09 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IES-R 
Intrusion 60 .58 <.001 [.42, .74] .56 <.001 [.41, .72] .56 <.001 [.39, .72] 
Age 61      .01 .04 [.00, .02] .01 .05 [.00, .02] 
Gender 61      -.85 .001 [-1.32,-.39] -.87 .001 [-1.35, -.39] 
Time since ICD 
implant 61      .00 .85 [-.002, .002] .00 .89 [-.002, .002] 
NYHA  
(I&II vs. III&IV) 
60      .42 .008 [.11, .72] .40 .02 [.08, .73] 
Group  61           .04 .77 [-.21, .28] 
Note. n = 50 for IES-R Intrusion follow-up. 
 
 
 
 
Table 27  
 
Simple model – regression of baseline IES-R Intrusion and grouping variable on IES-R Intrusion 
 
  Model 1 Model 2 
R2 .522 .524 
∆R2 .522 .002 
P value   <.001 .63 
F value  F[1,47]=51.28 F[1,46]=.24 
  n Β p 95% CI Β p 95% CI 
Baseline IES-R 
Intrusion 58 .58 <.001 [.42,.74] .57 <.001 [.39,.74] 
Group  61      .07 .63  [-.21, .35] 
Note. n = 50 for IES-R Intrusion follow-up. 
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Table 28 
 
Regression of baseline IES-R Avoidance and demographic, control, and grouping variables on IES-
R Avoidance 
 
  Model 1 Model 2 Model 3 
R2  .236 .377 .410 
∆R2 .236 .141 .033  
P value   <.001 .06 .13 
F value  F[1, 47]=14.54 F[4,43]=2.43 F[1,42]=2.38 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IES-R 
Avoidance 60 .43 <.001 [.20, .66] .42 .001 [.18, .66] .38 .003 [.14, .63] 
Age 61      .01 .36 [-.01, .02] .01 .31 [-.01, .02] 
Gender 61      -.60 .11 [-1.34,.13] -.72 .06 [-1.46, .02] 
Time since ICD 
implant 61      -.003 .06 [-.01, .00] -.003 .03 [-.01, .00] 
NYHA  
(I&II vs. III&IV) 
60      .32 .21 [-.18, .81] .20 .45 [-.32, .71] 
Group  61           .28 .13 [-.09, .66] 
Note. n = 50 for IES-R Avoidance follow-up. 
 
 
 
 
Table 29  
 
Simple model – regression of baseline IES-R Avoidance and grouping variable on IES-R Avoidance 
 
  Model 1 Model 2 
R2 .236 .266 
∆R2 .236 .029 
P value   <.001 .18 
F value  F[1,47]=14.54 F[1,46]=1.83 
  n Β p 95% CI Β p 95% CI 
Baseline IES-R 
Avoidance 58 .43 <.001 [.20, .66] .39 .002 [.15, .62] 
Group  61      .25 .18  [-.12, .62] 
Note. n = 50 for IES-R Avoidance follow-up. 
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Table 30 
  
Regression of baseline IES-R Hyperarousal and demographic, control, and grouping variables on 
IES-R Hyperarousal 
 
  Model 1 Model 2 Model 3 
R2  .536 .687 .692 
∆R2 .536 .152 .004  
P value   <.001 .002 .46 
F value  F[1, 47]=54.24 F[4,43]=5.22 F[1,42]=.56 
  n Β p 95% CI Β p 95% CI Β p 95% CI 
Baseline IES-R 
Hyperarousal 60 .61 <.001 [.44, .77] .52 <.001 [.36, .67] .50 <.001 [.34, .67] 
Age 61      .01 .33 [-.01, .02] .01 .30 [-.01, .02] 
Gender 61      -.80 .003 [-1.30, .30] -.84 .002 [-1.36, .32] 
Time since ICD 
implant 61      -.001 .30 [-.003, .001] -.001 .23 [-.003, .001] 
NYHA  
(I&II vs. III&IV) 
60      .41 .02 [.07, .75] .37 .05 [.01, .72] 
Group  61           .10 .46 [-.17, .36] 
Note. n = 50 for IES-R Hyperarousal follow-up. 
 
 
 
 
Table 31  
 
Simple model – regression of baseline IES-R Hyperarousal and grouping variable on IES-R 
Hyperarousal 
 
  Model 1 Model 2 
R2 .536 .539 
∆R2 .536 .003 
P value   <.001 .57 
F value  F[1,47]=54.24 F[1,46]=.32 
  n Β p 95% CI Β p 95% CI 
Baseline IES-R 
Hyperarousal 58 .61 <.001 [.44, .77] .59 <.001 [.42, .76] 
Group  61      .08 .57  [-.21, .37] 
Note. n = 50 for IES-R Hyperarousal follow-up. 
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Figure 1. Patient Accrual 
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Quality of Life and Psychosocial Well-Being Following VT Ablation  
Information Letter 
 
We are writing to let you know about an opportunity to participate in a study which aims to better 
understand how treatments for ventricular tachycardia (VT) influence health and well-being. This 
study will involve two groups of patients. One group consists of individuals who have an 
implantable cardioverter defibrillator (ICD) and who are undergoing an ablation procedure. The 
other group consists of individuals who have an ICD and who are not undergoing an ablation 
procedure. The general aim of this study is to better understand the impact of various types of 
treatment for VT on health and well-being. Individuals who choose to participate will fill out one 
questionnaire package at the time of recruitment and one following a 6-month period. 
  
We are sending you this letter as you have been contacted by your health care provider and have 
expressed interest in learning more about this study. In addition to this letter, we are sending you a 
consent form, and a questionnaire package. A member of our study staff will explain the study in 
detail, review the consent form with you, and answer any questions or concerns that you may have. 
  
You will be asked to sign the consent form, complete the questionnaire package, and send back the 
signed consent form and the questionnaire package in a stamped, self-addressed envelope which will 
be provided to you. The questionnaires ask about your experiences, general mood, and feelings.    
 
Please note that participating in this study is completely voluntary and that you are free to withdraw 
at any point during the study. Your medical care will not be affected in any way by whether or not 
you choose to participate in this research study. All information obtained for this study will be kept 
strictly confidential and will be used for research purposes only. Your name will not be used or 
associated with the information which you provide, and any identifying information, such as names 
or locations, will be removed from the study.   
 
If you have not already returned the completed questionnaire package, a member of our study team 
will contact you by phone to follow up in approximately two weeks.  
 
If you have any questions about the research study, please feel free to contact Dr. Jane Irvine at 416-
736-2100, ext. 22444 or Dr. Nanthakumar at 416-340-4800 ext. 4442. 
 
Sincerely, 
 
 
Dr. Jane Irvine and Dr. Nanthakumar 
 
 
 
Appendix A: Information Letter 
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Appendix B: Informed Consent Form – University Health Network 
 
 
Consent Form for Participation in a Research Study 
 
Title:  Quality of Life and Psychosocial Well-Being Following VT Ablation  
 
Principal Investigators: Dr. Nanthakumar 416-340-4800 ext. 4442, FRCPC, MD, Division of 
Experimental Therapeutics, Dr. Jane Irvine, D. Phil, C. Psych, Affiliate Scientist, 
Division of Behavioural Sciences and Health, 416-736-2100; Ext. 22444, 
 Leora Wanounou, RN, BScN, CCN(c), 416-419-5672, Co-investigator, and Ana Bilanovic, MA, 
Co-investigator, 416-419-5672 
 
 
You are being asked to take part in a research study. Before agreeing to participate in this study, it is 
important that you read and understand the following explanation of the proposed study procedures. 
The following information describes the purpose, procedures, benefits, discomforts, risks and 
precautions associated with this study. It also describes your right to refuse to participate or 
withdraw from the study at any time. In order to decide whether you wish to participate in this 
research study, you should understand enough about its risks and benefits to be able to make an 
informed decision. This is known as the informed consent process. Please ask the study staff to 
explain any words you don’t understand before signing this consent form. Make sure all your 
questions have been answered to your satisfaction before signing this document. 
 
Background 
To date, much of the research in arrhythmia populations has focused on examining the impact of 
having an implantable cardioverter defibrillator (ICD). In these studies, issues such as quality of life, 
anxiety, and depression levels have been examined. However, less research has been conducted on 
catheter ablation, an increasingly common method for treating ventricular tachycardias (VT), and the 
associated quality of life and psychosocial well-being.    
 
Purpose 
This study aims to better understand how treatments for ventricular arrhythmias influence health and 
well-being. It aims to study two groups of patients. One group consists of individuals with an ICD 
who are undergoing an ablation procedure. The other group consists of individuals with an ICD who 
are not undergoing an ablation procedure. The general aim of this study is to better understand the 
impact of various types of treatment for VT on health and well-being over a 6-month period. 
 
Procedures 
Your healthcare team has noted that you are eligible to participate in this research study. You have 
either been approached by a member of your health care team during your regularly scheduled 
hospital visit or you have been contacted by a member of your health care team by phone. Because 
you expressed interest in hearing about this study you are receiving this consent form, in addition to 
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an information letter, and a questionnaire package. Our study coordinator will review this consent 
form with you either while you are at the hospital for your regularly scheduled visit or by phone. At 
that time, the study coordinator will explain the study to you in detail and address any questions or 
concerns that you may have. In this package you will find several questionnaires which will ask 
about your experiences, general mood, and feelings. You will be asked to please send back the 
completed questionnaire package with a signed consent form in a stamped, self-addressed envelope 
which will be provided to you in a timely manner. The study will follow all participants for a 6-
month period. This means that you will receive another package, similar to the one you received 
when you enrolled in the study, after 6 months. At that time, you will be asked to send back the 
questionnaire package in a stamped, self-addressed envelope which will be provided to you. The 
questionnaire packages will take approximately 30-45 minutes to complete. 
   
Additionally, we would like your permission to review information about your previous medical 
history by examining your hospital chart. 
 
Risks  
This is a minimal risk study. It is possible that you may find some questions in the questionnaires to 
be personal in nature, and you may choose to not answer these questions. In the unlikely event that 
you experience great distress as a result of a questionnaire, a psychologist on our research team will 
provide you with assistance in finding appropriate counseling resources should you ask for such 
assistance. 
 
Benefits 
While you will not receive any medical benefit from participating in this study, your participation 
will help provide a further understanding of the quality of life and psychological well-being 
following a catheter ablation procedure. Information learned from this study may help improve 
patient care by enhancing the healthcare provider’s ability to determine the plan of care for these 
patients.  
 
Confidentiality  
All information obtained during the study will be held in strict confidence. You will be identified 
with a study number only. No names or identifying information will be used in any publication or 
presentations. No information identifying you will be transferred outside the investigators in this 
study or this hospital. The information obtained from this study will be used for research purposes 
only. The University Health Network Research Ethics Board (a body that oversees the ethical 
conduct of research studies) may look at the study information for auditing purposes. Following their 
completion and return, the questionnaire packages will be kept confidential by being stored within a 
double-locked cabinet within a locked office for five years following the completion of this study. 
Once five years have passed, data will be destroyed by shredding. Upon completion, the study 
results and research dissertation will become public property and may be published. Your identity 
will remain anonymous at all times.   
 
Participation 
Participation in this study is voluntary. At any time you may choose not to answer a given question. 
You can choose not to participate in the study or you may withdraw at any time without affecting 
your medical care.  
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Questions  
If you have any general questions about the study, please contact the Principal Investigators:  
 
Dr. Nanthakumar 416-340-4800 ext. 4442 or Dr. Jane Irvine, 416-736-2100 ext. 22444, 
or one of the co-investigators 
Leora Wanounou, 416-419-5672 or Ana Bilanovic, 416-419-5672  
 
For any questions about your rights as a research participant, please contact the Chair of UHN 
Research Ethics Board, at (416) 581-7849.  
This person is not involved with the research project in any way and calling them will not affect your 
participation in the study. 
 
Consent  
I have had the opportunity to discuss this study and my questions have been answered to my 
satisfaction. I consent to take part in the study with the understanding I may withdraw at any time 
without affecting my medical care. I have received a signed copy of this consent form. I voluntarily 
consent to participate in this study.  
 
__________________________    _______________________  ____________ 
Participant’s Name (Please Print) Participant’s Signature                       Date  
 
 
I confirm that I have explained the nature and purpose of the study to the study participant named 
above. I have answered all questions.  
 
_________________________ ______________________      _____________ 
Name of Person                    Signature                                                       Date 
Obtaining Consent 
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Appendix C: Informed Consent Form – St. Michael’s Hospital 
 
 
 
 
 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
 
Title: Quality of Life and Psychosocial Well-Being Following VT Ablation  
 
 
Investigator:  
 
24 Hour / 7 Day Emergency Number: St. Michael’s Hospital, Locating 416.864.5431  
Ask for the Electrophysiologist on call 
 
1. INTRODUCTION 
 
You are being invited to consider taking part in a research study.  Before agreeing to take part in 
this research study, it is important that you read the information in this consent form. It includes 
details we think you need to know in order to decide if you wish to take part in the study. If you have 
any questions, ask a study doctor or study staff.  You should not sign this form until you are sure 
you understand the information. All research is voluntary.  You may also wish to discuss the study 
with your family doctor, a family member or close friend. If you decide to take part in the study, it is 
important that you are completely truthful about your health history and any medications you are 
taking.  This will help prevent unnecessary harm to you. 
 
This document describes the purpose, procedures, benefits and risks of the study.  It also describes 
your right to withdraw from the study at any time.  Please read this consent form carefully and ask 
as many questions as you like before deciding whether you want to take part in this study.   
 
2.  PURPOSE OF THE RESEARCH 
 
The purpose of this study is to better understand how treatments for ventricular arrhythmias 
(abnormal rapid heart rhythm that originates in the lower chamber of the heart called the ventricles) 
influence health and well-being.  It aims to study two groups of patients. One group consists of 
individuals with an implantable cardioverter defibrillator (ICD) who are undergoing an ablation 
procedure. The other group consists of individuals with an ICD who are not undergoing an ablation 
procedure. The general aim of this study is to better understand the impact of various types of 
treatment for ventricular tachycardia (VT) on health and well-being over a 6-month period. 
 
To date, much of the research in arrhythmia populations has focused on examining the impact of 
having an implantable cardioverter defibrillator (ICD) to prevent sudden death in patients with 
ventricular tachycardia (VT). In these studies, issues such as quality of life, anxiety, and depression 
Principal Investigator: Sub-Investigator: Research Coordinator 
Dr. Paul Angaran Dr Iqwal Mangat  
 
Zana Mariano 
St. Michael’s Hospital St. Michael’s Hospital St. Michael’s Hospital 
6-050 Queen wing 6-050 Queen wing 8-026 Bond Wing 
416-864-5104 416-864-5104 416-864-6060 ext 2696 
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levels have been examined. However, less research has been conducted on catheter ablation. 
Catheter ablation involves placing catheters (wires) inside your heart. The wires are used to destroy 
the abnormal electrical impulses that are thought to cause VT. This is an increasingly common 
method for treating VT, and the associated quality of life and psychosocial well-being.    
 
3.  DESCRIPTION OF THE RESEARCH 
 
This study aims to evaluate the long term outcomes (6 months) of various types of treatment for VT 
on quality of life and psychosocial well-being in patients with an ICD.  It is anticipated that St. 
Michael’s Hospital will enroll between 20-30 participants.     
 
The study has 2 parts:  
1.  This initial contact requesting your consent to access your medical chart (there is no other 
action required of you); and  
 
2. A follow-up health survey shortly after your clinic visit and at 6 months   
 
Enrollment 
 
Your healthcare team has noted that you are eligible to participate in this research study. You have 
either been approached by a member of your health care team during your regularly scheduled 
hospital visit or you have been contacted by a member of your health care team by phone. Since 
you expressed interest in hearing about this study, you are receiving this consent form, in addition 
to an information letter, and a questionnaire package. Our study coordinator will review this consent 
form with you either while you are at the hospital for your regularly scheduled visit or by phone.  
 
At that time, the study coordinator will explain the study to you in detail and address any questions 
or concerns that you may have.  In this package you will find several questionnaires which will ask 
about your experiences, general mood, and feelings. You will be asked to please send back the 
completed questionnaire package with a signed consent form in a stamped, self-addressed 
envelope which will be provided to you, in a timely manner. If you are willing to participate in the 
study, please read and sign this consent form.  Contact details of your family doctor and/or 
specialist (who looks after your heart) will be extracted from your hospital records.     
 
At St Michael’s Hospital, providing contact information is required to ensure complete follow-up of 
all patients and to make sure that data collected are precise.  No identifiable information or data will 
be sent to the sponsor.  Your doctors will be notified about your participation in this study and the 
details of this research.      
Additional clinical information such as details regarding other medical disorders that you may have, 
results of blood/urine tests, results of a heart sonogram (if done) will be obtained from your hospital 
record and if necessary, by contacting one of your physicians.  If you are on blood thinning 
medications, we will attempt to get results of relevant testing (INR result) from your family doctor or 
specialist doctor. 
 
 
Follow-up  
 
After 6 months, you will be contacted (in person, telephone and/or mail) and asked 
satisfaction questions regarding your health.   
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You will be asked to send back a set of questionnaires, similar to those received upon enrollment 
into the study, in a stamped, self-addressed envelope, which will be provided to you and asked to 
mail it back within three weeks of receiving the questionnaires. If you have not returned a 
questionnaire package within the 3-week time period, you will be contacted up to three times and 
reminded to please return the questionnaire package. The questionnaire packages will take 
approximately 30-45 minutes to complete.    
 
If additional information is needed, we would like your permission to review information about your 
previous medical history by examining your hospital chart. 
 
 
4. POTENTIAL HARMS (INJURY, DISCOMFORTS OR INCONVENIENCE) 
 
This is a minimal risk study.  It is possible that you may find some questions in the questionnaires 
to be personal in nature, and you may choose to not answer these questions.  In the unlikely event 
that you experience great distress as a result of a questionnaire, a psychologist on our research 
team will provide you with assistance in finding appropriate counseling resources should you ask for 
such assistance. 
 
5. POTENTIAL BENEFITS 
 
While you will not receive any medical benefit from participating in this study, your participation will 
help provide a further understanding of the quality of life and psychological well-being following a 
catheter ablation procedure. Information learned from this study may help improve patient care by 
enhancing the healthcare provider’s ability to determine the plan of care for these patients. 
 
6.    PROTECTING YOUR HEALTH INFORMATION 
 
All St. Michael’s Hospital (SMH) study staff (study investigators, coordinators, nurses and 
delegates) are committed to respecting your privacy. No other persons will have access to your 
personal health information or identifying information without your consent, unless required by law. 
The study staff will make every effort to keep your personal health information private and 
confidential in accordance with all applicable laws, regulations, guidelines and privacy legislations, 
including the Personal Health Information Protection Act (PHIPA) of Ontario. 
 
Any personal health information or personal information collected about you will be “de-identified” 
by replacing your personal identifying information with a “study number”.  The SMH study staff is in 
control of the study code key, which is needed to connect your personal health information/personal 
information to you.  The link between the study number and your personal identity will be 
safeguarded by the SMH study staff. Our guidelines include the following: 
 
 All information that identifies you, both paper copy and electronic information, will be kept 
confidential and stored and locked in a secure place that only the study staff will be able to 
access.  
 Electronic files will be stored securely on hospital or institutional networks or securely on 
any portable electronic devices. 
 No information identifying you will be allowed off site in any form. Examples include your 
hospital or clinic charts, copies of any part of your charts, or notes made from your charts. 
 Questionnaires and data will be stored in a secure server at Toronto General Hospital.  No 
identifying information will be sent off site. 
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It is important to understand that despite these protections being in place, there continues to be the 
risk of unintentional release of information.  The SMH study staff will protect your records and keep 
all the information in your study file confidential to the greatest extent possible.  The chance that 
this information will be accidentally released is small. 
 
Although all of your study data will be kept confidential, your medical records may be accessed by 
the study staff or the St. Michael’s Hospital Research Ethics Board. Such access will be used only 
for the purpose of verifying the authenticity and accuracy of the information collected for the study, 
without violating your confidentiality to the extent permitted by applicable laws and regulations.   
 
Federal and Provincial Data Protection regulations, including the Personal Information Protection 
and Electronic Documents Act (PIPEDA 2000) and the Personal Health Information Protection Act 
(PHIPA 2004) of Ontario, protect your personal information. They also give you the right to control 
the use of your personal information (including personal health information) and require your written 
permission for this personal information to be collected, used, or disclosed for the purposes of this 
study, as described in this consent form.  You have the right to review and copy your personal 
information collected in this study.  However, if you decide to be in this study or choose to withdraw 
from it, your right to look at or copy your personal information related to this study will be delayed 
until after the research is completed. 
 
Study data will be retained for 10 years. 
   
7. STUDY RESULTS 
 
The results of this study may be presented at meetings or in publications. Your identity will not be 
disclosed in those presentations. At the end of the study, the study results, and conclusions may be 
disclosed to you, if you so wish. 
 
8. POTENTIAL COSTS/REIMBURSEMENTS 
 
There will be no charge to you for your participation in this study. 
 
9. PARTICIPATION AND WITHDRAWAL 
 
Participation in any research study is voluntary.  At any time you may choose not to answer a given 
question.  If you do decide to take part you will be asked to sign this consent form.  If you choose 
not to participate, you and your family will continue to have access to customary care at St. 
Michael’s Hospital.  If you decided to participate in this study and signed the consent form you can 
change your mind without giving a reason, and you may withdraw from the study at any time 
without affecting the care you and your family will receive at St. Michael’s Hospital.  You should talk 
to your study doctor to determine how best to complete the withdrawal process.   
 
 
10. NEW FINDINGS OR INFORMATION 
 
We may learn new things during the study that you may need to know.  You will be notified about 
any new information in a timely manner.   
 
You will be kept informed, in a timely manner, of any information that may relate to your willingness 
to continue participation in the study.  At the discretion of your doctor(s), you may be asked to sign 
a revised informed consent or consent addendum that provides this information. 
 
152 
 
You may ask questions at any time about this study.  You should contact Research Coordinator, 
Zana Mariano at 416-864-6060 ext. 2696. 
 
 
11. RESEARCH ETHICS BOARD CONTACT 
 
If you have any questions regarding your rights as a research participant, you may contact Dr 
David Mazer, Chair, Research Ethics Board at 416-864-6060 ext 2557 during business hours. 
 
12. STUDY CONTACTS 
 
If you have any questions about this study, or if you feel you have experienced a research-related 
injury, contact the study doctor: 
 
 Dr. Paul Angaran, Cardiologist 
 St. Michael’s Hospital 
 Room 6-050, Queen Wing 
 30 Bond Street, Toronto, Ontario 
 M5B 1W8 
Tel: 416-864-5104 
 
In case of emergency, please go to the nearest emergency department and let them know 
that you are in a study, and the principal investigators name.   
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Title:  “Quality of Life and Psychosocial Well-Being Following VT Ablation” 
 
Consent Signature: 
I acknowledge that the study described above has been explained to me and that any 
questions that I have asked have been answered to my satisfaction.  I have been informed of 
the alternatives to participation in this study, including the right not to participate and the 
right to withdraw without compromising the quality of medical care at St. Michael’s Hospital 
for me and for other members of my family. As well, the potential harms have been explained 
to me and I also understand the benefits (if any) of participating in the research study.  
 
I understand that I have not waived my legal rights nor released the investigators, sponsors, 
or involved institutions from their legal and professional responsibilities.  I know that I may 
ask now, or in the future, any questions I have about the study.  I have been told that records 
relating to me and my care will be kept confidential and that no information that will be 
disclosed without my permission unless required by law.  I have been given sufficient time 
to read and understand the above information. 
 
I hereby voluntarily consent to participate in the research study described above.  I will 
receive two copies of the consent form - one signed copy which I will keep and the other 
which will be returned to the study team. 
 
I understand that my family physician and/or specialist and pharmacist will be informed of 
my participation in this study. 
 
 
_______________________________    ________________  
Participant’s Signature                  Date 
 
_______________________________    
Participant’s Printed Name  
 
 
Participant’s telephone number: ________________________________                    
 
STUDY PERSONNEL STATEMENT  
 
The person signing this consent form has had the study fully and carefully explained and has 
been given an opportunity to ask any questions regarding the nature, risks and benefits of the 
subject’s participation in this research study. 
 
 
_______________________________       ________________  
Signature of Person Obtaining Consent      Date 
 
 
_______________________________     
Printed Name of Person Obtaining Consent 
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Participant #: _______________      Date: _______________ 
 
Appendix D – Baseline Questionnaire 
 
 
STUDY QUESTIONNAIRE 
Baseline  
 
 
Thank you for completing the following questionnaire. Your answers will help us assess the results 
of this study and get a better understanding of how treatments for ventricular arrhythmias influence 
health and well-being. 
 
Please return the completed questionnaire in the pre-stamped self-addressed envelope provided.  
 
You may find some of the questions in this survey to be personal in nature and we appreciate your 
willingness to complete the items. Your replies will be kept strictly confidential and only the 
research team will see your answers. If you have any questions, please contact the study co-
ordinators at 416-419-5672. 
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DEMOGRAPHIC INFORMATION 
 
Please try to answer all of the questions.  However, if there are any that you would rather not 
answer, you are free to leave them blank.   
 
There is no single correct answer to the following questions.  The correct response is the one 
which comes closest to describing you. 
 
 
1. Sex:  □ Male   2. Year of Birth:_______ 3. Age:_______ 
  □ Female         
                 
4.  How many years of school did you finish? 
 □     Less than high school 
□   High school graduate 
 □   Trade or technical training after high school   
 □   Community college graduate 
 □   University graduate 
 □   Postgraduate university degree 
 
5.  What is your current living situation: 
 □   Living with a partner or a family member 
 □   Living with a friend or a roommate 
 □   Living alone 
 □   Living in a residential setting 
 
 
Health 
 
Ablations 
 
 
6.  Have you had an ablation? 
□ No 
□ Yes 
 
 
7.  How many ablations have you had to-date? ________ 
 
8.  How many of your ablations were deemed successful? ___ 
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ICD 
 
 
9.  How many recorded ICD shocks have you experienced to-date?  
□ None 
□ 1 – 2 shocks 
□ 3 – 4 shocks 
□ more than 4 shocks 
 
10.  Have you ever experienced a shock and been told that it was not recorded?   
□ No   
□ Yes If yes, how many times have you had a shock and been told it was not 
recorded? ____ 
 
11.  Are you currently taking any antiarrhythmic medication? 
 □ No 
 □ Yes  If yes, please list the medications: 
   _______________________________ 
   _______________________________ 
 
12.  Are you currently taking any beta blockers? 
 □ No 
 □ Yes  If yes, please list the medications: 
   _______________________________ 
   _______________________________ 
 
 
13.  Are you currently taking any medications to help with mood? 
 □ No 
 □ Yes  If yes, please list the medications: 
   ___________________________ 
   ___________________________ 
   
14.  Are you currently taking any medications to help you sleep? 
 □ No 
 □ Yes  If yes, please list the medications: 
   ___________________________ 
   ___________________________ 
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Your Health and Well-Being (SF-36) 
 
This portion of the questionnaire asks for your views about your health. For each of the following 
questions, please mark an ‘x’ in the box that best describes your answer. 
 
 1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
    1     2     3     4     5 
 
 
 2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
    1     2     3     4     5 
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 3. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much?  
 
 
 
4.During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities                                  1                              2                              3                             4                          5
 b Accomplished less than you  
  would like                                         1                2                3               4             5 
 c Were limited in the kind of  
  work or other activities                     1                2                3                            4                        5
 d Had difficulty performing the  
  the work or other activities (for  
  example, it took extra effort)            1                               2                             3                             4                          5 
  
Yes, 
Limited 
a lot 
 
Yes, 
limited 
a little 
 
No, not 
limited 
at all 
    
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports                      1                             2                            3
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf                            1                             2                            3
 c Lifting or carrying groceries                                                   1                             2                            3
 d Climbing several flights of stairs                                            1                             2                            3
 e Climbing one flight of stairs                                                   1                             2                            3
 f Bending, kneeling, or stooping                                               1                             2                            3
 g Walking more than a kilometre                                               1                             2                            3
 h Walking several hundred metres                                            1                             2                            3
 i Walking one hundred metres                                                  1                             2                            3
 j Bathing or dressing yourself                                                    1                             2                             3 
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 5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities                                  1                             2                            3                             4                            5
 b Accomplished less than you  
  would like                                         1                           2                              3                             4                           5 
 c Did work or other activities 
  less carefully than usual                   1                            2                              3                             4                           5
 
 
 
 
 6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
    1     2   3   4     5 
 
 
 
 
 7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
      
    1     2   3   4   5     6 
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 8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
    1     2   3   4     5 
 
 
 
 
 
 9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the past 4 weeks… 
 
 
 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Did you feel full of life?                   1                          2                               3                           4                             5
 b Have you been very nervous?         1                             2                              3                           4                             5
 c Have you felt so down in the  
dumps that nothing could  
cheer you up?                                   1                             2                            3                             4                            5
 d Have you felt calm and   
peaceful?                                          1                             2                             3                            4                             5
 e Did you have a lot of energy?          1                             2                            3                             4                             5
 f Have you felt downhearted   
and depressed?                                 1                              2                            3                             4                             5
 g Did you feel worn out?                    1                             2                             3                             4                            5
 h Have you been happy?                     1                            2                             3                              4                            5
 i Did you feel tired?                            1                             2                            3                             4                             5 
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 10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, 
etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
            1            2            3          4            5
 
 
 
 
 
 11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely
false 
  
 a I seem to get sick a little 
easier than other people                   1                             2                               3                         4                              5
 b I am as healthy as  
anybody I know                               1                             2                               3                          4                             5
 c I expect my health to  
get worse                                          1                            2                                3                          4                             5
 d My health is excellent                      1                            2                                3                          4                             5
 
 
 
 
 
 
 
 
 
 
 
 
162 
 
 
EMOTIONS IN THE PAST WEEK (HADS) 
 
The following questions ask about how you have been feeling. Health care professionals are aware that 
emotions play an important part in most illnesses. If your health care professional knows about these feelings 
he or she will be able to help you more. Read each item below and place a check () in the box beside the 
reply which comes closest to how you have been feeling in the past week.  
 
1. I feel tense or “wound up”  
  □ Most of the time  
  □ A lot of time  
  □ From time to time  
  □ Not at all  
8. I feel as if I am slowed down  
  □ Nearly all the time  
  □ Very often  
  □ Sometimes  
  □ Not at all  
 
2. I still enjoy the things I used to enjoy  
  □ Definitely as much  
  □ Not quite so much  
  □ Only a little  
  □ Hardly at all  
9. I get a sort of frightened feeling like  
“butterflies” in the stomach  
  □ Not at all  
  □ Occasionally  
  □ Quite often  
  □ Very often  
 
3. I get sort of frightened feeling as if something 
awful is about to happen 
  □ Very definitely and quite badly  
  □ Yes, but not too badly  
  □ A little, but it doesn’t worry me  
  □ Not at all  
 
10. I have lost interest in my appearance  
  □ Definitely  
  □ I don’t take as much care as I should  
  □ I may not take quite much care   
  □ I take just as much care as ever  
 
4. I can laugh and see the funny side of things  
  □ As much as I always could   
  □ Not quite so much now  
  □ Definitely not so much now  
  □ Not at all  
 
11. I feel restless as if I have to be on the move  
  □ Very much indeed  
  □ Quite a lot  
  □ Not very much  
  □ Not at all  
 
5. Worrying thoughts go through my mind  
  □ A great deal of the time  
  □ A lot of the time  
  □ Not too often  
  □ Very little  
 
12. I look forward with enjoyment to things  
  □ As much as I ever did  
  □ Rather less than I used to  
  □ Definitely less than I used to  
  □ Hardly at all  
 
6. I feel cheerful  
  □ Never  
  □ Not often  
  □ Sometimes  
  □ Most of the time 
13. I get sudden feelings of panic  
  □ Very often indeed  
  □ Quite often  
  □ Not very often  
  □ Not at all  
 
7. I can sit at ease and feel relaxed  
   □ Definitely  
   □ Usually  
   □ Not often  
   □ Not at all 
14. I can enjoy a good book or radio or  
TV program  
  □ Often  
  □ Sometimes  
  □ Not often  
  □ Very seldom 
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RESPONDING TO STRESSFUL EVENTS (IES-R) 
 
The following is a list of difficulties people sometimes have after stressful life events. Please read 
each item and then indicate how distressing each difficulty has been for you during the past 7 days 
with respect to your arrhythmia (i.e., heart rhythm problem) or its treatment (i.e., having an ICD or 
ablation) by checking off under the most appropriate response. How much were you distressed or 
bothered by these difficulties? 
 
  Not at all 
0 
A little bit 
1 
Moderately 
2 
Quite a bit 
3 
Extremely 
     4 
1. Any reminder brought back 
feeling about it. 
     
2. I had trouble staying 
asleep. 
     
3. Other things kept making 
me think about it. 
     
4. I felt irritable and angry      
5. I avoided letting myself get 
upset when I thought about 
it or was reminded of it.  
     
6. I thought about it when I 
didn’t mean to.  
     
7. I felt as if it hadn’t 
happened or wasn’t real.  
     
8. I stayed away from 
reminders about it. 
     
9.  Pictures about it popped 
into my mind.  
     
10.  I was jumpy and easily 
startled.  
     
11.   I tried not to think about it.       
12. I was aware that I still had 
a lot of feelings about it, 
but I didn’t deal with them.  
     
13.  My feelings about it were 
kind of numb.  
     
14. I found myself acting or 
feeling like I was back at 
that time. 
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15.  I had trouble falling asleep. 
 
     
16. I had waves of strong 
feelings about it.  
     
17. I tried to remove it from 
my memory.  
     
18. I had trouble concentrating.       
19. Reminders of it caused me 
to have physical reactions, 
such as sweating, trouble 
breathing, nausea, or a 
pounding heart.  
     
20. I had dreams about it.       
21. I felt watchful and on 
guard.  
 
     
22. I tried not to talk about it.       
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LIFE STRESS 
 
The next set of questions asks about possible difficulties or stresses that you may have experienced 
in your life. 
 
Have you experienced any of the following in the past year? 
 
  NO YES 
1. Serious illness or injury   
2. Serious illness or injury to a close relative or friend   
3. Marriage   
4. Death of a spouse or partner   
5. Death of a close relative or friend   
6. Death of a pet   
7. Marital separation/divorce   
8. Financial difficulties   
9. Loss of job   
10. Retirement   
11. Business failure   
12. Major family conflict   
13. Pregnancy   
14. Gaining a new family member through birth or marriage   
15. Change in residence   
16. 
Other major stress or difficulty – please specify 
________________________________________________ 
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EXPECTATIONS OF OUTCOMES (LOT) 
 
In the next few sections, we are interested in measuring peoples’ expectations for certain events or 
results. Please be as honest and accurate as you can throughout. Try not to let your response to one 
statement influence your responses to other statements. There are no “correct” or “incorrect” answers. 
Answer according to your own feelings, rather than how you think “most people” would answer. 
(Check one answer for each question) 
 
 I agree a 
lot 
 
 
0 
I agree 
a little 
 
 
1 
I neither 
agree nor 
disagree 
 
2 
I disagree 
a little 
 
 
3 
I disagree a lot 
 
 
 
4 
1) In uncertain times, I 
usually expect the best. 
     
2) It’s easy for me to 
relax. 
     
3) If something can go 
wrong for me, it will. 
     
4) I always look on the 
bright side of things. 
     
5) I’m always optimistic 
about my future. 
 
     
6) I enjoy my friends a 
lot. 
     
7) It’s important for me 
to keep busy. 
     
8) I hardly expect things 
to go my way. 
 
     
9) Things never work 
out the way I want them 
to. 
     
10) I don’t get upset too 
easily. 
     
11) I’m a believer in the 
idea that “every cloud 
has a silver lining.” 
     
12) I rarely count on 
good things happening 
to me. 
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HEALTH EXPECTATIONS (PHE) 
 
1. How confident are you that your cardiac arrhythmia intervention (i.e., ICD, ablation therapy, 
or medication) treatments will work?  
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
2. To what extent do you anticipate that you will lead a full and healthy life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
3. To what extent do you anticipate that you will return to full physical functioning? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
4. To what extent do you anticipate that you will survive for at least 5 more years? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
5. Overall, to what extent do you expect that medical treatments will change your life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Will be much  
worse than before 
Will be about 
the same as before 
Will be much 
better than before
6. Overall, how would you rate your future outlook? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Extremely  
negative 
Neutral Extremely 
Positive
7. How would you rate your feelings about yourself? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Extremely  
negative 
Neutral Extremely 
positive
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Managing Arrhythmia Treatments 
 
 
 
Please rate the confidence you feel today: 
1. I am able to deal with the physical changes caused by my arrhythmia treatment  
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
2. I can manage my own nervousness since my arrhythmia treatment  
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
3. I feel confident that I can eventually get back to my normal activities around the house and at 
work 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
4. I have the skills to deal with the pressures my arrhythmia treatment is causing in my close 
relationships 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
5. I am able to manage interactions with my doctors, nurses, and other health care providers 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
6. I have the ability to deal with an arrhythmia event should it occur in the future 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
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Rate your agreement or disagreement as of today: 
1. If I have a plan in place for dealing with arrhythmia events, then I feel safer if this occurs 
5 4 3 2 1 
Definitely True    Definitely not 
true 
2. If I address my emotional reactions to the arrhythmia treatment, then I am less likely to be 
distressed by them 
5 4 3 2 1 
Definitely True    Definitely not 
true 
3. If I share information related to my arrhythmia treatment and heart symptoms, then my 
health care providers can more effectively treat them 
5 4 3 2 1 
Definitely True    Definitely not 
true 
4. If my partner and I are open to each other’s experiences about my arrhythmia treatment, then 
we can begin to deal with this together 
5 4 3 2 1 
Definitely True    Definitely not 
true 
5. If I follow the safe activity suggestions prescribed by my health care providers, then 
complications related to my arrhythmia treatments will be reduced 
5 4 3 2 1 
Definitely True    Definitely not 
true 
6. If I am physically active during my recovery from the arrhythmia treatment, then my 
physical recovery will be faster 
5 4 3 2 1 
Definitely True    Definitely not 
true 
7. My arrhythmia treatment will prevent me from having a life-threatening arrhythmia event 
5 4 3 2 1 
Definitely True    Definitely not 
true 
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Participant #: _______________      Date: _______________ 
 
Appendix E – Follow-up Questionnaire  
 
STUDY QUESTIONNAIRE 
Follow-Up 
 
 
Thank you for completing the following questionnaire. Your answers will help us assess the results 
of this study and get a better understanding of how treatments for ventricular arrhythmias influence 
health and well-being. 
 
Please return the completed questionnaire in the pre-stamped self-addressed envelope provided.  
 
You may find some of the questions in this survey to be personal in nature and we appreciate your 
willingness to complete the items. Your replies will be kept strictly confidential and only the 
research team will see your answers. If you have any questions, please contact the study co-
ordinators at 416-419-5672. 
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DEMOGRAPHIC INFORMATION 
 
Please try to answer all of the questions.  However, if there are any that you would rather not 
answer, you are free to leave them blank.   
 
There is no single correct answer to the following questions.  The correct response is the one 
which comes closest to describing you. 
 
 
1. Sex:  □ Male   2. Year of Birth:_______ 3. Age:_______ 
  □ Female         
                 
4.  How many years of school did you finish? 
 □     Less than high school 
□   High school graduate 
 □   Trade or technical training after high school   
 □   Community college graduate 
 □   University graduate 
 □   Postgraduate university degree 
 
5.  What is your current living situation: 
 □   Living with a partner or a family member 
 □   Living with a friend or a roommate 
 □   Living alone 
 □   Living in a residential setting 
 
 
Health 
 
Ablations 
 
 
6.  Have you had an ablation? 
□ No 
□ Yes 
 
 
7.  How many ablations have you had to-date? ________ 
 
8.  How many of your ablations were deemed successful? ___ 
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ICD 
 
 
9.  How many recorded ICD shocks have you experienced to-date?  
□ None 
□ 1 – 2 shocks 
□ 3 – 4 shocks 
□ more than 4 shocks 
 
10.  Have you ever experienced a shock and been told that it was not recorded?   
□ No   
□ Yes If yes, how many times have you had a shock and been told it was not 
recorded? ____ 
 
11.  Are you currently taking any antiarrhythmic medication? 
 □ No 
 □ Yes  If yes, please list the medications: 
   _______________________________ 
   _______________________________ 
 
12.  Are you currently taking any beta blockers? 
 □ No 
 □ Yes  If yes, please list the medications: 
   _______________________________ 
   _______________________________ 
 
 
13.  Are you currently taking any medications to help with mood? 
 □ No 
 □ Yes  If yes, please list the medications: 
   ___________________________ 
   ___________________________ 
   
14.  Are you currently taking any medications to help you sleep? 
 □ No 
 □ Yes  If yes, please list the medications: 
   ___________________________ 
   ___________________________ 
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Your Health and Well-Being (SF-36) 
 
This portion of the questionnaire asks for your views about your health. For each of the following 
questions, please mark an ‘x’ in the box that best describes your answer. 
 
 1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
    1     2     3     4     5 
 
 
 2. Compared to one year ago, how would you rate your health in general now? 
Much better 
now than one 
year ago 
Somewhat 
better 
now than one 
year ago 
About the 
same as 
one year ago 
Somewhat 
worse 
now than one 
year ago 
Much worse 
now than one 
year ago 
     
    1     2     3     4     5 
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 3. The following questions are about activities you might do during a typical day.  Does 
your health now limit you in these activities?  If so, how much?  
 
 
 
4.During the past 4 weeks, how much of the time have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities                                  1                              2                              3                             4                          5
 b Accomplished less than you  
  would like                                         1                2                3               4             5 
 c Were limited in the kind of  
  work or other activities                     1                2                3                            4                        5
 d Had difficulty performing the  
  the work or other activities (for  
  example, it took extra effort)            1                               2                             3                             4                          5 
  
Yes, 
Limited 
a lot 
 
Yes, 
limited 
a little 
 
No, not 
limited 
at all 
    
 a Vigorous activities, such as running, lifting  
heavy objects, participating in strenuous sports                      1                             2                            3
 b Moderate activities, such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf                            1                             2                            3
 c Lifting or carrying groceries                                                   1                             2                            3
 d Climbing several flights of stairs                                            1                             2                            3
 e Climbing one flight of stairs                                                   1                             2                            3
 f Bending, kneeling, or stooping                                               1                             2                            3
 g Walking more than a kilometre                                               1                             2                            3
 h Walking several hundred metres                                            1                             2                            3
 i Walking one hundred metres                                                  1                             2                            3
 j Bathing or dressing yourself                                                    1                             2                             3 
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 5. During the past 4 weeks, how much of the time have you had any of the following 
problems with your work or other regular daily activities as a result of any emotional 
problems (such as feeling depressed or anxious)? 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Cut down on the amount of  
  time you spent on work or  
  other activities                                  1                             2                            3                             4                            5
 b Accomplished less than you  
  would like                                         1                           2                              3                             4                           5 
 c Did work or other activities 
  less carefully than usual                   1                            2                              3                             4                           5
 
 
 
 
 6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
    1     2   3   4     5 
 
 
 
 
 7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
      
    1     2   3   4   5     6 
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 8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
    1     2   3   4     5 
 
 
 
 
 
 9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the past 4 weeks… 
 
 
 
 
 
 All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
      
 a Did you feel full of life?                   1                          2                               3                           4                             5
 b Have you been very nervous?         1                             2                              3                           4                             5
 c Have you felt so down in the  
dumps that nothing could  
cheer you up?                                   1                             2                            3                             4                            5
 d Have you felt calm and   
peaceful?                                          1                             2                             3                            4                             5
 e Did you have a lot of energy?          1                             2                            3                             4                             5
 f Have you felt downhearted   
and depressed?                                 1                              2                            3                             4                             5
 g Did you feel worn out?                    1                             2                             3                             4                            5
 h Have you been happy?                     1                            2                             3                              4                            5
 i Did you feel tired?                            1                             2                            3                             4                             5 
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 10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)? 
All of 
the time 
Most of 
the time 
Some of 
the time 
A little of 
the time 
None of 
the time 
     
            1            2            3          4             5
 
 
 
 
 
 11. How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don’t 
know 
Mostly 
false 
Definitely
false 
  
 a I seem to get sick a little 
easier than other people                   1                             2                               3                         4                              5
 b I am as healthy as  
anybody I know                               1                             2                               3                          4                             5
 c I expect my health to  
get worse                                          1                            2                                3                          4                             5
 d My health is excellent                      1                            2                                3                          4                             5
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EMOTIONS IN THE PAST WEEK (HADS) 
 
The following questions ask about how you have been feeling. Health care professionals are 
aware that emotions play an important part in most illnesses. If your health care professional 
knows about these feelings he or she will be able to help you more. Read each item below and 
place a check () in the box beside the reply which comes closest to how you have been 
feeling in the past week.  
 
1. I feel tense or “wound up”  
  □ Most of the time  
  □ A lot of time  
  □ From time to time  
  □ Not at all  
8. I feel as if I am slowed down  
  □ Nearly all the time  
  □ Very often  
  □ Sometimes  
  □ Not at all  
 
2. I still enjoy the things I used to enjoy  
  □ Definitely as much  
  □ Not quite so much  
  □ Only a little  
  □ Hardly at all  
9. I get a sort of frightened feeling like  
“butterflies” in the stomach  
  □ Not at all  
  □ Occasionally  
  □ Quite often  
  □ Very often  
 
3. I get sort of frightened feeling as if something awful 
is about to happen 
  □ Very definitely and quite badly  
  □ Yes, but not too badly  
  □ A little, but it doesn’t worry me  
  □ Not at all  
 
10. I have lost interest in my appearance  
  □ Definitely  
  □ I don’t take as much care as I should  
  □ I may not take quite much care   
  □ I take just as much care as ever  
 
4. I can laugh and see the funny side of things  
  □ As much as I always could   
  □ Not quite so much now  
  □ Definitely not so much now  
  □ Not at all  
 
11. I feel restless as if I have to be on the move  
  □ Very much indeed  
  □ Quite a lot  
  □ Not very much  
  □ Not at all  
 
5. Worrying thoughts go through my mind  
  □ A great deal of the time  
  □ A lot of the time  
  □ Not too often  
  □ Very little  
 
12. I look forward with enjoyment to things  
  □ As much as I ever did  
  □ Rather less than I used to  
  □ Definitely less than I used to  
  □ Hardly at all  
 
6. I feel cheerful  
  □ Never  
  □ Not often  
  □ Sometimes  
  □ Most of the time 
13. I get sudden feelings of panic  
  □ Very often indeed  
  □ Quite often  
  □ Not very often  
  □ Not at all  
 
7. I can sit at ease and feel relaxed  
   □ Definitely  
   □ Usually  
   □ Not often  
   □ Not at all 
14. I can enjoy a good book or radio or  
TV program  
  □ Often  
  □ Sometimes  
  □ Not often  
  □ Very seldom 
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RESPONDING TO STRESSFUL EVENTS (IES-R) 
 
The following is a list of difficulties people sometimes have after stressful life events. Please 
read each item and then indicate how distressing each difficulty has been for you during the past 
7 days with respect to your arrhythmia (i.e., heart rhythm problem) or its treatment (i.e., having 
an ICD or ablation) by checking off under the most appropriate response. How much were you 
distressed or bothered by these difficulties? 
 
  Not at all 
0 
A little bit 
1 
Moderately 
2 
Quite a bit 
3 
Extremely 
     4 
1. Any reminder brought back 
feeling about it. 
     
2. I had trouble staying 
asleep. 
     
3. Other things kept making 
me think about it. 
     
4. I felt irritable and angry      
5. I avoided letting myself get 
upset when I thought about 
it or was reminded of it.  
     
6. I thought about it when I 
didn’t mean to.  
     
7. I felt as if it hadn’t 
happened or wasn’t real.  
     
8. I stayed away from 
reminders about it. 
     
9.  Pictures about it popped 
into my mind.  
     
10.  I was jumpy and easily 
startled.  
     
11.   I tried not to think about it.       
12. I was aware that I still had 
a lot of feelings about it, 
but I didn’t deal with them.  
     
13.  My feelings about it were 
kind of numb.  
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14. I found myself acting or 
feeling like I was back at 
that time. 
     
15.  I had trouble falling asleep. 
 
     
16. I had waves of strong 
feelings about it.  
     
17. I tried to remove it from 
my memory.  
     
18. I had trouble concentrating.       
19. Reminders of it caused me 
to have physical reactions, 
such as sweating, trouble 
breathing, nausea, or a 
pounding heart.  
     
20. I had dreams about it.       
21. I felt watchful and on 
guard.  
 
     
22. I tried not to talk about it.       
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LIFE STRESS 
 
The next set of questions asks about possible difficulties or stresses that you may have 
experienced in your life. 
 
Have you experienced any of the following in the past year? 
 
  NO YES 
1. Serious illness or injury   
2. Serious illness or injury to a close relative or friend   
3. Marriage   
4. Death of a spouse or partner   
5. Death of a close relative or friend   
6. Death of a pet   
7. Marital separation/divorce   
8. Financial difficulties   
9. Loss of job   
10. Retirement   
11. Business failure   
12. Major family conflict   
13. Pregnancy   
14. Gaining a new family member through birth or marriage   
15. Change in residence   
16. 
Other major stress or difficulty – please specify 
________________________________________________ 
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HEALTH EXPECTATIONS (PHE) 
 
1. How confident are you that your cardiac arrhythmia intervention (i.e., ICD, ablation therapy, 
or medication) treatments will work?  
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
2. To what extent do you anticipate that you will lead a full and healthy life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
3. To what extent do you anticipate that you will return to full physical functioning? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
4. To what extent do you anticipate that you will survive for at least 5 more years? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Certain this  
will not occur 
Somewhat sure 
this will occur 
Certain this 
will occur
5. Overall, to what extent do you expect that medical treatments will change your life? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Will be much  
worse than before 
Will be about 
the same as before 
Will be much 
better than before
6. Overall, how would you rate your future outlook? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Extremely  
negative 
Neutral Extremely 
Positive
7. How would you rate your feelings about yourself? 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
Extremely  
negative 
Neutral Extremely 
positive
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Managing Arrhythmia Treatments 
 
 
 
Please rate the confidence you feel today: 
7. I am able to deal with the physical changes caused by my arrhythmia treatment  
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
8. I can manage my own nervousness since my arrhythmia treatment  
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
9. I feel confident that I can eventually get back to my normal activities around the house and at 
work 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
10. I have the skills to deal with the pressures my arrhythmia treatment is causing in my close 
relationships 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
11. I am able to manage interactions with my doctors, nurses, and other health care providers 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
12. I have the ability to deal with an arrhythmia event should it occur in the future 
0 1 2 3 4 5 6 7 8 9 10 
Not at all 
confident 
         Very 
Confident
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Rate your agreement or disagreement as of today: 
8. If I have a plan in place for dealing with arrhythmia events, then I feel safer if this occurs 
5 4 3 2 1 
Definitely True    Definitely not 
true 
9. If I address my emotional reactions to the arrhythmia treatment, then I am less likely to be 
distressed by them 
5 4 3 2 1 
Definitely True    Definitely not 
true 
10. If I share information related to my arrhythmia treatment and heart symptoms, then my 
health care providers can more effectively treat them 
5 4 3 2 1 
Definitely True    Definitely not 
true 
11. If my partner and I are open to each other’s experiences about my arrhythmia treatment, then 
we can begin to deal with this together 
5 4 3 2 1 
Definitely True    Definitely not 
true 
12. If I follow the safe activity suggestions prescribed by my health care providers, then 
complications related to my arrhythmia treatments will be reduced 
5 4 3 2 1 
Definitely True    Definitely not 
true 
13. If I am physically active during my recovery from the arrhythmia treatment, then my 
physical recovery will be faster 
5 4 3 2 1 
Definitely True    Definitely not 
true 
14. My arrhythmia treatment will prevent me from having a life-threatening arrhythmia event 
5 4 3 2 1 
Definitely True    Definitely not 
true 
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Managing Arrhythmia Treatments II  
 
Mark the number that best describes the extent to which you have: 
13. Dealt with the physical changes caused by your arrhythmia treatment 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
         Totally 
14. Managed your nervousness since your arrhythmia treatment 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
         Totally
15. Resumed normal household and work activities 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
         Totally
16. Dealt with pressure in your close relationship since the arrhythmia treatment 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
 
         Totally
17. Managed interactions with doctors and nurses successfully 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
         Totally
18. Dealt satisfactorily with arrhythmia events when they occurred 
0 1 2 3 4 5 6 7 8 9 10 
Not at 
all  
         Totally
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Appendix F: Thank You Letter 
 
 
 
 
 
  
 
 
Thank You Letter to Participants 
 
 
 
Date_____________________________________ 
Dear Mr./Mrs.______________________________ 
 
 
 
We are sending you this letter along with the 6-month follow-up questionnaire. When 
you have completed the questionnaire package, please use the self-addressed, stamped envelope 
to mail it back to us.  
We want to thank you very much for participating in our study “Quality of Life and 
Psychosocial Well-Being Following VT Ablation.” Your participation is greatly appreciated. By 
participating in this study you will help us better understand both the positive and negative 
effects of arrhythmia treatments on health and well-being. 
 
Thank you, 
 
 
 
Dr. Nanthakumar, Dr. Irivne, Leora Wanounou, and Ana Bilanovic 
 
 
 
 
